0001493152-19-005137.txt : 20190411 0001493152-19-005137.hdr.sgml : 20190411 20190411080108 ACCESSION NUMBER: 0001493152-19-005137 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20190228 FILED AS OF DATE: 20190411 DATE AS OF CHANGE: 20190411 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Novo Integrated Sciences, Inc. CENTRAL INDEX KEY: 0001138978 STANDARD INDUSTRIAL CLASSIFICATION: ENGINES & TURBINES [3510] IRS NUMBER: 593691650 FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-109118 FILM NUMBER: 19742866 BUSINESS ADDRESS: STREET 1: 11120 NE 2ND STREET STREET 2: SUITE 200 CITY: BELLEVUE STATE: WA ZIP: 98004 BUSINESS PHONE: (206) 617-9797 MAIL ADDRESS: STREET 1: 11120 NE 2ND STREET STREET 2: SUITE 200 CITY: BELLEVUE STATE: WA ZIP: 98004 FORMER COMPANY: FORMER CONFORMED NAME: TURBINE TRUCK ENGINES INC DATE OF NAME CHANGE: 20010420 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended February 28, 2019

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______, 20___, to _____, 20___.

Commission File Number 333-109118

Novo Integrated Sciences, Inc.

(Exact Name of Registrant as Specified in its Charter)

Nevada		59-3691650
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification Number)

11120 NE 2nd Street, Suite 200

Bellevue, Washington

98004

(Address of Principal Executive Offices)

(Zip Code)

(206) 617-9797

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former name or former address, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “accelerated filer,” “large accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[ ]	Accelerated filer	[ ]
Non-accelerated filer	[X]	Smaller reporting company	[X]
Emerging growth company	[ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes [ ] No [X]

There were 223,164,283 shares of the Registrant’s $0.001 par value common stock outstanding as of April 8, 2019.

Novo Integrated Sciences, Inc.

Contents

PART I – FINANCIAL INFORMATION		3

Item 1.	Financial Statements	3

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operation	16

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	24

Item 4.	Controls and Procedures	24

PART II – OTHER INFORMATION		24

Item 1.	Legal Proceedings	24

Item 1A.	Risk Factors	24

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24

Item 3.	Defaults Upon Senior Securities	25

Item 4.	Mine Safety Disclosures	25

Item 5.	Other Information	25

Item 6.	Exhibits	26

Signatures		27

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

As of February 28, 2019 (unaudited) and August 31, 2018

	February 28, 2019			August 31, 2018
		(unaudited)
ASSETS
Current Assets:
Cash and cash equivalents	$	2,373,936		$	675,705
Accounts receivable, net		1,378,894			1,337,545
Other receivables, current portion		586,734			393,821
Prepaid expenses and other current assets		163,323			161,838
Total current assets		4,502,887			2,568,909

Property and equipment, net		427,195			400,321
Intangible assets		22,358,567			-
Other receivables, net of current portion		87,354			57,352
Acquisition deposits		1,104,985			1,112,404
Goodwill		600,084			604,113
TOTAL ASSETS	$	29,081,072		$	4,743,099

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities:
Accounts payable	$	1,254,234		$	1,307,599
Accrued expenses		254,667			383,998
Accrued interest (principally to related parties)		181,740			156,121
Due to related parties		966,102			1,116,261
Notes payable, current portion		379,800			382,350
Total current liabilities		3,036,543			3,346,329

Debentures, related parties		1,215,837			1,224,000
TOTAL LIABILITIES		4,252,380			4,570,329

Commitments and contingencies		-			-

STOCKHOLDERS’ EQUITY
Novo Integrated Sciences, Inc.
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at February 28, 2019 and August 31, 2018
Common stock; $0.001par value; 499,000,000 shares authorized; 223,048,205 and 207,881,743 shares issued and outstanding at February 28, 2019 and August 31, 2018		223,048			207,882
Additional paid-in capital		35,047,853			10,053,683
Other comprehensive income		1,165,795			1,139,815
Accumulated deficit		(11,570,906	)		(11,199,989	)
Total Novo Integrated Sciences, Inc. stockholders’ equity		24,865,790			201,391
Noncontrolling interest		(37,098	)		(28,621	)
Total stockholders’ equity		24,828,692			172,770
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	29,081,072		$	4,743,099

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

For the Three and Six Months Ended February 28, 2019 and 2018 (unaudited)

	Three Months Ended						Six Months Ended
	February 28, 2019			February 28, 2018			February 28, 2019			February 28, 2018
	(unaudited)			(unaudited)			(unaudited)			(unaudited)
Revenues	$	2,200,410		$	2,145,919		$	4,512,032		$	4,399,656

Cost of revenues		1,320,740			1,307,596			2,748,823			2,715,289

Gross profit		879,670			838,323			1,763,209			1,684,367

Operating expenses:
Selling expenses		4,016			30,601			29,239			68,740
General and administrative expenses		954,341			1,934,479			2,028,009			2,914,754
Total operating expenses		958,357			1,965,080			2,057,248			2,983,494

Loss from operations		(78,687	)		(1,126,757	)		(294,039	)		(1,299,127	)

Non operating income (expense)
Interest income		4,294			160			9,383			211
Interest expense		(48,587	)		(304,132	)		(94,908	)		(438,285	)
Total other income (expense)		(44,293	)		(303,972	)		(85,525	)		(438,074	)

Loss before income taxes		(122,980	)		(1,430,729	)		(379,564	)		(1,737,201	)

Income tax expense		-			(54,216	)		-			-

Net loss	$	(122,980	)	$	(1,376,513	)	$	(379,564	)	$	(1,737,201	)

Net loss attributed to noncontrolling interest		(3,479	)		(1,956	)		(8,647	)		(5,356	)

Net loss attributed to Novo Integrated Sciences, Inc.	$	(119,501	)	$	(1,374,557	)	$	(370,917	)	$	(1,731,845	)

Comprehensive loss:
Net loss		(122,980	)		(1,376,513	)		(379,564	)		(1,737,201	)
Foreign currency translation gain (loss)		27,765			(211,528	)		25,980			(87,341	)
Comprehensive loss:	$	(95,215	)	$	(1,588,041	)	$	(353,584	)	$	(1,824,542	)

Weighted average common shares outstanding - basic and diluted		214,281,342			206,091,162			211,094,982			203,953,457

Net loss per common share - basic and diluted	$	(0.00	)	$	(0.01	)	$	(0.00	)	$	(0.01	)

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Six Months Ended February 28, 2019 and 2018 (unaudited)

	Six Months Ended
	February 28, 2019			February 28, 2018
	(unaudited)			(unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(379,564	)	$	(1,737,201	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		46,474			32,719
Fair value of vested stock options		70,846			1,109,416
Changes in operating assets and liabilities:
Accounts receivable		(50,152	)		(250,133	)
Prepaid expenses and other current assets		(2,541	)		30,326
Accounts payable		(44,730	)		80,084
Accrued expenses		(126,470	)		(43,843	)
Accrued interest		26,597			303,699
Net cash used in operating activities		(459,540	)		(474,933	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of furniture and equipment		(75,947	)		(43,431	)
Amounts loaned for other receivables		(225,924	)		(39,215	)
Net cash used in investing activities		(301,871	)		(82,646	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments to related parties		(142,376	)		(263,403	)
Proceeds from the sale of common stock		2,579,923			-
Payments on notes payable		-			(7,108	)
Net cash provided by (used in) financing activities		2,437,547			(270,511	)

Effect of exchange rate changes on cash and cash equivalents		22,095			(31,880	)

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		1,698,231			(859,970	)

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		675,705			1,896,572

CASH AND CASH EQUIVALENTS, END OF PERIOD	$	2,373,936		$	1,036,602

CASH PAID FOR:
Interest	$	69,289		$	128,098
Income taxes	$	-		$	-

SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Common stock issued for intangible assets	$	22,358,567		$	-

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

NOVO INTEGRATED SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Six Months Ended February 28, 2019 and 2018 (unaudited)

Note 1 - Organization and Basis of Presentation

Organization and Line of Business

Novo Integrated Sciences, Inc. (“Novo Integrated”) was incorporated in Delaware on November 27, 2000, under the name Turbine Truck Engines, Inc. On February 20, 2008, the Company was re-domiciled to the State of Nevada. Effective July 12, 2017, the Company’s name was changed to Novo Integrated Sciences, Inc. When used herein, the terms the “Company,” “we,” “us” and “our” refer to Novo Integrated and its consolidated subsidiaries.

Through Novo Healthnet Limited (“NHL”), our wholly owned Canadian subsidiary, we deliver multi-disciplinary primary healthcare to over 400,000 patients annually through our 15 corporate-owned clinics and a contracted network of 97 affiliate clinics and 222 eldercare centric homes located across Canada. Our team of practitioners and staff are trained for assessment, diagnosis, treatment, pain management, rehabilitation and primary prevention. Our specialized services and products include physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, chiropody, neurological functions, kinesiology, concussion management and baseline testing, women’s pelvic health, sports medicine therapy, assistive devices and private personal training. We do not provide primary care medical services, none of our employees practices primary care medicine, and our services do not require a medical or nursing license.

As we continue to build our health science platform of services and products through the integration of technology and rehabilitative science, one component of our lateral business growth strategy includes developing business units centered on the direct control of the grow, extraction, manufacturing and distribution processes for hemp and medical cannabidiol products. Additionally, we continue to expand on our patient care philosophy of maintaining an on-going continuous connection with our patient community, beyond the traditional confines of a clinic, by extending oversight of patient diagnosis, care and monitoring, directly into the patient’s home, through various mobile telemedicine and diagnostic tools.

Since inception and through May 9, 2017, our activities and business operations were limited to raising capital, organizational matters and the implementation of our business plan related to research, development, testing and commercialization of various alternative energy technologies.

On April 25, 2017 (the “Effective Date”), the Company entered into a Share Exchange Agreement (the “Share Exchange Agreement”) by and between (i) the Company; (ii) NHL; (iii) ALMC-ASAP Holdings Inc. (“ALMC”); (iv) Michael Gaynor Family Trust (the “MGFT”); (v) 1218814 Ontario Inc. (“1218814”); and (vi) Michael Gaynor Physiotherapy Professional Corp. (“MGPP,” and together with ALMC, MGFT and 1218814, the “NHL Shareholders”). Pursuant to the terms of the Share Exchange Agreement, the Company agreed to acquire from the NHL Shareholders all of the shares of both common and preferred stock of NHL, held by the NHL Shareholders, in exchange for the issuance by the Company to the NHL Shareholders of shares of the Company’s common stock, such that following the closing of the Share Exchange Agreement, the NHL Shareholders would own 167,797,406 restricted shares of Company common stock, representing 85% of the issued and outstanding Company common stock, calculated including all granted and issued options or warrants to acquire the Company common stock as of the Effective Date, but to exclude shares of Company common stock that are subject to a then-current Regulation S offering that was undertaking by the Company (the “Exchange”).

On May 9, 2017, the Exchange closed and, as a result, NHL became a wholly owned subsidiary of Novo Integrated Sciences, Inc.

The Exchange was accounted for as a reverse acquisition under the purchase method of accounting since NHL obtained control of Novo Integrated Sciences, Inc. Accordingly, the Exchange was recorded as a recapitalization of NHL, with NHL being treated as the continuing entity. The historical financial statements presented are the financial statements of NHL. The Exchange was treated as a recapitalization and not as a business combination; therefore, no pro forma information is disclosed. At the closing date of the Exchange, the net assets of the legal acquirer, Novo Integrated Sciences, Inc., were $6,904.

The unaudited consolidated financial statements are prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The information furnished herein reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management, are necessary to fairly state the Company’s financial position, the results of its operations, and cash flows for the periods presented. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) were omitted pursuant to such rules and regulations. The results of operations for the six months ended February 28, 2019 are not necessarily indicative of the results for the year ending August 31, 2019.

Basis of Presentation

The accompanying consolidated financial statements were prepared in conformity with U.S. GAAP. The Company’s Canadian subsidiaries’ functional currency is the Canadian Dollar (“CAD” or “CAD$”); however, the accompanying consolidated financial statements were translated and presented in United States Dollars (“$” or “USD”).

Foreign Currency Translation

The accounts of the Company’s Canadian subsidiaries are maintained in CAD. The accounts of these subsidiaries are translated into USD in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 830, Foreign Currency Transaction, with the CAD as the functional currency. According to Topic 830, all assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders’ equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220, Comprehensive Income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statement of operations and comprehensive income. The following table details the exchange rates used for the respective periods:

	February 28, 2019		February 28, 2018		August 31, 2018
Period end: CAD to USD exchange rate	$	0.7596	$	0.7808	$	0.7647
Average period: CAD to USD exchange rate	$	0.7578	$	0.7959

Note 2 – Summary of Significant Accounting Policies

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, NHL, Novo Healthnet Rehab Limited, Novo Assessments Inc., and an 80% interest in Novo Healthnet Kemptville Centre, Inc., a Back on Track Physiotherapy and Health Centre clinic operated by NHL. All of the Company’s subsidiaries are incorporated under the laws of the Province of Ontario, Canada. All intercompany transactions have been eliminated.

Noncontrolling Interest

The Company follows FASB ASC Topic 810, Consolidation, which governs the accounting for and reporting of non-controlling interests (“NCIs”) in partially owned consolidated subsidiaries and the loss of control of subsidiaries. Certain provisions of this standard indicate, among other things, that NCIs be treated as a separate component of equity, not as a liability, that increases and decreases in the parent’s ownership interest that leave control intact be treated as equity transactions rather than as step acquisitions or dilution gains or losses, and that losses of a partially owned consolidated subsidiary be allocated to the NCI even when such allocation might result in a deficit balance.

The net income (loss) attributed to the NCI is separately designated in the accompanying consolidated statements of operations and other comprehensive income (loss).

Cash Equivalents

For the purpose of the statement of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less.

Accounts Receivable

Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of February 28, 2019 and August 31, 2018, the allowance for uncollectible accounts receivable was $473,585 and $464,527, respectively.

Property and Equipment

Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows:

	Leasehold improvements	5 years
	Clinical equipment	5 years
	Computer equipment	3 years
	Office equipment	5 years
	Furniture and fixtures	5 years

Long-Lived Assets

The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at February 28, 2019 and August 31, 2018, the Company believes there was no impairment of its long-lived assets.

Intangible Assets

The Company’s intangible assets consist of land use rights and a software license which will be amortized over 50 and 7 years, respectively. Amortization will begin when the assets are fully placed in service. The Company will perform a test for impairment annually. The land use rights and the software license intangible assets were acquired in January and February, 2019, respectively. Therefore, the first annual impairment test will be performed as of August 31, 2019.

Goodwill

Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under accounting requirements, goodwill is not amortized but is subject to annual impairment tests. At February 28, 2019, the Company recorded goodwill of $379,800 and $220,284, respectively, related to its acquisition of Apka Health, Inc. during the fiscal year ended August 31, 2017 and Executive Fitness Leaders during the fiscal year ended August 31, 2018. As of August 31, 2018, the Company performed the required impairment review. Based on its review, the Company believes there was no impairment of its goodwill.

Acquisition Deposits

The Company has signed letters of understanding with two potential acquisition candidates which include refundable acquisition deposits totaling $1,104,985 and $1,112,404 at February 28, 2019 and August 31, 2018, respectively.

Fair Value of Financial Instruments

For certain of the Company’s financial instruments, including cash and equivalents, restricted cash, accounts receivable, advances to suppliers, accounts payable, accrued liabilities and short-term debt, the carrying amounts approximate their fair values due to their short maturities.

FASB ASC Topic 820, Fair Value Measurements and Disclosures, requires disclosure of the fair value of financial instruments held by the Company. FASB ASC Topic 825, Financial Instruments, defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:

	●	Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.

	●	Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

	●	Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement.

The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity, and FASB ASC Topic 815, Derivatives and Hedging.

As of February 28, 2019 and August 31, 2018, respectively, the Company did not identify any assets and liabilities required to be presented on the balance sheet at fair value.

Revenue Recognition

Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“Topic 606”), became effective for the Company on March 1, 2018. The Company’s revenue recognition disclosure reflects its updated accounting policies that are affected by this new standard. The Company applied the “modified retrospective” transition method for open contracts for the implementation of Topic 606. As sales are and have been primarily from providing healthcare services, and the Company has no significant post-delivery obligations, this new standard did not result in a material recognition of revenue on the Company’s accompanying consolidated financial statements for the cumulative impact of applying this new standard. The Company made no adjustments to its previously-reported total revenues, as those periods continue to be presented in accordance with its historical accounting practices under Topic 605, Revenue Recognition.

Revenue from providing healthcare services are recognized under Topic 606 in a manner that reasonably reflects the delivery of its services to customers in return for expected consideration and includes the following elements:

	●	executed contracts with the Company’s customers that it believes are legally enforceable;
	●	identification of performance obligations in the respective contract;
	●	determination of the transaction price for each performance obligation in the respective contract;
	●	allocation the transaction price to each performance obligation; and
	●	recognition of revenue only when the Company satisfies each performance obligation.

These five elements, as applied to healthcare services, the Company’s sole revenue category, is summarized below:

●

Healthcare services - gross service revenue is recorded in the accounting records at the time the service is provided on an accrual basis at the provider’s established rates, regardless of whether the provider expects to collect that amount. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes.

Income Taxes

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.

Stock-Based Compensation

The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation. FASB ASC Topic 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the requisite service period. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.

Basic and Diluted Earnings Per Share

Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share. Basic earnings per share (“EPS”) is based on the weighted average number of common shares outstanding. Diluted EPS assumes that all dilutive securities are converted. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. There were 10,095,000 options/warrants outstanding as of February 28, 2019. Due to the net loss incurred, potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss for all periods presented.

Foreign Currency Transactions and Comprehensive Income

U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the CAD. Translation gains of $1,165,795 and $1,139,815 at February 28, 2019 and August 31, 2018, respectively, are classified as an item of other comprehensive income in the stockholders’ equity section of the balance sheet.

Statement of Cash Flows

Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets.

Recent Accounting Pronouncements

In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory, which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. ASU 2016-16 is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. The Company is in the process of evaluating the impact of this ASU on its financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and interim periods in fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is in the process of evaluating the impact of this ASU on its financial statements.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company adopted this ASU beginning on March 1, 2018 and used the modified retrospective method of adoption. The adoption of this ASU did not have a material impact on the Company’s financial statements and disclosures.

Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Note 3 – Related Party Transactions

Due to related parties

Amounts loaned to the Company by stockholders and officers of the Company are non-interest bearing and payable upon demand. At February 28, 2019 and August 31, 2018, the amount due to related parties was $966,102 and $1,116,261, respectively.

On January 31, 2018, a related party converted $813,125 of outstanding principal and accrued interest into 1,976,483 shares of the Company’s common stock. The per share price used for the conversion of this loan was $0.4114 which was determined based on the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price.

Note 4 – Accounts Receivables, net

Accounts receivables, net at February 28, 2019 and August 31, 2018 consisted of the following:

	February 28, 2019			August 31, 2018
Trade receivables	$	1,610,117		$	1,564,180
Amounts earned but not billed		242,362			237,892
		1,852,479			1,802,072
Allowance for doubtful accounts		(473,585	)		(464,527	)
Accounts receivable, net	$	1,378,894		$	1,337,545

Note 5 – Other Receivables

Other receivables at February 28, 2019 and August 31, 2018 consisted of the following:

	February 28, 2019			August 31, 2018
Notes receivable dated April 1, 2015 and amended on May 23, 2017; accrued interest at 8% per annum; secured by certain assets; due March 1, 2019	$	284,849		$	286,763

Advance to corporation; non-interest bearing; unsecured; due no later than November 18, 2020		30,384			30,588

Advance to corporation; accrues interest at 12% per annum; unsecured; due September 2019		75,960			76,470

Advance to corporation; accrues interest at 10% per annum; unsecured; due May 1, 2022		56,970			57,352

Advance to corporation; accrues interest at 10% per annum after the first 60 days; unsecured; due February 7, 2020		225,924			-
Total other receivables		674,087			451,173
Current portion		(586,733	)		(393,821	)
Long-term portion	$	87,354		$	57,352

Note 6 – Property and Equipment

Property and equipment at February 28, 2019 and August 31, 2018 consisted of the following:

	February 28, 2019			August 31, 2018
Leasehold Improvements	$	433,756		$	372,010
Clinical equipment		276,954			269,741
Computer equipment		22,485			22,636
Office equipment		27,382			24,658
Furniture and fixtures		39,356			39,620
		799,933			728,665
Accumulated depreciation		(372,738	)		(328,344	)
Total	$	427,195		$	400,321

Depreciation expense for the six months ended February 28, 2019 and 2018 was $46,474 and $32,719, respectively.

Note 7 – Intangible Assets

Intangible assets at February 28, 2019 and August 31, 2018 consisted of the following:

	February 28, 2019		August 31, 2018
Land use rights	$	21,600,000	$	-
Software license		758,567		-
		22,358,567		-
Accumulated amortization		-		-
Total	$	22,358,567	$	-

There was no amortization expense during the six months ended February 28, 2019 and 2018.

Note 8 – Accrued Expenses

Accrued expenses at February 28, 2019 and August 31, 2018 consisted of the following:

	February 28, 2019		August 31, 2018
Accrued liabilities	$	131,422	$	266,123
Accrued payroll		89,637		106,761
Other		33,608		11,114
	$	254,667	$	383,998

Note 9 – Notes Payable

Notes payable at February 28, 2019 and August 31, 2018 consisted of the following:

	February 28, 2019			August 31, 2018
Notes payable issued in connection with purchase of assets; accrues interest at 0% per annum; due on March 27, 2019.	$	379,800		$	382,350
		379,800			382,350
Current portion		(379,800	)		(382,350	)
Long-term portion	$	-		$	-

Note 10 – Debentures, related parties

On September 30, 2013, the Company issued five debentures totaling CAD$6,402,512 ($4,968,990 at November 30, 2017) in connection with the acquisition of certain business assets. The holders of the debentures are current stockholders, officers and/or affiliates of the Company. The debentures are secured by all the assets of the Company, accrue interest at 8% per annum and were originally due on September 30, 2016. On December 2, 2017, the debenture holders agreed to extend the due date to September 30, 2019.

On January 31, 2018, the debenture holders converted 75% of the debenture value of $3,894,809 plus accrued interest of $414,965 into 10,475,872 shares of the Company’s common stock. The per share price used for the conversion of each debenture was $0.4114 which was determined based on the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price. At February 28, 2019, the amount of debentures outstanding was $1,215,837.

Note 11 – Stockholders’ Deficit

Convertible preferred stock

The Company has authorized 1,000,000 shares of $0.001 par value convertible preferred stock. At February 28, 2019 and August 31, 2018 there were 0 and 0 convertible preferred shares issued and outstanding, respectively.

Common stock

The Company has authorized 499,000,000 shares of $0.001 par value common stock. At February 28, 2019 and August 31, 2018 there were 223,048,205 and 207,881,743 common shares issued and outstanding, respectively.

During the six months ended February 28, 2019, the Company issued:

	●	2,708,113 restricted shares of common stock for cash proceeds of $2,579,923

	●	12,000,000 restricted shares of common stock as consideration for the Assignment, to the Company, of a Joint Venture Agreement with a value of $21,600,000 based on the closing share price of $1.80 on the execution date of the Closing Certificate

	●	458,349 restricted shares of common stock as consideration for a Licensing Agreement based on a per share price of $1.655 with a value of $758,567.

Stock options/warrants

On September 8, 2015, the Company adopted the 2015 Incentive Compensation Plan (the “2015 Plan”), which authorizes the issuance of up to 5,000,000 shares of common stock to employees, officers, directors or independent consultants of the Company, provided that no person can be granted shares under the 2015 Plan for services related to raising capital or promotional activities. As of February 28, 2019, 4,987,500 shares were available under the 2015 Plan for future grants, awards, options or share issuances. However, because the shares issuable under the 2015 Plan or issuable upon conversion of awards granted under the 2015 Plan are no longer registered under the Securities Exchange Act of 1934, as amended, the Company does not intend to issue any additional grants under the 2015 Plan.

On January 16, 2018, the Company adopted the Novo Integrated Sciences, Inc. 2018 Incentive Plan (the “2018 Plan”). Under the 2018 Plan, 10,000,000 shares of common stock are authorized for issuance to employees, non-employees, directors and key consultants to the Company or its subsidiaries. The 2018 Plan authorizes equity-based and cash-based incentives for participants. There were 9,875,000 shares available for award at February 28, 2019 under the 2018 Plan.

The following is a summary of stock option/warrant activity:

						Weighted
				Weighted		Average
	Options/			Average		Remaining		Aggregate
	Warrants			Exercise		Contractual		Intrinsic
	Outstanding			Price		Life		Value
Outstanding, August 31, 2018		10,030,000			0.30		4.56	$	7,045,500
Granted		75,000			0.95
Forfeited		(10,000	)		2.00
Exercised		-
Outstanding, February 28, 2019		10,095,000			0.30		4.08	$	13,106,250
Exercisable, February 28, 2019		10,095,000		$	0.30		4.08	$	13,106,250

The exercise price for options/warrants outstanding at February 28, 2019:

Outstanding and Exercisable
	Number of
	Options/		Exercise
	Warrants		Price
	5,500,000	$	0.16
	1,000,000		0.32
	50,000		0.33
	120,000		0.40
	2,000,000		0.42
	100,000		0.50
	1,000,000		0.62
	250,000		0.80
	75,000		0.95
	10,095,000

For options granted during the fiscal year ending August 31, 2019 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $0.94 and the weighted-average exercise price of such options/warrants was $0.95. No options were granted during the fiscal year ending August 31, 2019 where the exercise price was less than the stock price at the date of grant or the exercise price was greater than the stock price at the date of grant.

For options granted during the fiscal year ended August 31, 2018 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $0.39 and the weighted-average exercise price of such options/warrants was $0.40. No options were granted during the fiscal year ended August 31, 2018 where the exercise price was less than the stock price at the date of grant or the exercise price was greater than the stock price at the date of grant.

The fair value of the stock options is being amortized to stock option expense over the vesting period. The Company recorded stock option expense of $70,846 and $1,109,416 during the six months ended February 28, 2019 and 2018, respectively. At February 28, 2019, the unamortized stock option expense was $0.

The assumptions used in calculating the fair value of options granted during the current fiscal year ending August 31, 2019 using the Black-Scholes option-pricing model for options granted, through February 28, 2019, are as follows:

Risk-free interest rate	2.78	%
Expected life of the options	3.5 years
Expected volatility	294	%
Expected dividend yield	0	%

Note 12 – Commitments and Contingencies

Litigation

The Company is party to certain legal proceedings from time to time incidental to the conduct of its business. These proceedings could result in fines, penalties, compensatory or treble damages or non-monetary relief. The nature of legal proceedings is such that the Company cannot assure the outcome of any particular matter, and an unfavorable ruling or development could have a materially adverse effect on our consolidated financial position, results of operations and cash flows in the period in which a ruling or settlement occurs. However, based on information available to the Company’s management to date, the Company’s management does not expect that the outcome of any matter pending against the Company is likely to have a materially adverse effect on the Company’s consolidated financial position as of February 28, 2019, results of operations, cash flows or liquidity of the Company.

Leases

The Company leases its office space and certain facilities under long-term operating leases expiring through fiscal year 2023. Rent expense under these leases was $498,237 and $409,350 for the six months ended February 28, 2019 and 2018, respectively.

Note 13 – Subsequent Events

On April 3, 2019, the Company sold 116,078 restricted shares of common stock to an accredited investor for a purchase price of $149,740.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), provide a safe harbor for forward-looking statements made by or on behalf of the Company. The Company and its representatives may from time to time make written or oral statements that are “forward-looking,” including statements contained in this report and other filings with the Securities and Exchange Commission (“SEC”) and in our reports and presentations to stockholders or potential stockholders. In some cases forward-looking statements can be identified by words such as “believe,” “expect,” “anticipate,” “plan,” “potential,” “continue” or similar expressions. Such forward-looking statements include risks and uncertainties and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties can be found in the Part I, Item 1A, “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended August 31, 2018.

Although we believe the expectations reflected in our forward-looking statements are based upon reasonable assumptions, it is not possible to foresee or identify all factors that could have a material effect on the future financial performance of the Company. The forward-looking statements in this report are made on the basis of management’s assumptions and analyses, as of the time the statements are made, in light of their experience and perception of historical conditions, expected future developments and other factors believed to be appropriate under the circumstances.

Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this Quarterly Report on Form 10-Q and the information incorporated by reference in this report to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based.

Overview of the Company

Our strict adherence to public regulatory standards, as well as self-imposed standards of excellence, have allowed us to navigate with ease through the industry’s licensing and regulatory framework. Compliant treatment, data and administrative protocols are managed through a team of highly-trained, certified healthcare and administrative professionals. We and our affiliates provide service to the Canadian property and casualty insurance industry, resulting in a regulated framework governed by the Financial Services Commission of Ontario. All of our services and those of our affiliates are regulated by the various professional associations related to the clinical professionals contracted or employed by us. In 2013, NHL received its accreditation from the Commission on Accreditation of Rehabilitation Facilities (“CARF”). Currently, NHL is undergoing the CARF re-accreditation process.

When used herein, the terms the “Company,” “we,” “us” and “our” refer to Novo Integrated Sciences, Inc. and its consolidated subsidiaries.

Recent Developments

Cloud DX Inc. License Agreement

On February 26, 2019, we entered into a Software License Agreement (the “Cloud DX License”) with Cloud DX Inc. (“Cloud DX”) pursuant to which Cloud DX agreed to sell, and NHL agreed to purchase, a fully paid up, perpetual license, with 5-year conditional exclusivity, for the Cloud DX Bundled Pulsewave PAD-1A USB Blood Pressure Device, up-to-date product releases and Licensed Software Products (the “Licensed Software”) to include the:

	●	Cloud DX Connected Health web portal for clinical users,
	●	Cloud DX Connected Health mobile app,
	●	Cloud DX Connected Health Windows app, and
	●	Cloud DX Connected Health MacOS app.

Pursuant to the terms of the Cloud DX License, Cloud DX also agreed to sell, and NHL agreed to purchase, 4,000 fully functional Pulsewave PAD 1A USB blood pressure monitor devices bundled with the perpetual license discussed above (the “Bundled Devices”).

The Cloud DX License granted to NHL and its majority-owned subsidiaries, holding companies, divisions and affiliates, other than physiotherapy clinics owned and operated by Closing The Gap Healthcare Inc., the right to use and sub-license the Licensed Software and re-sell the Bundled Devices pursuant to the terms of the Cloud DX License in the physical therapy clinic marketplace in North America in exchange for the purchase price as set forth below:

	●	Upon the closing, the Company issued 458,349 restricted shares of its common stock having a value (as calculated as set forth in the Cloud DX License) of CAD$1,000,000 (approximately $758,567 as of February 26, 2019), and

	●	Cloud DX will invoice CAD$250,000 (approximately $189,642 as of February 26, 2019) to NHL based on the following deliverables, and paid on the following schedule:

Cloud DX deliverable		Novo payment (terms: Net 15)
Heart Friendly Program launches in Clinic #1		CAD$50,000 (approximately $37,929 as of February 26, 2019)
Novo-branded Android app delivered as APK file		CAD$35,000 (approximately $26,550 as of February 26, 2019)
Novo-branded Clinical portal website delivered		CAD$35,000 (approximately $26,550 as of February 26, 2019)
Pulsewave PAD-1A devices – 1st delivery		CAD$20,000 (approximately $15,171 as of February 26, 2019)
Marketing services / materials delivered		CAD$25,000 (approximately $18,964 as of February 26, 2019)
Cloud DX hires dedicated Novo support FTE		CAD$85,000 (approximately $64,478 as of February 26, 2019)

Pulse Rx Inc. Share Purchase and Exchange Agreement

On February 20, 2019, we entered into a Share Purchase and Exchange Agreement (the “SPEA”) with Pulse Rx Inc. (“Pulse Rx”) and the Pulse Rx Stockholders (as hereinafter defined), pursuant to which Pulse Rx will become a wholly owned subsidiary of NHL.

Pursuant to the terms of the SPEA, on March 15, 2019 (the “Escrow Closing Date”), the holders of Pulse Rx Class A common shares (the “Pulse Class A Stockholders”) will endorse for transfer all of their Pulse Rx Class A common shares in our favor and deliver them to the escrow agent. The purchase price for the Pulse Rx Class A common shares is CAD$10.00 and the condition precedent that up to CAD$6,000,000 loan is arranged by us and advanced to Pulse Rx (the “Loan”) to discharge payables and restructure debt as provided in the SPEA.

In addition, on the terms and subject to the conditions set forth in the SPEA, on the Escrow Closing Date, the holders of Pulse Rx Class B common shares (the “Pulse Class B Stockholders” and together with the Pulse Class A Stockholders, the “Pulse Rx Stockholders”) will endorse for transfer all of their Pulse Rx Class B common shares in favor of NHL and deliver them to the escrow agent. In exchange for the Pulse Rx Class B common shares, on the Escrow Closing Date, NHL will issue in favor of the Pulse Class B Stockholders exchangeable preferred shares (the “NHL Exchangeable Shares”), which shares can only be utilized for the purpose of exchange for restricted shares of Company common stock and will be delivered to the escrow agent. The Company will allot in favor of the Pulse Class B Stockholders $4,546,013 worth of restricted shares of the Company’s common stock, based on a per share price of $1.7975, or 2,529,076 shares of Company common stock. The transactions described in this paragraph are referred to herein as the “Exchange”.

The closing of the transactions contemplated under the SPEA will occur upon our advancing the Loan funds to Pulse Rx, and the mutual delivery of the Pulse Rx Class A common shares, the Pulse Rx Class B common shares, and the NHL Exchangeable Shares held by the escrow agent to the respective parties by April 15, 2019 (the “Closing Date”). Notwithstanding the foregoing, the Closing Date will be accelerated by the earlier availability to us of the Loan funds, which availability will immediately trigger an earlier Closing Date, to be effected within 10 business days thereof. At the closing:

	●	The escrow agent will deliver the NHL Exchangeable Shares to the Pulse Class B Stockholders and the Pulse Rx Class A common shares and the Pulse Rx Class B common shares to NHL.

	●	We will have caused the Loan funds to be advanced to Pulse Rx such that they may be disbursed pursuant to the terms of the SPEA.

The Exchange is intended to qualify as a reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended.

Assignment of Joint Venture Agreement

On January 7, 2019, 2478659 Ontario Ltd. (“247”) and Kainai Cooperative (“Kainai”) entered into a Joint Venture Agreement (the “Joint Venture Agreement”) for the purpose of developing, managing and arranging for financing of greenhouse and farming projects involving hemp and cannabis cash crops on Kainai related lands, and developing additional infrastructure projects creating jobs and food supply to local communities. On January 8, 2019, we and 247 entered into an Agreement of Transfer and Assignment, pursuant to which 247 agreed to sell, assign and transfer to the Company all rights, contracts, contacts and any and all other assets related in any way to the Joint Venture Agreement. Pursuant to the terms of the Joint Venture Agreement, as assigned to us, the parties will work in a joint venture relationship with the Company providing the finance, development and operation of the project, including sales, and Kainai providing the land and approvals for the development of the projects.

The joint venture will distribute to the Company and Kainai all net proceeds after debt and principal servicing and repayment allocation, as well as operating capital allotment, on a ratio equal to 80% to the Company and 20% to Kainai.

The Joint Venture Agreement has an initial term of 50 years and Kainai may renew the Joint Venture Agreement within five years of the expiry of the initial term upon mutual agreement.

In January 2019, pursuant to the terms of the Joint Venture Agreement, we issued 12,000,000 restricted common shares to 247 with a value of $21,600,000.

CannaPiece Group Inc. Share Exchange Agreement, as Amended, & Subscriptions

On December 18, 2018, we entered into a Share Exchange Agreement (the “SEA”) with CannaPiece Group Inc. (“CannaPiece”).

Pursuant to the terms of the SEA, CannaPiece agreed that it would issue to NHL shares representing 25% of CannaPiece’s outstanding shares, which shares are valued at CAD$25,000,000 ($18,672,500) in the aggregate, based on an agreed pre-revenue, post-licensing valuation of CannaPiece in the amount of CAD$100,000,000 ($74,690,000).

In exchange for the issuance of the CannaPiece shares to NHL, the Company agreed to issue to CannaPiece CAD$25,000,000 ($18,672,500) worth of Company restricted common stock. The number of shares of Company common stock to be issued will be based on a per share price of $0.92, as determined by establishing the 30-trading day closing average ($1.15 per share) on October 10, 2018, the execution date of the binding letter of intent between the parties, with a 20% discount to the determined average.

In addition, CannaPiece agreed to execute one or more subscription agreements for Company common stock with an aggregate value of CAD$5,000,000 (approximately $3,734,500) (the “Investment”) no later than January 7, 2019. CannaPiece’s obligation is independent of the closing of the exchange. The parties agreed that the per share price for the subscription agreements will be $0.92 per share, determined by establishing the 30-trading day closing average ($1.15 per share) on October 10, 2018, the execution date of the binding letter of intent among the parties, with a 20% discount to the determined average. Of this aggregate subscription amount, $501,929 was paid prior to execution of the SEA. In addition, on December 18, 2018, the Company accepted a $1,867,250 subscription agreement from CannaPiece for 2,029,620 shares of the Company’s restricted common stock, resulting in an effective price per share of $0.92.

We have the right to appoint one board member, with voting rights, to CannaPiece’s board of directors, and CannaPiece has the right to appoint one board member, with voting rights, to the Company’s Board of Directors. As of the closing, the Company and CannaPiece will take such actions as required to expand the size of each board of directors such that the Company and CannaPiece can each appoint one member to the other party’s board of directors.

The parties also agreed that the Company’s shares issued to CannaPiece and the CannaPiece shares issued to NHL pursuant to the terms of the SEA will be held in escrow until the earlier of the termination date (June 1, 2019, as the same may be amended by the parties) or the date on which CannaPiece receives approved Licensed Producer Status under the Cannabis Act (Canada) and its associated regulations.

The SEA may be terminated in certain circumstances including, among others, by the mutual written consent of the parties; and by us, or by CannaPiece, if certain closing conditions have not been met by June 1, 2019.

The parties have agreed to extend the delivery date of the Investment to April 30, 2019.

For the three months ended February 28, 2019 compared to the three months ended February 28, 2018

Revenues for the three months ended February 28, 2019 were $2,200,410, representing an increase of $54,491, or 2.5%, from $2,145,919 for the same period in 2018. The increase in revenue is due to the opening of a new clinic in September 2018 and the relocation of certain clinics, during the summer of 2018, allowing the Company to sell additional services to customers as a result of more spacious facilities.

Cost of revenues for the three months ended February 28, 2019 were $1,320,740, representing an increase of $13,144, or 1.0%, from $1,307,596 for the same period in 2018. The increase in cost of revenues is principally due the increase in revenue. Cost of revenues as a percentage of revenue was 60.0% for the three months ended February 28, 2019 and 60.9% for same period in 2018. The decrease in cost of revenues as a percentage of revenue is principally due to slightly lower costs.

Operating costs for the three months ended February 28, 2019 were $958,357, representing a decrease of $1,006,723, or 51.2%, from $1,965,080 for the same period in 2018. The decrease in operating costs is attributed to a decrease in stock-based compensation of $966,751 and a decrease in professional fees.

Interest expense for the three months ended February 28, 2019 was $48,587, representing a decrease of $255,545, or 84.0%, from $304,132 for the same period in 2018. The decrease is due to less debt outstanding as a result of approximately $5.1 million of related party debt being converted to common stock in January 2018.

Net loss for the three months ended February 28, 2019 was $122,980, representing a decrease of $1,253,533, or 91.1%, from $1,376,513 for the same period in 2018. The decrease in net loss is due to the reasons described above.

For the six months ended February 28, 2019 compared to the six months ended February 28, 2018

Revenues for the six months ended February 28, 2019 were $4,512,032, representing an increase of $112,376, or 2.6%, from $4,399,656 for the same period in 2018. The increase in revenue is due to us being able to sell additional services to customers as a result of the acquisition of Executive Fitness Leaders in December 2017, the opening of a new clinic in September 2018, and the relocation of certain clinics during the summer of 2018 to more spacious facilities.

Cost of revenues for the six months ended February 28, 2019 were $2,748,823, representing an increase of $33,534, or 1.2%, from $2,715,289 for the same period in 2018. The increase in cost of revenues is principally due to the increase in revenue. Cost of revenues as a percentage of revenue was 60.9% for the six months ended February 28, 2019 and 61.7% for same period in 2018. The decrease in cost of revenues as a percentage of revenue is principally due to slightly lower costs.

Operating costs for the six months ended February 28, 2019 were $2,057,248, representing a decrease of $926,246, or 31.0%, from $2,983,494 for the same period in 2018. The decrease in operating costs is attributed to a decrease in stock-based compensation of $1,038,570 offset by an increase in payroll and rental fees.

Interest expense for the six months ended February 28, 2019 was $94,908, representing a decrease of $343,377, or 78.3%, from $438,285 for the same period in 2018. The decrease is due to less debt outstanding as a result of approximately $5.1 million of related party debt being converted to common stock in January 2018.

Net loss for the six months ended February 28, 2019 was $379,564, representing a decrease of $1,357,637, or 78.2%, from $1,737,201 for the same period in 2018. The decrease in net loss is due to the reasons described above.

Liquidity and Capital Resources

As shown in the accompanying financial statements, for the six months ended February 28, 2019, the Company had a net loss of $379,564.

During the six months ended February 28, 2019, the Company used cash in operating activities of $459,540 compared to $474,933 for the same period in 2018. The principal reason for the decrease is the decrease in net loss incurred during the six months ended February 28, 2019 as compared to the same period in 2018, changes in non-cash expenses of depreciation and stock-based compensation and changes in working capital accounts during the six months ended February 28, 2019 compared to the same period in 2018.

During the six months ended February 28, 2019, the Company used cash in investing activities of $301,871 compared to $82,646 for the same period in 2018. The principal reason for the change is the increase of amounts loaned for other receivables and of investment in leasehold improvements during the six months ended February 28, 2019 compared to the same period in 2018.

During the six months ended February 28, 2019, the Company generated cash of $2,437,547 from financing activities compared to cash used in financing activities of $270,511 for the same period in 2018. The principal reason for the change is the sale of shares of common stock for $2,579,923 during the six months ended February 28, 2019, and the decrease of repayments of amounts due to related parties of $121,027. During the six months ended February 28, 2018 there were no sales of shares of common stock.

On November 16, 2018, the Company accepted a $30,000 subscription agreement from an accredited investor residing outside the United States for the sale of 17,647 shares of restricted common stock, resulting in an effective price per share of $1.70. The shares were issued on November 20, 2018.

Also on November 16, 2018, the Company accepted a $501,929 subscription agreement from an accredited investor residing outside the United States for the sale of 545,575 shares of restricted common stock, resulting in an effective price per share of $0.92. The shares were issued on November 20, 2018.

On December 18, 2018, the Company accepted a $1,867,250 subscription agreement from an accredited investor residing outside the United States for the sale of 2,029,620 shares of restricted common stock, resulting in an effective price per share of $0.92. The shares were issued on December 20, 2018.

On January 15, 2019, the Company accepted a $180,744 subscription agreement from an accredited investor residing outside the United States for the sale of 115,271 shares of restricted common stock, resulting in an effective price per share of $1.57. The shares were issued on January 18, 2019.

On April 3, 2019, the Company accepted a $149,740 subscription agreement from an accredited investor residing outside the United States for the sale of 116,078 shares of restricted common stock, resulting in an effective price per share of $1.29. The shares were issued on April 5, 2019.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

We believe that the following critical policies affect our more significant judgments and estimates used in preparation of our financial statements.

Use of Estimates

Noncontrolling Interest

The Company follows Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 810, Consolidation, which governs the accounting for and reporting of non-controlling interests (“NCIs”) in partially owned consolidated subsidiaries and the loss of control of subsidiaries. Certain provisions of this standard indicate, among other things, that NCIs be treated as a separate component of equity, not as a liability, that increases and decreases in the parent’s ownership interest that leave control intact be treated as equity transactions rather than as step acquisitions or dilution gains or losses, and that losses of a partially owned consolidated subsidiary be allocated to the NCI even when such allocation might result in a deficit balance.

The net income (loss) attributed to the NCI is separately designated in the accompanying consolidated statements of operations and other comprehensive income (loss).

Revenue Recognition

	●	executed contracts with the Company’s customers that it believes are legally enforceable;
	●	identification of performance obligations in the respective contract;
	●	determination of the transaction price for each performance obligation in the respective contract;
	●	allocation the transaction price to each performance obligation; and
	●	recognition of revenue only when the Company satisfies each performance obligation.

These five elements, as applied to healthcare services, the Company’s sole revenue category, is summarized below:

●

Healthcare services - gross service revenue is recorded in the accounting records at the time the services are provided on an accrual basis at the provider’s established rates, regardless of whether the provider expects to collect that amount. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes.

Stock-Based Compensation

Basic and Diluted Earnings Per Share

Foreign Currency Transactions and Comprehensive Income

U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the Canadian dollar. Translation gains (losses) are classified as an item of other comprehensive income in the stockholders’ equity section of the balance sheet.

New Accounting Pronouncements

Recent accounting pronouncements issued by the FASB, the American Institute of Certified Public Accountants and the SEC did not or are not believed by management to have a material effect on the Company’s financial statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

The Company’s Chief Executive Officer and Principal Financial Officer have evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of February 28, 2019. Based upon such evaluation, the Chief Executive Officer and Principal Financial Officer have concluded that, as of February 28, 2019, the Company’s disclosure controls and procedures were not effective as required under Rules 13a-15(e) and 15d-15(e) under the Exchange Act.

Changes in Internal Control Over Financial Reporting

There were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or 15d-15 of the Exchange Act that occurred during the fiscal quarter ended February 28, 2019 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Except as set forth herein, as of the date of this Quarterly Report on Form 10-Q, there are no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which we are a party or which our property is the subject. In addition, none of our officers, directors, affiliates or 5% stockholders (or any associates thereof) is a party adverse to us, or has a material interest adverse to us, in any material proceeding.

ITEM 1A. RISK FACTORS

Not required for smaller reporting companies.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On December 18, 2018, the Company sold 2,029,620 restricted shares of common stock to an accredited investor for a purchase price of $1,867,250. The shares were issued on December 20, 2018.

On January 15, 2019, the Company sold 115,271 restricted shares of common stock to an accredited investor for a purchase price of $180,744. The shares were issued on January 18, 2019.

In January 2019, the Company issued 12,000,000 restricted shares of common stock to 247 pursuant to the terms of the Joint Venture Agreement. The shares had a value of $21,600,000.

On February 26, 2019, the Company issued 458,349 restricted shares of its common stock to Cloud DX in connection with entry into a software license agreement. Such shares had a value of CAD$1,000,000 (approximately $758,567 as of February 26, 2019).

The above sales were made pursuant to an exemption from registration as set forth in Regulation S under the Securities Act. The issuances involved an offer and sale of securities outside the United States. The offers and sales were made in offshore transactions and no directed selling efforts were made by the issuer, a distributor, their affiliates or any persons acting on their behalf.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

There have been no defaults in any material payments during the covered period.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

(a) None.

(b) There have been no material changes to the procedures by which security holders may recommend nominees to the Company’s Board of Directors since the Company last provided disclosure in response to the requirements of Item 407(c)(3) of Regulation S-K.

ITEM 6. EXHIBITS

Exhibit Number		Description of Document

10.1		Share Exchange Agreement dated December 18, 2018 by and among the registrant, Novo Healthnet Limited and CannaPiece Group Inc. (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed on December 21, 2018).

10.2		Amendment No. 1 to Share Exchange Agreement dated January 7, 2019 by and between the registrant, Novo Healthnet Limited and CannaPiece Group, Inc. (incorporated by reference to Exhibit 10.5 to the registrant’s Quarterly Report on Form 10-Q filed on January 11, 2019).

10.3		Letter Agreement effective January 7, 2019 by and between the registrant and Activa Clinics. (incorporated by reference to Exhibit 10.6 to the registrant’s Quarterly Report on Form 10-Q filed on January 11, 2019).

10.4		Agreement of Transfer and Assignment dated January 8, 2019 by and between the registrant and 2478659 Ontario Ltd. (incorporated by reference to Exhibit 10.7 to the registrant’s Quarterly Report on Form 10-Q filed on January 11, 2019).

10.5		Amendment No. 2 to Share Exchange Agreement dated January 31, 2019 by and between the registrant, Novo Healthnet Limited and CannaPiece Group, Inc. (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed on February 6, 2019).

10.6		Letter of Intent dated February 4, 2019 among the registrant, Novo Healthnet Limited and Pulse Rx Inc. (incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K filed on February 6, 2019).

10.7		Share Purchase and Exchange Agreement dated February 20, 2019 by and among the registrant, Novo Healthnet Limited, Pulse Rx Inc. and the shareholders of Pulse Rx Inc. (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed on February 26, 2019).

10.8		Software License Agreement dated February 26, 2019 by and among Novo Integrated Sciences, Inc., Novo Healthnet Limited and Cloud DX Inc. (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed on March 5, 2019).

10.9		Letter Agreement dated February 27, 2019 by and among Novo Integrated Sciences, Inc., Novo Healthnet Limited and Activa Clinics (incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K filed on March 5, 2019).

10.10		Amendment No. 3, dated February 27, 2019, to Share Exchange Agreement dated December 18, 2018, as amended, by and among Novo Integrated Sciences, Inc., Novo Healthnet Limited and CannaPiece Group Inc. (incorporated by reference to Exhibit 10.3 to the registrant’s Current Report on Form 8-K filed on March 5, 2019).

31.1		Rule 13a-14(a) Certification of Principal Executive Officer.

31.2		Rule 13a-14(a) Certification of Principal Financial Officer.

32.1		Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of Principal Executive Officer and Principal Financial Officer.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase

101.DEF		XBRL Taxonomy Extension Definition Linkbase

101.LAB		XBRL Taxonomy Extension Labels Linkbase

101.PRE		XBRL Taxonomy Extension Presentation Linkbase

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereto duly authorized:

	NOVO INTEGRATED SCIENCES, INC.

Dated: April 11, 2019	By:	/s/ Robert Mattacchione
		Robert Mattacchione
		Chief Executive Officer

	By:	/s/ Klara Radulyne
		Klara Radulyne
		Principal Financial Officer

EX-31.1 2 ex31-1.htm

EXHIBIT 31.1

CERTIFICATIONS

I, Robert Mattacchione, certify that:

1.	I have reviewed this quarterly report on Form 10-Q for the quarter ended February 28, 2019 of Novo Integrated Sciences, Inc.; and

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; and

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; and

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 11, 2019	By:	/s/ Robert Mattacchione
		Robert Mattacchione
		Chief Executive Officer (principal executive officer)

EX-31.2 3 ex31-2.htm

EXHIBIT 31.2

CERTIFICATIONS

I, Klara Radulyne, certify that:

1.	I have reviewed this quarterly report on Form 10-Q for the quarter ended February 28, 2019 of Novo Integrated Sciences, Inc.; and

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; and

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; and

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 11, 2019	By:	/s/ Klara Radulyne
		Klara Radulyne
		Principal Financial Officer

EX-32.1 4 ex32-1.htm

EXHIBIT 32.1

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Novo Integrated Sciences, Inc. (the “Company”) on Form 10-Q for the quarter ended February 28, 2019 as filed with the Securities and Exchange Commission (the “Report”), I, Robert Mattacchione, Chief Executive Officer of the Company, and I, Klara Radulyne, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: April 11, 2019	/s/ Robert Mattacchione
	Robert Mattacchione, Chief Executive Officer (principal executive officer)

	/s/ Klara Radulyne
	Klara Radulyne, Principal Financial Officer (principal financial officer)

This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

EX-101.INS 5 nvos-20190228.xml XBRL INSTANCE FILE 0001138978 2018-09-01 2019-02-28 0001138978 2019-04-08 0001138978 2017-08-31 0001138978 2018-08-31 0001138978 NVOS:TurbineTruckEnginesIncMember 2018-09-01 2019-02-28 0001138978 NVOS:TurbineTruckEnginesIncOneMember 2018-09-01 2019-02-28 0001138978 NVOS:ShareExchangeAgreementMember NVOS:NHLMember 2017-04-23 2017-04-25 0001138978 NVOS:NotesReceivableDatedAprilOneTwoThousandAndFifteenAndMayTwentyThreeTwoThousandSeventeenMember 2019-02-28 0001138978 NVOS:AdvanceToCorporationOneMember 2019-02-28 0001138978 NVOS:AdvanceToCorporationTwoMember 2019-02-28 0001138978 NVOS:NotesReceivableDatedAprilOneTwoThousandAndFifteenAndMayTwentyThreeTwoThousandSeventeenMember 2018-09-01 2019-02-28 0001138978 NVOS:NotesReceivableDatedAprilOneTwoThousandAndFifteenAndMayTwentyThreeTwoThousandSeventeenMember 2017-09-01 2018-08-31 0001138978 us-gaap:LeaseholdImprovementsMember 2018-08-31 0001138978 NVOS:ClinicalEquipmentMember 2018-08-31 0001138978 us-gaap:ComputerEquipmentMember 2018-08-31 0001138978 us-gaap:OfficeEquipmentMember 2018-08-31 0001138978 us-gaap:FurnitureAndFixturesMember 2018-08-31 0001138978 NVOS:NotesPayableMember 2018-08-31 0001138978 NVOS:NotesPayableMember 2018-09-01 2019-02-28 0001138978 NVOS:ExercisePriceRangeOneMember 2019-02-28 0001138978 NVOS:ExercisePriceRangeTwoMember 2019-02-28 0001138978 NVOS:ExercisePriceRangeThreeMember 2019-02-28 0001138978 NVOS:ExercisePriceRangeFourMember 2019-02-28 0001138978 NVOS:ExercisePriceRangeFiveMember 2019-02-28 0001138978 NVOS:NotesPayableMember 2017-09-01 2018-08-31 0001138978 NVOS:FiveDebenturesMember 2013-09-30 0001138978 NVOS:FiveDebenturesMember NVOS:CADMember 2013-09-30 0001138978 NVOS:FiveDebenturesMember 2017-11-29 2017-12-02 0001138978 NVOS:TwoThousandAndFifteenIncentiveCompensationPlanMember srt:MaximumMember 2015-09-07 2015-09-08 0001138978 NVOS:TwoThousandAndFifteenIncentiveCompensationPlanMember 2018-09-01 2019-02-28 0001138978 NVOS:ExercisePriceRangeSixMember 2019-02-28 0001138978 NVOS:PeriodEndMember NVOS:CADMember 2018-08-31 0001138978 NVOS:AveragePeriodMember NVOS:CADMember 2018-08-31 0001138978 NVOS:NotesReceivableDatedAprilOneTwoThousandAndFifteenAndMayTwentyThreeTwoThousandSeventeenMember 2018-08-31 0001138978 NVOS:AdvanceToCorporationOneMember 2018-08-31 0001138978 NVOS:AdvanceToCorporationTwoMember 2018-08-31 0001138978 NVOS:ExercisePriceRangeSevenMember 2019-02-28 0001138978 2018-01-29 2018-01-31 0001138978 2018-01-31 0001138978 NVOS:FiveDebenturesMember 2013-09-29 2013-09-30 0001138978 NVOS:TwoThousandAndEighteenIncentivePlanMember 2018-01-15 2018-01-16 0001138978 NVOS:ExercisePriceRangeEightMember 2019-02-28 0001138978 NVOS:ExercisePriceRangeNineMember 2019-02-28 0001138978 NVOS:DebenturesMember 2018-01-29 2018-01-31 0001138978 NVOS:DebenturesMember 2018-01-31 0001138978 NVOS:TwoThousandAndEighteenIncentivePlanMember 2018-09-01 2019-02-28 0001138978 NVOS:AdvanceToCorporationThreeMember 2018-08-31 0001138978 NVOS:AdvanceToCorporationThreeMember 2019-02-28 0001138978 NVOS:AdvanceToCorporationTwoMember 2017-09-01 2018-08-31 0001138978 NVOS:AdvanceToCorporationTwoMember 2018-09-01 2019-02-28 0001138978 NVOS:AdvanceToCorporationThreeMember 2017-09-01 2018-08-31 0001138978 NVOS:AdvanceToCorporationThreeMember 2018-09-01 2019-02-28 0001138978 2019-02-28 0001138978 2017-09-01 2018-02-28 0001138978 NVOS:PeriodEndMember NVOS:CADMember 2019-02-28 0001138978 NVOS:PeriodEndMember NVOS:CADMember 2018-02-28 0001138978 NVOS:AveragePeriodMember NVOS:CADMember 2019-02-28 0001138978 NVOS:AveragePeriodMember NVOS:CADMember 2018-02-28 0001138978 NVOS:AdvanceToCorporationOneMember 2017-09-01 2018-08-31 0001138978 NVOS:AdvanceToCorporationOneMember 2018-09-01 2019-02-28 0001138978 NVOS:NotesPayableMember 2019-02-28 0001138978 2017-09-01 2018-08-31 0001138978 NVOS:AugustThirtyOneTwoThousandAndNineteenMember 2018-09-01 2019-02-28 0001138978 NVOS:NovoHealthnetKemptvilleCentreIncMember 2019-02-28 0001138978 us-gaap:LeaseholdImprovementsMember 2018-09-01 2019-02-28 0001138978 NVOS:ClinicalEquipmentMember 2018-09-01 2019-02-28 0001138978 us-gaap:ComputerEquipmentMember 2018-09-01 2019-02-28 0001138978 us-gaap:OfficeEquipmentMember 2018-09-01 2019-02-28 0001138978 us-gaap:FurnitureAndFixturesMember 2018-09-01 2019-02-28 0001138978 us-gaap:LeaseholdImprovementsMember 2019-02-28 0001138978 NVOS:ClinicalEquipmentMember 2019-02-28 0001138978 us-gaap:ComputerEquipmentMember 2019-02-28 0001138978 us-gaap:OfficeEquipmentMember 2019-02-28 0001138978 us-gaap:FurnitureAndFixturesMember 2019-02-28 0001138978 NVOS:FiveDebenturesMember 2017-11-30 0001138978 NVOS:ApkaHealthIncMember 2017-08-31 0001138978 NVOS:ExecutiveFitnessLeadersMember 2018-08-31 0001138978 2018-12-01 2019-02-28 0001138978 2017-12-01 2018-02-28 0001138978 2018-02-28 0001138978 NVOS:SoftwareLicenseMember 2018-09-01 2019-02-28 0001138978 NVOS:LandUseRightsMember 2018-09-01 2019-02-28 0001138978 NVOS:AdvanceToCorporationFourMember 2019-02-28 0001138978 NVOS:AdvanceToCorporationFourMember 2018-08-31 0001138978 NVOS:AdvanceToCorporationFourMember 2018-09-01 2019-02-28 0001138978 NVOS:AdvanceToCorporationFourMember 2017-09-01 2018-08-31 0001138978 NVOS:LandUseRightsMember 2019-02-28 0001138978 NVOS:LandUseRightsMember 2018-08-31 0001138978 NVOS:SoftwareLicenseMember 2019-02-28 0001138978 NVOS:SoftwareLicenseMember 2018-08-31 0001138978 NVOS:JointVentureAgreementMember 2018-09-01 2019-02-28 0001138978 NVOS:JointVentureAgreementMember 2019-02-28 0001138978 NVOS:LicensingAgreementMember 2018-09-01 2019-02-28 0001138978 NVOS:LicensingAgreementMember 2019-02-28 0001138978 us-gaap:SubsequentEventMember NVOS:AccreditedInvestorMember 2019-04-02 2019-04-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:CAD Novo Integrated Sciences, Inc. 0001138978 10-Q 2019-02-28 false --08-31 Non-accelerated Filer Q2 223164283

1896572

675705

2373936

1036602

1337545

1378894

161838

163323

400321

427195

4743099

29081072

1307599

1254234

156121

414965

181740

1116261

966102

382350

379800

4570329

4252380

207882

223048

10053683

35047853

1139815

1165795

-11199989

-11570906

4743099

29081072

2748823

2715289

1320740

1307596

1763209

1684367

879670

838323

29239

68740

4016

30601

2057248

2983494

958357

1965080

-294039

-1299127

-78687

-1126757

-85525

-438074

-44293

-303972

-379564

-1737201

-122980

-1430729

-8647

-5356

-3479

-1956

-370917

-1731845

-119501

-1374557

-353584

-1824542

-95215

-1588041

-0.00

-0.01

-0.00

-0.01

211094982

203953457

214281342

206091162

0.001

1000000

0.001

499000000

207881743

223048205

207881743

223048205

46474

32719

-44730

80084

-126470

-43843

26597

303699

22095

-31880

1698231

-859970

50152

250133

75947

43431

7108

2708113

167797406

12000000

458349

116078

-28621

-37098

172770

24828692

201391

24865790

2028009

2914754

954341

1934479

-379564

-1737201

-122980

-1376513

6904

2019

1224000

6402512

3894809

1215837

4968990

604113

600084

379800

220284

69289

128098

The per share price used for the conversion of this loan was $0.4114 which was determined based on the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price.

The per share price used for the conversion of each debenture was $0.4114 which was determined based on the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price.

1112404

1104985

NVOS

2568909

4502887

3346329

3036543

25980

-87341

27765

-211528

813125

1976483

10475872

0.4114

2579923

2541

-30326

142376

263403

-459540

-474933

-301871

-82646

2437547

-270511

Note 1 - Organization and Basis of Presentation   Organization and Line of Business   Novo Integrated Sciences, Inc. (“Novo Integrated”) was incorporated in Delaware on November 27, 2000, under the name Turbine Truck Engines, Inc. On February 20, 2008, the Company was re-domiciled to the State of Nevada. Effective July 12, 2017, the Company’s name was changed to Novo Integrated Sciences, Inc. When used herein, the terms the “Company,” “we,” “us” and “our” refer to Novo Integrated and its consolidated subsidiaries.   Through Novo Healthnet Limited (“NHL”), our wholly owned Canadian subsidiary, we deliver multi-disciplinary primary healthcare to over 400,000 patients annually through our 15 corporate-owned clinics and a contracted network of 97 affiliate clinics and 222 eldercare centric homes located across Canada. Our team of practitioners and staff are trained for assessment, diagnosis, treatment, pain management, rehabilitation and primary prevention. Our specialized services and products include physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, chiropody, neurological functions, kinesiology, concussion management and baseline testing, women’s pelvic health, sports medicine therapy, assistive devices and private personal training. We do not provide primary care medical services, none of our employees practices primary care medicine, and our services do not require a medical or nursing license.   As we continue to build our health science platform of services and products through the integration of technology and rehabilitative science, one component of our lateral business growth strategy includes developing business units centered on the direct control of the grow, extraction, manufacturing and distribution processes for hemp and medical cannabidiol products. Additionally, we continue to expand on our patient care philosophy of maintaining an on-going continuous connection with our patient community, beyond the traditional confines of a clinic, by extending oversight of patient diagnosis, care and monitoring, directly into the patient’s home, through various mobile telemedicine and diagnostic tools.   Since inception and through May 9, 2017, our activities and business operations were limited to raising capital, organizational matters and the implementation of our business plan related to research, development, testing and commercialization of various alternative energy technologies.   On April 25, 2017 (the “Effective Date”), the Company entered into a Share Exchange Agreement (the “Share Exchange Agreement”) by and between (i) the Company; (ii) NHL; (iii) ALMC-ASAP Holdings Inc. (“ALMC”); (iv) Michael Gaynor Family Trust (the “MGFT”); (v) 1218814 Ontario Inc. (“1218814”); and (vi) Michael Gaynor Physiotherapy Professional Corp. (“MGPP,” and together with ALMC, MGFT and 1218814, the “NHL Shareholders”). Pursuant to the terms of the Share Exchange Agreement, the Company agreed to acquire from the NHL Shareholders all of the shares of both common and preferred stock of NHL, held by the NHL Shareholders, in exchange for the issuance by the Company to the NHL Shareholders of shares of the Company’s common stock, such that following the closing of the Share Exchange Agreement, the NHL Shareholders would own 167,797,406 restricted shares of Company common stock, representing 85% of the issued and outstanding Company common stock, calculated including all granted and issued options or warrants to acquire the Company common stock as of the Effective Date, but to exclude shares of Company common stock that are subject to a then-current Regulation S offering that was undertaking by the Company (the “Exchange”).   On May 9, 2017, the Exchange closed and, as a result, NHL became a wholly owned subsidiary of Novo Integrated Sciences, Inc.   The Exchange was accounted for as a reverse acquisition under the purchase method of accounting since NHL obtained control of Novo Integrated Sciences, Inc. Accordingly, the Exchange was recorded as a recapitalization of NHL, with NHL being treated as the continuing entity. The historical financial statements presented are the financial statements of NHL. The Exchange was treated as a recapitalization and not as a business combination; therefore, no pro forma information is disclosed. At the closing date of the Exchange, the net assets of the legal acquirer, Novo Integrated Sciences, Inc., were $6,904.   The unaudited consolidated financial statements are prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The information furnished herein reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management, are necessary to fairly state the Company’s financial position, the results of its operations, and cash flows for the periods presented. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) were omitted pursuant to such rules and regulations. The results of operations for the six months ended February 28, 2019 are not necessarily indicative of the results for the year ending August 31, 2019.   Basis of Presentation   The accompanying consolidated financial statements were prepared in conformity with U.S. GAAP. The Company’s Canadian subsidiaries’ functional currency is the Canadian Dollar (“CAD” or “CAD$”); however, the accompanying consolidated financial statements were translated and presented in United States Dollars (“$” or “USD”).   Foreign Currency Translation   The accounts of the Company’s Canadian subsidiaries are maintained in CAD. The accounts of these subsidiaries are translated into USD in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 830, Foreign Currency Transaction, with the CAD as the functional currency. According to Topic 830, all assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders’ equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220, Comprehensive Income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statement of operations and comprehensive income. The following table details the exchange rates used for the respective periods:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">February 28, 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">February 28, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">August 31, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 107%">Period end: CAD to USD exchange rate</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">0.7596</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">0.7808</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">0.7647</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Average period: CAD to USD exchange rate</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.7578</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.7959</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> </table>

Note 2 – Summary of Significant Accounting Policies   Use of Estimates   The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.   Principles of Consolidation   The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, NHL, Novo Healthnet Rehab Limited, Novo Assessments Inc., and an 80% interest in Novo Healthnet Kemptville Centre, Inc., a Back on Track Physiotherapy and Health Centre clinic operated by NHL. All of the Company’s subsidiaries are incorporated under the laws of the Province of Ontario, Canada. All intercompany transactions have been eliminated.   Noncontrolling Interest   The Company follows FASB ASC Topic 810, Consolidation, which governs the accounting for and reporting of non-controlling interests (“NCIs”) in partially owned consolidated subsidiaries and the loss of control of subsidiaries. Certain provisions of this standard indicate, among other things, that NCIs be treated as a separate component of equity, not as a liability, that increases and decreases in the parent’s ownership interest that leave control intact be treated as equity transactions rather than as step acquisitions or dilution gains or losses, and that losses of a partially owned consolidated subsidiary be allocated to the NCI even when such allocation might result in a deficit balance.   The net income (loss) attributed to the NCI is separately designated in the accompanying consolidated statements of operations and other comprehensive income (loss).   Cash Equivalents   For the purpose of the statement of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less.   Accounts Receivable   Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of February 28, 2019 and August 31, 2018, the allowance for uncollectible accounts receivable was $473,585 and $464,527, respectively.   Property and Equipment   Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 50%; line-height: 107%">Leasehold improvements</td> <td style="width: 47%; line-height: 107%">5 years</td></tr> <tr style="vertical-align: top; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">Clinical equipment</td> <td style="line-height: 107%">5 years</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">Computer equipment</td> <td style="line-height: 107%">3 years</td></tr> <tr style="vertical-align: top; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">Office equipment</td> <td style="line-height: 107%">5 years</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">Furniture and fixtures</td> <td style="line-height: 107%">5 years</td></tr> </table>   Long-Lived Assets   The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at February 28, 2019 and August 31, 2018, the Company believes there was no impairment of its long-lived assets.   Intangible Assets   The Company’s intangible assets consist of land use rights and a software license which will be amortized over 50 and 7 years, respectively. Amortization will begin when the assets are fully placed in service. The Company will perform a test for impairment annually. The land use rights and the software license intangible assets were acquired in January and February, 2019, respectively. Therefore, the first annual impairment test will be performed as of August 31, 2019.   Goodwill   Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under accounting requirements, goodwill is not amortized but is subject to annual impairment tests. At February 28, 2019, the Company recorded goodwill of $379,800 and $220,284, respectively, related to its acquisition of Apka Health, Inc. during the fiscal year ended August 31, 2017 and Executive Fitness Leaders during the fiscal year ended August 31, 2018. As of August 31, 2018, the Company performed the required impairment review. Based on its review, the Company believes there was no impairment of its goodwill.   Acquisition Deposits   The Company has signed letters of understanding with two potential acquisition candidates which include refundable acquisition deposits totaling $1,104,985 and $1,112,404 at February 28, 2019 and August 31, 2018, respectively.   Fair Value of Financial Instruments   For certain of the Company’s financial instruments, including cash and equivalents, restricted cash, accounts receivable, advances to suppliers, accounts payable, accrued liabilities and short-term debt, the carrying amounts approximate their fair values due to their short maturities.   FASB ASC Topic 820, Fair Value Measurements and Disclosures, requires disclosure of the fair value of financial instruments held by the Company. FASB ASC Topic 825, Financial Instruments, defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; line-height: 107%"> </td> <td style="width: 24px; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement.</td></tr> </table>   The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity, and FASB ASC Topic 815, Derivatives and Hedging.   As of February 28, 2019 and August 31, 2018, respectively, the Company did not identify any assets and liabilities required to be presented on the balance sheet at fair value.   Revenue Recognition   Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“Topic 606”), became effective for the Company on March 1, 2018. The Company’s revenue recognition disclosure reflects its updated accounting policies that are affected by this new standard. The Company applied the “modified retrospective” transition method for open contracts for the implementation of Topic 606. As sales are and have been primarily from providing healthcare services, and the Company has no significant post-delivery obligations, this new standard did not result in a material recognition of revenue on the Company’s accompanying consolidated financial statements for the cumulative impact of applying this new standard. The Company made no adjustments to its previously-reported total revenues, as those periods continue to be presented in accordance with its historical accounting practices under Topic 605, Revenue Recognition.   Revenue from providing healthcare services are recognized under Topic 606 in a manner that reasonably reflects the delivery of its services to customers in return for expected consideration and includes the following elements:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; line-height: 107%"> </td> <td style="width: 24px; text-align: justify; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">executed contracts with the Company’s customers that it believes are legally enforceable;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">identification of performance obligations in the respective contract;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">determination of the transaction price for each performance obligation in the respective contract;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">allocation the transaction price to each performance obligation; and</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">recognition of revenue only when the Company satisfies each performance obligation.</td></tr> </table>   These five elements, as applied to healthcare services, the Company’s sole revenue category, is summarized below:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; line-height: 107%"> </td> <td style="width: 24px; text-align: justify; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">Healthcare services - gross service revenue is recorded in the accounting records at the time the service is provided on an accrual basis at the provider’s established rates, regardless of whether the provider expects to collect that amount. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes.</td></tr> </table>   Income Taxes   The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.   Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.   Stock-Based Compensation   The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation. FASB ASC Topic 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the requisite service period. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.   Basic and Diluted Earnings Per Share   Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share. Basic earnings per share (“EPS”) is based on the weighted average number of common shares outstanding. Diluted EPS assumes that all dilutive securities are converted. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. There were 10,095,000 options/warrants outstanding as of February 28, 2019. Due to the net loss incurred, potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss for all periods presented.   Foreign Currency Transactions and Comprehensive Income   U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the CAD. Translation gains of $1,165,795 and $1,139,815 at February 28, 2019 and August 31, 2018, respectively, are classified as an item of other comprehensive income in the stockholders’ equity section of the balance sheet.   Statement of Cash Flows   Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets.   Recent Accounting Pronouncements   In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory, which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. ASU 2016-16 is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. The Company is in the process of evaluating the impact of this ASU on its financial statements.   In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and interim periods in fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is in the process of evaluating the impact of this ASU on its financial statements.   In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company adopted this ASU beginning on March 1, 2018 and used the modified retrospective method of adoption. The adoption of this ASU did not have a material impact on the Company’s financial statements and disclosures.   Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Note 3 – Related Party Transactions   Due to related parties   Amounts loaned to the Company by stockholders and officers of the Company are non-interest bearing and payable upon demand. At February 28, 2019 and August 31, 2018, the amount due to related parties was $966,102 and $1,116,261, respectively.   On January 31, 2018, a related party converted $813,125 of outstanding principal and accrued interest into 1,976,483 shares of the Company’s common stock. The per share price used for the conversion of this loan was $0.4114 which was determined based on the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price.

Note 5 – Other Receivables   Other receivables at February 28, 2019 and August 31, 2018 consisted of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">February 28, 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">August 31, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%">Notes receivable dated April 1, 2015 and amended on May 23, 2017; accrued interest at 8% per annum; secured by certain assets; due March 1, 2019</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">284,849</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 17%; text-align: right; line-height: 107%">286,763</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Advance to corporation; non-interest bearing; unsecured; due no later than November 18, 2020</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">30,384</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">30,588</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Advance to corporation; accrues interest at 12% per annum; unsecured; due September 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">75,960</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">76,470</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Advance to corporation; accrues interest at 10% per annum; unsecured; due May 1, 2022</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">56,970</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">57,352</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Advance to corporation; accrues interest at 10% per annum after the first 60 days; unsecured; due February 7, 2020</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">225,924</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Total other receivables</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">674,087</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">451,173</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Current portion</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(586,733</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(393,821</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Long-term portion</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">87,354</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">57,352</td> <td style="line-height: 107%"> </td></tr> </table>

Note 6 – Property and Equipment   Property and equipment at February 28, 2019 and August 31, 2018 consisted of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">February 28, 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">August 31, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%">Leasehold Improvements</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">433,756</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 17%; text-align: right; line-height: 107%">372,010</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Clinical equipment</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">276,954</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">269,741</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Computer equipment</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">22,485</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">22,636</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Office equipment</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">27,382</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">24,658</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Furniture and fixtures</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">39,356</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">39,620</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">799,933</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">728,665</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Accumulated depreciation</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(372,738</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(328,344</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">427,195</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">400,321</td> <td style="line-height: 107%"> </td></tr> </table>   Depreciation expense for the six months ended February 28, 2019 and 2018 was $46,474 and $32,719, respectively.

Note 9 – Notes Payable   Notes payable at February 28, 2019 and August 31, 2018 consisted of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">February 28, 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">August 31, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%">Notes payable issued in connection with purchase of assets; accrues interest at 0% per annum; due on March 27, 2019.</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">379,800</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 17%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">382,350</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">379,800</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">382,350</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Current portion</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(379,800</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(382,350</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Long-term portion</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>

Note 10 – Debentures, related parties   On September 30, 2013, the Company issued five debentures totaling CAD$6,402,512 ($4,968,990 at November 30, 2017) in connection with the acquisition of certain business assets. The holders of the debentures are current stockholders, officers and/or affiliates of the Company. The debentures are secured by all the assets of the Company, accrue interest at 8% per annum and were originally due on September 30, 2016. On December 2, 2017, the debenture holders agreed to extend the due date to September 30, 2019.   On January 31, 2018, the debenture holders converted 75% of the debenture value of $3,894,809 plus accrued interest of $414,965 into 10,475,872 shares of the Company’s common stock. The per share price used for the conversion of each debenture was $0.4114 which was determined based on the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price. At February 28, 2019, the amount of debentures outstanding was $1,215,837.

Note 11 – Stockholders’ Deficit   Convertible preferred stock   The Company has authorized 1,000,000 shares of $0.001 par value convertible preferred stock. At February 28, 2019 and August 31, 2018 there were 0 and 0 convertible preferred shares issued and outstanding, respectively.   Common stock   The Company has authorized 499,000,000 shares of $0.001 par value common stock. At February 28, 2019 and August 31, 2018 there were 223,048,205 and 207,881,743 common shares issued and outstanding, respectively.   During the six months ended February 28, 2019, the Company issued:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; line-height: 107%"> </td> <td style="width: 24px; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">2,708,113 restricted shares of common stock for cash proceeds of $2,579,923</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">12,000,000 restricted shares of common stock as consideration for the Assignment, to the Company, of a Joint Venture Agreement with a value of $21,600,000 based on the closing share price of $1.80 on the execution date of the Closing Certificate</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">458,349 restricted shares of common stock as consideration for a Licensing Agreement based on a per share price of $1.655 with a value of $758,567.</td></tr> </table>   Stock options/warrants   On September 8, 2015, the Company adopted the 2015 Incentive Compensation Plan (the “2015 Plan”), which authorizes the issuance of up to 5,000,000 shares of common stock to employees, officers, directors or independent consultants of the Company, provided that no person can be granted shares under the 2015 Plan for services related to raising capital or promotional activities. As of February 28, 2019, 4,987,500 shares were available under the 2015 Plan for future grants, awards, options or share issuances. However, because the shares issuable under the 2015 Plan or issuable upon conversion of awards granted under the 2015 Plan are no longer registered under the Securities Exchange Act of 1934, as amended, the Company does not intend to issue any additional grants under the 2015 Plan.   On January 16, 2018, the Company adopted the Novo Integrated Sciences, Inc. 2018 Incentive Plan (the “2018 Plan”). Under the 2018 Plan, 10,000,000 shares of common stock are authorized for issuance to employees, non-employees, directors and key consultants to the Company or its subsidiaries. The 2018 Plan authorizes equity-based and cash-based incentives for participants. There were 9,875,000 shares available for award at February 28, 2019 under the 2018 Plan.   The following is a summary of stock option/warrant activity:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Options/</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Remaining</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Aggregate</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Warrants</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Exercise</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Contractual</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Intrinsic</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Outstanding</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Price</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Life</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Value</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 47%; line-height: 107%">Outstanding, August 31, 2018</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">10,030,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">0.30</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 9%; text-align: right; line-height: 107%">4.56</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 9%; text-align: right; line-height: 107%">7,045,500</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">75,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.95</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Forfeited</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(10,000</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2.00</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding, February 28, 2019</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">10,095,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.30</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">4.08</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">13,106,250</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercisable, February 28, 2019</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">10,095,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.30</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">4.08</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">13,106,250</td> <td style="line-height: 107%"> </td></tr> </table>   The exercise price for options/warrants outstanding at February 28, 2019:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Outstanding and Exercisable</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">Number of</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">Options/</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">Exercise</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Warrants</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Price</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 48%; text-align: right; line-height: 107%">5,500,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 46%; text-align: right; line-height: 107%">0.16</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,000,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.32</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">50,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.33</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">120,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.40</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,000,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.42</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">100,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.50</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,000,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.62</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">250,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.80</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">75,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.95</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">10,095,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> </table>   For options granted during the fiscal year ending August 31, 2019 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $0.94 and the weighted-average exercise price of such options/warrants was $0.95. No options were granted during the fiscal year ending August 31, 2019 where the exercise price was less than the stock price at the date of grant or the exercise price was greater than the stock price at the date of grant.   For options granted during the fiscal year ended August 31, 2018 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $0.39 and the weighted-average exercise price of such options/warrants was $0.40. No options were granted during the fiscal year ended August 31, 2018 where the exercise price was less than the stock price at the date of grant or the exercise price was greater than the stock price at the date of grant.   The fair value of the stock options is being amortized to stock option expense over the vesting period. The Company recorded stock option expense of $70,846 and $1,109,416 during the six months ended February 28, 2019 and 2018, respectively. At February 28, 2019, the unamortized stock option expense was $0.   The assumptions used in calculating the fair value of options granted during the current fiscal year ending August 31, 2019 using the Black-Scholes option-pricing model for options granted, through February 28, 2019, are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 80%; line-height: 107%">Risk-free interest rate</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 17%; text-align: right; line-height: 107%">2.78</td> <td style="width: 1%; line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected life of the options</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3.5 years</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">294</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected dividend yield</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0</td> <td style="line-height: 107%">%</td></tr> </table>

Note 12 – Commitments and Contingencies   Litigation   The Company is party to certain legal proceedings from time to time incidental to the conduct of its business. These proceedings could result in fines, penalties, compensatory or treble damages or non-monetary relief. The nature of legal proceedings is such that the Company cannot assure the outcome of any particular matter, and an unfavorable ruling or development could have a materially adverse effect on our consolidated financial position, results of operations and cash flows in the period in which a ruling or settlement occurs. However, based on information available to the Company’s management to date, the Company’s management does not expect that the outcome of any matter pending against the Company is likely to have a materially adverse effect on the Company’s consolidated financial position as of February 28, 2019, results of operations, cash flows or liquidity of the Company.   Leases   The Company leases its office space and certain facilities under long-term operating leases expiring through fiscal year 2023. Rent expense under these leases was $498,237 and $409,350 for the six months ended February 28, 2019 and 2018, respectively.

Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 50%; line-height: 107%">Leasehold improvements</td> <td style="width: 47%; line-height: 107%">5 years</td></tr> <tr style="vertical-align: top; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">Clinical equipment</td> <td style="line-height: 107%">5 years</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">Computer equipment</td> <td style="line-height: 107%">3 years</td></tr> <tr style="vertical-align: top; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">Office equipment</td> <td style="line-height: 107%">5 years</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">Furniture and fixtures</td> <td style="line-height: 107%">5 years</td></tr></table> Other receivables at February 28, 2019 and August 31, 2018 consisted of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">February 28, 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">August 31, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%">Notes receivable dated April 1, 2015 and amended on May 23, 2017; accrued interest at 8% per annum; secured by certain assets; due March 1, 2019</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">284,849</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 17%; text-align: right; line-height: 107%">286,763</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Advance to corporation; non-interest bearing; unsecured; due no later than November 18, 2020</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">30,384</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">30,588</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Advance to corporation; accrues interest at 12% per annum; unsecured; due September 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">75,960</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">76,470</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Advance to corporation; accrues interest at 10% per annum; unsecured; due May 1, 2022</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">56,970</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">57,352</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Advance to corporation; accrues interest at 10% per annum after the first 60 days; unsecured; due February 7, 2020</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">225,924</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Total other receivables</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">674,087</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">451,173</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Current portion</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(586,733</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(393,821</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Long-term portion</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">87,354</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">57,352</td> <td style="line-height: 107%"> </td></tr> </table>

Property and equipment at February 28, 2019 and August 31, 2018 consisted of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">February 28, 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">August 31, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%">Leasehold Improvements</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">433,756</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 17%; text-align: right; line-height: 107%">372,010</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Clinical equipment</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">276,954</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">269,741</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Computer equipment</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">22,485</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">22,636</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Office equipment</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">27,382</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">24,658</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Furniture and fixtures</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">39,356</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">39,620</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">799,933</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">728,665</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Accumulated depreciation</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(372,738</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(328,344</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">427,195</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">400,321</td> <td style="line-height: 107%"> </td></tr> </table>

Notes payable at February 28, 2019 and August 31, 2018 consisted of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">February 28, 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">August 31, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%">Notes payable issued in connection with purchase of assets; accrues interest at 0% per annum; due on March 27, 2019.</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">379,800</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="width: 17%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">382,350</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">379,800</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">382,350</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Current portion</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(379,800</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(382,350</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Long-term portion</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>

The following is a summary of stock option/warrant activity:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Options/</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Remaining</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Aggregate</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Warrants</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Exercise</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Contractual</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Intrinsic</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Outstanding</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Price</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Life</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Value</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 47%; line-height: 107%">Outstanding, August 31, 2018</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">10,030,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">0.30</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 9%; text-align: right; line-height: 107%">4.56</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 9%; text-align: right; line-height: 107%">7,045,500</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">75,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.95</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Forfeited</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(10,000</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2.00</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding, February 28, 2019</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">10,095,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.30</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">4.08</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">13,106,250</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercisable, February 28, 2019</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">10,095,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.30</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">4.08</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">13,106,250</td> <td style="line-height: 107%"> </td></tr> </table>

The exercise price for options/warrants outstanding at February 28, 2019:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="7" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Outstanding and Exercisable</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">Number of</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">Options/</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">Exercise</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Warrants</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Price</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 48%; text-align: right; line-height: 107%">5,500,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 46%; text-align: right; line-height: 107%">0.16</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,000,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.32</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">50,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.33</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">120,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.40</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,000,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.42</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">100,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.50</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,000,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.62</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">250,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.80</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">75,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0.95</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">10,095,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> </table>

The assumptions used in calculating the fair value of options granted during the current fiscal year ending August 31, 2019 using the Black-Scholes option-pricing model for options granted, through February 28, 2019, are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 80%; line-height: 107%">Risk-free interest rate</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 17%; text-align: right; line-height: 107%">2.78</td> <td style="width: 1%; line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected life of the options</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3.5 years</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">294</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected dividend yield</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">0</td> <td style="line-height: 107%">%</td></tr> </table>

Use of Estimates   The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

Principles of Consolidation   The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, NHL, Novo Healthnet Rehab Limited, Novo Assessments Inc., and an 80% interest in Novo Healthnet Kemptville Centre, Inc., a Back on Track Physiotherapy and Health Centre clinic operated by NHL. All of the Company’s subsidiaries are incorporated under the laws of the Province of Ontario, Canada. All intercompany transactions have been eliminated.

Noncontrolling Interest   The Company follows FASB ASC Topic 810, Consolidation, which governs the accounting for and reporting of non-controlling interests (“NCIs”) in partially owned consolidated subsidiaries and the loss of control of subsidiaries. Certain provisions of this standard indicate, among other things, that NCIs be treated as a separate component of equity, not as a liability, that increases and decreases in the parent’s ownership interest that leave control intact be treated as equity transactions rather than as step acquisitions or dilution gains or losses, and that losses of a partially owned consolidated subsidiary be allocated to the NCI even when such allocation might result in a deficit balance.   The net income (loss) attributed to the NCI is separately designated in the accompanying consolidated statements of operations and other comprehensive income (loss).

Cash Equivalents   For the purpose of the statement of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less.

Accounts Receivable   Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of February 28, 2019 and August 31, 2018, the allowance for uncollectible accounts receivable was $473,585 and $464,527, respectively.

Property and Equipment   Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 50%; line-height: 107%">Leasehold improvements</td> <td style="width: 47%; line-height: 107%">5 years</td></tr> <tr style="vertical-align: top; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">Clinical equipment</td> <td style="line-height: 107%">5 years</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">Computer equipment</td> <td style="line-height: 107%">3 years</td></tr> <tr style="vertical-align: top; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">Office equipment</td> <td style="line-height: 107%">5 years</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">Furniture and fixtures</td> <td style="line-height: 107%">5 years</td></tr> </table>

Long-Lived Assets   The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at February 28, 2019 and August 31, 2018, the Company believes there was no impairment of its long-lived assets.

Goodwill   Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under accounting requirements, goodwill is not amortized but is subject to annual impairment tests. At February 28, 2019, the Company recorded goodwill of $379,800 and $220,284, respectively, related to its acquisition of Apka Health, Inc. during the fiscal year ended August 31, 2017 and Executive Fitness Leaders during the fiscal year ended August 31, 2018. As of August 31, 2018, the Company performed the required impairment review. Based on its review, the Company believes there was no impairment of its goodwill.

Acquisition Deposits   The Company has signed letters of understanding with two potential acquisition candidates which include refundable acquisition deposits totaling $1,104,985 and $1,112,404 at February 28, 2019 and August 31, 2018, respectively.

Fair Value of Financial Instruments   For certain of the Company’s financial instruments, including cash and equivalents, restricted cash, accounts receivable, advances to suppliers, accounts payable, accrued liabilities and short-term debt, the carrying amounts approximate their fair values due to their short maturities.   FASB ASC Topic 820, Fair Value Measurements and Disclosures, requires disclosure of the fair value of financial instruments held by the Company. FASB ASC Topic 825, Financial Instruments, defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; line-height: 107%"> </td> <td style="width: 24px; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement.</td></tr> </table>   The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity, and FASB ASC Topic 815, Derivatives and Hedging.   As of February 28, 2019 and August 31, 2018, respectively, the Company did not identify any assets and liabilities required to be presented on the balance sheet at fair value.

Income Taxes   The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.   Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.

Basic and Diluted Earnings Per Share   Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share. Basic earnings per share (“EPS”) is based on the weighted average number of common shares outstanding. Diluted EPS assumes that all dilutive securities are converted. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. There were 10,095,000 options/warrants outstanding as of February 28, 2019. Due to the net loss incurred, potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss for all periods presented.

Foreign Currency Transactions and Comprehensive Income   U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the CAD. Translation gains of $1,165,795 and $1,139,815 at February 28, 2019 and August 31, 2018, respectively, are classified as an item of other comprehensive income in the stockholders’ equity section of the balance sheet.

Statement of Cash Flows   Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets.

Recent Accounting Pronouncements   In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory, which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. ASU 2016-16 is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. The Company is in the process of evaluating the impact of this ASU on its financial statements.   In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and interim periods in fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is in the process of evaluating the impact of this ASU on its financial statements.   In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company adopted this ASU beginning on March 1, 2018 and used the modified retrospective method of adoption. The adoption of this ASU did not have a material impact on the Company’s financial statements and disclosures.   Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

true false false

451173

284849

30384

75960

286763

30588

76470

57352

56970

674087

225924

Note 4 – Accounts Receivables, net   Accounts receivables, net at February 28, 2019 and August 31, 2018 consisted of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">February 28, 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">August 31, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%">Trade receivables</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">1,610,117</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 17%; text-align: right; line-height: 107%">1,564,180</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Amounts earned but not billed</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">242,362</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">237,892</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,852,479</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,802,072</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Allowance for doubtful accounts</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(473,585</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(464,527</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Accounts receivable, net</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,378,894</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,337,545</td> <td style="line-height: 107%"> </td></tr> </table>

Note 8 – Accrued Expenses   Accrued expenses at February 28, 2019 and August 31, 2018 consisted of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">February 28, 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">August 31, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%">Accrued liabilities</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">131,422</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 17%; text-align: right; line-height: 107%">266,123</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Accrued payroll</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">89,637</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">106,761</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Other</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">33,608</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">11,114</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">254,667</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">383,998</td> <td style="line-height: 107%"> </td></tr> </table>

Note 13 – Subsequent Events   On April 3, 2019, the Company sold 116,078 restricted shares of common stock to an accredited investor for a purchase price of $149,740.

Accounts receivables, net at February 28, 2019 and August 31, 2018 consisted of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">February 28, 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">August 31, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%">Trade receivables</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">1,610,117</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 17%; text-align: right; line-height: 107%">1,564,180</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Amounts earned but not billed</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">242,362</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">237,892</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,852,479</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,802,072</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Allowance for doubtful accounts</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(473,585</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(464,527</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Accounts receivable, net</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,378,894</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,337,545</td> <td style="line-height: 107%"> </td></tr> </table>

Accrued expenses at February 28, 2019 and August 31, 2018 consisted of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">February 28, 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">August 31, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%">Accrued liabilities</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">131,422</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 17%; text-align: right; line-height: 107%">266,123</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Accrued payroll</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">89,637</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">106,761</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Other</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">33,608</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">11,114</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">254,667</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">383,998</td> <td style="line-height: 107%"> </td></tr> </table>

Delaware State of Nevada 2000-11-27 2008-02-20 0.85

0.80

57352

87354

0.08

0.12

0.10

2019-03-01

2019-09-30

2022-05-01

2020-11-18

2020-02-07

382350

379800

0.00

2019-03-27

2016-09-30

383998

254667

4512032

4399656

2200410

2145919

The following table details the exchange rates used for the respective periods:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">February 28, 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">February 28, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">August 31, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 107%">Period end: CAD to USD exchange rate</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">0.7596</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">0.7808</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">0.7647</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Average period: CAD to USD exchange rate</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.7578</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.7959</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> </table>

0.7647

0.7596

0.7808

0.7578

0.7959

-54216

464527

473585

10095000

P5Y

P3Y

P5Y

1564180 1610117

237892

242362

1802072

1852479

728665

372010

269741

22636

24658

39620

799933

433756

276954

22485

27382

39356

328344

372738

266123

131422

106761

89637

11114

33608

Stock-Based Compensation   The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation. FASB ASC Topic 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the requisite service period. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.

9383

211

4294

160

94908

438285

48587

304132

225924

39215

22358567

Note 7 – Intangible Assets   Intangible assets at February 28, 2019 and August 31, 2018 consisted of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">February 28, 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">August 31, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%">Land use rights</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">21,600,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 17%; text-align: right; line-height: 107%">        -</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Software license</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">758,567</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">22,358,567</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Accumulated amortization</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">22,358,567</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>   There was no amortization expense during the six months ended February 28, 2019 and 2018.

Intangible assets at February 28, 2019 and August 31, 2018 consisted of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">February 28, 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">August 31, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%">Land use rights</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">21,600,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 17%; text-align: right; line-height: 107%">        -</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Software license</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">758,567</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">22,358,567</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Accumulated amortization</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">22,358,567</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>

P7Y

P50Y

22358567

21600000

758567

393821

586734

0.08

2019-09-30

0.75

2579923

21600000

758567

149740

1.655

1.80

1.655

5000000

10000000

4987500

9875000

0.39

0.94

0.40

0.95

70846

1109416

10030000

10095000

75000

10000

10095000

0.30

0.95

2.00

0.30

P4Y6M21D

P4Y29D

7045500

13106250

5500000

1000000

50000

120000

2000000

100000

1000000

250000

75000

10095000

0.16

0.32

0.33

0.40

0.42

0.50

0.62

0.80

0.95

5500000

1000000

50000

120000

2000000

100000

1000000

250000

75000

10095000

0.16

0.32

0.33

0.40

0.42

0.50

0.62

0.80

0.95

0.0278

P3Y6M

2.94

0.00

2023

498237

409350

70846

1109416

Revenue Recognition   Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“Topic 606”), became effective for the Company on March 1, 2018. The Company’s revenue recognition disclosure reflects its updated accounting policies that are affected by this new standard. The Company applied the “modified retrospective” transition method for open contracts for the implementation of Topic 606. As sales are and have been primarily from providing healthcare services, and the Company has no significant post-delivery obligations, this new standard did not result in a material recognition of revenue on the Company’s accompanying consolidated financial statements for the cumulative impact of applying this new standard. The Company made no adjustments to its previously-reported total revenues, as those periods continue to be presented in accordance with its historical accounting practices under Topic 605, Revenue Recognition.   Revenue from providing healthcare services are recognized under Topic 606 in a manner that reasonably reflects the delivery of its services to customers in return for expected consideration and includes the following elements:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; line-height: 107%"> </td> <td style="width: 24px; text-align: justify; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">executed contracts with the Company’s customers that it believes are legally enforceable;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">identification of performance obligations in the respective contract;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">determination of the transaction price for each performance obligation in the respective contract;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">allocation the transaction price to each performance obligation; and</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">recognition of revenue only when the Company satisfies each performance obligation.</td></tr> </table>   These five elements, as applied to healthcare services, the Company’s sole revenue category, is summarized below:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; line-height: 107%"> </td> <td style="width: 24px; text-align: justify; line-height: 107%">●</td> <td style="text-align: justify; line-height: 107%">Healthcare services - gross service revenue is recorded in the accounting records at the time the service is provided on an accrual basis at the provider’s established rates, regardless of whether the provider expects to collect that amount. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes.</td></tr> </table>

Intangible Assets   The Company’s intangible assets consist of land use rights and a software license which will be amortized over 50 and 7 years, respectively. Amortization will begin when the assets are fully placed in service. The Company will perform a test for impairment annually. The land use rights and the software license intangible assets were acquired in January and February, 2019, respectively. Therefore, the first annual impairment test will be performed as of August 31, 2019.

EX-101.SCH 6 nvos-20190228.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Organization and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Accounts Receivables, Net link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Other Receivables link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Debentures, Related Parties link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Organization and Basis of Presentation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Accounts Receivables, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Other Receivables (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Stockholders' Deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Organization and Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Organization and Basis of Presentation - Schedule of Foreign Currency Translation, Exchange Rate Used (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Accounts Receivables, Net - Schedule of Accounts Receivables, Net (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Other Receivables - Schedule of Other Receivables (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Other Receivables - Schedule of Other Receivables (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Debentures, Related Parties (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Stockholders' Deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Stockholders' Deficit - Schedule of Stock Option and Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Stockholders' Deficit - Schedule of Options and Warrants Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Stockholders' Deficit - Schedule of Fair Value of Options Granted by Using Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 nvos-20190228_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 nvos-20190228_def.xml XBRL DEFINITION FILE EX-101.LAB 9 nvos-20190228_lab.xml XBRL LABEL FILE Legal Entity [Axis] Turbine Truck Engines, Inc [Member] Turbine Truck Engines, Inc One [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Share Exchange Agreement [Member] NHL [Member] Receivable Type [Axis] Notes Receivable Dated April 1, 2015 and May 23, 2017 [Member] Advance to Corporation One [Member] Advance to Corporation Two [Member] Property, Plant and Equipment, Type [Axis] Leasehold Improvements [Member] Clinical Equipment [Member] Computer Equipment [Member] Office Equipment [Member] Furniture and Fixtures [Member] Debt Instrument [Axis] Notes Payable [Member] Exercise Price Range [Axis] Exercise Price Range One [Member] Exercise Price Range Two [Member] Exercise Price Range Three [Member] Exercise Price Range Four [Member] Exercise Price Range Five [Member] Five Debentures [Member] Award Type [Axis] CAD [Member] Plan Name [Axis] 2015 Incentive Compensation Plan [Member] Range [Axis] Maximum [Member] Exercise Price Range Six [Member] Award Date [Axis] Period End [Member] Average Period [Member] Exercise Price Range Seven [Member] 2018 Incentiven Plan [Member] Exercise Price Range Eight [Member] Exercise Price Range Nine [Member] Debentures [Member] Advance to Corporation Three [Member] August 31, 2019 [Member] Novo Healthnet Kemptville Centre, Inc. [Member] Business Acquisition [Axis] Apka Health, Inc. [Member] Executive Fitness Leaders [Member] Finite-Lived Intangible Assets by Major Class [Axis] Software License [Member] Land Use Rights [Member] Advance to Corporation Four [Member] Joint Venture Agreement [Member] Licensing Agreement [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Title of Individual [Axis] Accredited Investor [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Ex Transition Period Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets: Cash and cash equivalents Accounts receivable, net Other receivables, current portion Prepaid expenses and other current assets Total current assets Property and equipment, net Intangible assets Other receivables, net of current portion Acquisition deposits Goodwill TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable Accrued expenses Accrued interest (principally to related parties) Due to related parties Notes payable, current portion Total current liabilities Debentures, related parties TOTAL LIABILITIES Commitments and contingencies STOCKHOLDERS' EQUITY Novo Integrated Sciences, Inc. Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at February 28, 2019 and August 31, 2018 Common stock; $0.001par value; 499,000,000 shares authorized; 223,048,205 and 207,881,743 shares issued and outstanding at February 28, 2019 and August 31, 2018 Additional paid-in capital Other comprehensive income Accumulated deficit Total Novo Integrated Sciences, Inc. stockholders' equity Noncontrolling interest Total stockholders' equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Convertible preferred stock, par value Convertible preferred stock, shares authorized Convertible preferred stock, shares issued Convertible preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Cost of revenues Gross profit Operating expenses: Selling expenses General and administrative expenses Total operating expenses Loss from operations Non operating income (expense) Interest income Interest expense Total other income (expense) Loss before income taxes Income tax expense Net loss Net loss attributed to noncontrolling interest Net loss attributed to Novo Integrated Sciences, Inc. Comprehensive loss: Net loss Foreign currency translation gain (loss) Comprehensive loss Weighted average common shares outstanding - basic and diluted Net loss per common share - basic and diluted Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Fair value of vested stock options Changes in operating assets and liabilities: Accounts receivable Prepaid expenses and other current assets Accounts payable Accrued expenses Accrued interest Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of furniture and equipment Amounts loaned for other receivables Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Repayments to related parties Proceeds from the sale of common stock Payments on notes payable Net cash provided by (used in) financing activities Effect of exchange rate changes on cash and cash equivalents NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS, END OF PERIOD CASH PAID FOR: Interest Income taxes SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES: Common stock issued for intangible assets Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Basis of Presentation Accounting Policies [Abstract] Summary of Significant Accounting Policies Related Party Transactions [Abstract] Related Party Transactions Receivables [Abstract] Accounts Receivables, Net Other Receivables Property, Plant and Equipment [Abstract] Property and Equipment Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Payables and Accruals [Abstract] Accrued Expenses Debt Disclosure [Abstract] Notes Payable Debentures, Related Parties Equity [Abstract] Stockholders' Deficit Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] EX-101.PRE 10 nvos-20190228_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Feb. 28, 2019	Apr. 08, 2019
Document And Entity Information
Entity Registrant Name	Novo Integrated Sciences, Inc.
Entity Central Index Key	0001138978
Document Type	10-Q
Document Period End Date	Feb. 28, 2019
Amendment Flag	false
Current Fiscal Year End Date	--08-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		223,164,283
Trading Symbol	NVOS
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Feb. 28, 2019	Aug. 31, 2018
Current Assets:
Cash and cash equivalents	$ 2,373,936	$ 675,705
Accounts receivable, net	1,378,894	1,337,545
Other receivables, current portion	586,734	393,821
Prepaid expenses and other current assets	163,323	161,838
Total current assets	4,502,887	2,568,909
Property and equipment, net	427,195	400,321
Intangible assets	22,358,567
Other receivables, net of current portion	87,354	57,352
Acquisition deposits	1,104,985	1,112,404
Goodwill	600,084	604,113
TOTAL ASSETS	29,081,072	4,743,099
Current Liabilities:
Accounts payable	1,254,234	1,307,599
Accrued expenses	254,667	383,998
Accrued interest (principally to related parties)	181,740	156,121
Due to related parties	966,102	1,116,261
Notes payable, current portion	379,800	382,350
Total current liabilities	3,036,543	3,346,329
Debentures, related parties	1,215,837	1,224,000
TOTAL LIABILITIES	4,252,380	4,570,329
Commitments and contingencies
Novo Integrated Sciences, Inc.
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at February 28, 2019 and August 31, 2018
Common stock; $0.001par value; 499,000,000 shares authorized; 223,048,205 and 207,881,743 shares issued and outstanding at February 28, 2019 and August 31, 2018	223,048	207,882
Additional paid-in capital	35,047,853	10,053,683
Other comprehensive income	1,165,795	1,139,815
Accumulated deficit	(11,570,906)	(11,199,989)
Total Novo Integrated Sciences, Inc. stockholders' equity	24,865,790	201,391
Noncontrolling interest	(37,098)	(28,621)
Total stockholders' equity	24,828,692	172,770
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 29,081,072	$ 4,743,099

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Feb. 28, 2019	Aug. 31, 2018
Statement of Financial Position [Abstract]
Convertible preferred stock, par value	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	1,000,000	1,000,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	499,000,000	499,000,000
Common stock, shares issued	223,048,205	207,881,743
Common stock, shares outstanding	223,048,205	207,881,743

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Feb. 28, 2019	Feb. 28, 2018	Feb. 28, 2019	Feb. 28, 2018
Income Statement [Abstract]
Revenues	$ 2,200,410	$ 2,145,919	$ 4,512,032	$ 4,399,656
Cost of revenues	1,320,740	1,307,596	2,748,823	2,715,289
Gross profit	879,670	838,323	1,763,209	1,684,367
Operating expenses:
Selling expenses	4,016	30,601	29,239	68,740
General and administrative expenses	954,341	1,934,479	2,028,009	2,914,754
Total operating expenses	958,357	1,965,080	2,057,248	2,983,494
Loss from operations	(78,687)	(1,126,757)	(294,039)	(1,299,127)
Non operating income (expense)
Interest income	4,294	160	9,383	211
Interest expense	(48,587)	(304,132)	(94,908)	(438,285)
Total other income (expense)	(44,293)	(303,972)	(85,525)	(438,074)
Loss before income taxes	(122,980)	(1,430,729)	(379,564)	(1,737,201)
Income tax expense		(54,216)
Net loss	(122,980)	(1,376,513)	(379,564)	(1,737,201)
Net loss attributed to noncontrolling interest	(3,479)	(1,956)	(8,647)	(5,356)
Net loss attributed to Novo Integrated Sciences, Inc.	(119,501)	(1,374,557)	(370,917)	(1,731,845)
Comprehensive loss:
Net loss	(122,980)	(1,376,513)	(379,564)	(1,737,201)
Foreign currency translation gain (loss)	27,765	(211,528)	25,980	(87,341)
Comprehensive loss	$ (95,215)	$ (1,588,041)	$ (353,584)	$ (1,824,542)
Weighted average common shares outstanding - basic and diluted	214,281,342	206,091,162	211,094,982	203,953,457
Net loss per common share - basic and diluted	$ (0.00)	$ (0.01)	$ (0.00)	$ (0.01)

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Feb. 28, 2019	Feb. 28, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (379,564)	$ (1,737,201)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	46,474	32,719
Fair value of vested stock options	70,846	1,109,416
Changes in operating assets and liabilities:
Accounts receivable	(50,152)	(250,133)
Prepaid expenses and other current assets	(2,541)	30,326
Accounts payable	(44,730)	80,084
Accrued expenses	(126,470)	(43,843)
Accrued interest	26,597	303,699
Net cash used in operating activities	(459,540)	(474,933)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of furniture and equipment	(75,947)	(43,431)
Amounts loaned for other receivables	(225,924)	(39,215)
Net cash used in investing activities	(301,871)	(82,646)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments to related parties	(142,376)	(263,403)
Proceeds from the sale of common stock	2,579,923
Payments on notes payable		(7,108)
Net cash provided by (used in) financing activities	2,437,547	(270,511)
Effect of exchange rate changes on cash and cash equivalents	22,095	(31,880)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	1,698,231	(859,970)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	675,705	1,896,572
CASH AND CASH EQUIVALENTS, END OF PERIOD	2,373,936	1,036,602
CASH PAID FOR:
Interest	69,289	128,098
Income taxes
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Common stock issued for intangible assets	$ 22,358,567

XML 16 R6.htm IDEA: XBRL DOCUMENT

Organization and Basis of Presentation

6 Months Ended

Feb. 28, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Basis of Presentation

Note 1 - Organization and Basis of Presentation

Organization and Line of Business

On May 9, 2017, the Exchange closed and, as a result, NHL became a wholly owned subsidiary of Novo Integrated Sciences, Inc.

Basis of Presentation

Foreign Currency Translation

	February 28, 2019		February 28, 2018		August 31, 2018
Period end: CAD to USD exchange rate	$	0.7596	$	0.7808	$	0.7647
Average period: CAD to USD exchange rate	$	0.7578	$	0.7959

XML 17 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Feb. 28, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

Use of Estimates

Principles of Consolidation

Noncontrolling Interest

The net income (loss) attributed to the NCI is separately designated in the accompanying consolidated statements of operations and other comprehensive income (loss).

Cash Equivalents

Accounts Receivable

Property and Equipment

	Leasehold improvements	5 years
	Clinical equipment	5 years
	Computer equipment	3 years
	Office equipment	5 years
	Furniture and fixtures	5 years

Long-Lived Assets

Intangible Assets

Goodwill

Acquisition Deposits

Fair Value of Financial Instruments

	●	Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.

	●	Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

	●	Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement.

As of February 28, 2019 and August 31, 2018, respectively, the Company did not identify any assets and liabilities required to be presented on the balance sheet at fair value.

Revenue Recognition

	●	executed contracts with the Company’s customers that it believes are legally enforceable;
	●	identification of performance obligations in the respective contract;
	●	determination of the transaction price for each performance obligation in the respective contract;
	●	allocation the transaction price to each performance obligation; and
	●	recognition of revenue only when the Company satisfies each performance obligation.

These five elements, as applied to healthcare services, the Company’s sole revenue category, is summarized below:

●

Income Taxes

Stock-Based Compensation

Basic and Diluted Earnings Per Share

Foreign Currency Transactions and Comprehensive Income

Statement of Cash Flows

Recent Accounting Pronouncements

XML 18 R8.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Feb. 28, 2019

Related Party Transactions

Note 3 – Related Party Transactions

Due to related parties

XML 19 R9.htm IDEA: XBRL DOCUMENT

Accounts Receivables, Net

6 Months Ended

Feb. 28, 2019

Receivables [Abstract]

Accounts Receivables, Net

Note 4 – Accounts Receivables, net

Accounts receivables, net at February 28, 2019 and August 31, 2018 consisted of the following:

	February 28, 2019			August 31, 2018
Trade receivables	$	1,610,117		$	1,564,180
Amounts earned but not billed		242,362			237,892
		1,852,479			1,802,072
Allowance for doubtful accounts		(473,585	)		(464,527	)
Accounts receivable, net	$	1,378,894		$	1,337,545

XML 20 R10.htm IDEA: XBRL DOCUMENT

Other Receivables

6 Months Ended

Feb. 28, 2019

Receivables [Abstract]

Other Receivables

Note 5 – Other Receivables

Other receivables at February 28, 2019 and August 31, 2018 consisted of the following:

	February 28, 2019			August 31, 2018
Notes receivable dated April 1, 2015 and amended on May 23, 2017; accrued interest at 8% per annum; secured by certain assets; due March 1, 2019	$	284,849		$	286,763

Advance to corporation; non-interest bearing; unsecured; due no later than November 18, 2020		30,384			30,588

Advance to corporation; accrues interest at 12% per annum; unsecured; due September 2019		75,960			76,470

Advance to corporation; accrues interest at 10% per annum; unsecured; due May 1, 2022		56,970			57,352

Advance to corporation; accrues interest at 10% per annum after the first 60 days; unsecured; due February 7, 2020		225,924			-
Total other receivables		674,087			451,173
Current portion		(586,733	)		(393,821	)
Long-term portion	$	87,354		$	57,352

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

Property and Equipment

6 Months Ended

Feb. 28, 2019

Property, Plant and Equipment [Abstract]

Property and Equipment

Note 6 – Property and Equipment

Property and equipment at February 28, 2019 and August 31, 2018 consisted of the following:

	February 28, 2019			August 31, 2018
Leasehold Improvements	$	433,756		$	372,010
Clinical equipment		276,954			269,741
Computer equipment		22,485			22,636
Office equipment		27,382			24,658
Furniture and fixtures		39,356			39,620
		799,933			728,665
Accumulated depreciation		(372,738	)		(328,344	)
Total	$	427,195		$	400,321

Depreciation expense for the six months ended February 28, 2019 and 2018 was $46,474 and $32,719, respectively.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Intangible Assets

6 Months Ended

Feb. 28, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Note 7 – Intangible Assets

Intangible assets at February 28, 2019 and August 31, 2018 consisted of the following:

	February 28, 2019		August 31, 2018
Land use rights	$	21,600,000	$	-
Software license		758,567		-
		22,358,567		-
Accumulated amortization		-		-
Total	$	22,358,567	$	-

There was no amortization expense during the six months ended February 28, 2019 and 2018.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Accrued Expenses

6 Months Ended

Feb. 28, 2019

Payables and Accruals [Abstract]

Accrued Expenses

Note 8 – Accrued Expenses

Accrued expenses at February 28, 2019 and August 31, 2018 consisted of the following:

	February 28, 2019		August 31, 2018
Accrued liabilities	$	131,422	$	266,123
Accrued payroll		89,637		106,761
Other		33,608		11,114
	$	254,667	$	383,998

XML 24 R14.htm IDEA: XBRL DOCUMENT

Notes Payable

6 Months Ended

Feb. 28, 2019

Debt Disclosure [Abstract]

Notes Payable

Note 9 – Notes Payable

Notes payable at February 28, 2019 and August 31, 2018 consisted of the following:

	February 28, 2019			August 31, 2018
Notes payable issued in connection with purchase of assets; accrues interest at 0% per annum; due on March 27, 2019.	$	379,800		$	382,350
		379,800			382,350
Current portion		(379,800	)		(382,350	)
Long-term portion	$	-		$	-

XML 25 R15.htm IDEA: XBRL DOCUMENT

Debentures, Related Parties

6 Months Ended

Feb. 28, 2019

Debt Disclosure [Abstract]

Debentures, Related Parties

Note 10 – Debentures, related parties

XML 26 R16.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit

6 Months Ended

Feb. 28, 2019

Equity [Abstract]

Stockholders' Deficit

Note 11 – Stockholders’ Deficit

Convertible preferred stock

Common stock

During the six months ended February 28, 2019, the Company issued:

	●	2,708,113 restricted shares of common stock for cash proceeds of $2,579,923

	●	12,000,000 restricted shares of common stock as consideration for the Assignment, to the Company, of a Joint Venture Agreement with a value of $21,600,000 based on the closing share price of $1.80 on the execution date of the Closing Certificate

	●	458,349 restricted shares of common stock as consideration for a Licensing Agreement based on a per share price of $1.655 with a value of $758,567.

Stock options/warrants

The following is a summary of stock option/warrant activity:

						Weighted
				Weighted		Average
	Options/			Average		Remaining		Aggregate
	Warrants			Exercise		Contractual		Intrinsic
	Outstanding			Price		Life		Value
Outstanding, August 31, 2018		10,030,000			0.30		4.56	$	7,045,500
Granted		75,000			0.95
Forfeited		(10,000	)		2.00
Exercised		-
Outstanding, February 28, 2019		10,095,000			0.30		4.08	$	13,106,250
Exercisable, February 28, 2019		10,095,000		$	0.30		4.08	$	13,106,250

The exercise price for options/warrants outstanding at February 28, 2019:

Outstanding and Exercisable
	Number of
	Options/		Exercise
	Warrants		Price
	5,500,000	$	0.16
	1,000,000		0.32
	50,000		0.33
	120,000		0.40
	2,000,000		0.42
	100,000		0.50
	1,000,000		0.62
	250,000		0.80
	75,000		0.95
	10,095,000

Risk-free interest rate	2.78	%
Expected life of the options	3.5 years
Expected volatility	294	%
Expected dividend yield	0	%

XML 27 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Feb. 28, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 12 – Commitments and Contingencies

Litigation

Leases

XML 28 R18.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Feb. 28, 2019

Subsequent Events [Abstract]

Subsequent Events

Note 13 – Subsequent Events

On April 3, 2019, the Company sold 116,078 restricted shares of common stock to an accredited investor for a purchase price of $149,740.

XML 29 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Feb. 28, 2019

Accounting Policies [Abstract]

Use of Estimates

Principles of Consolidation

Noncontrolling Interest

The net income (loss) attributed to the NCI is separately designated in the accompanying consolidated statements of operations and other comprehensive income (loss).

Cash Equivalents

Accounts Receivable

Property and Equipment

	Leasehold improvements	5 years
	Clinical equipment	5 years
	Computer equipment	3 years
	Office equipment	5 years
	Furniture and fixtures	5 years

Fair Value of Financial Instruments

	●	Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.

	●	Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

	●	Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement.

As of February 28, 2019 and August 31, 2018, respectively, the Company did not identify any assets and liabilities required to be presented on the balance sheet at fair value.

Revenue Recognition

	●	executed contracts with the Company’s customers that it believes are legally enforceable;
	●	identification of performance obligations in the respective contract;
	●	determination of the transaction price for each performance obligation in the respective contract;
	●	allocation the transaction price to each performance obligation; and
	●	recognition of revenue only when the Company satisfies each performance obligation.

These five elements, as applied to healthcare services, the Company’s sole revenue category, is summarized below:

●

Income Taxes

Stock-Based Compensation

Basic and Diluted Earnings Per Share

Foreign Currency Transactions and Comprehensive Income

Statement of Cash Flows

Recent Accounting Pronouncements

XML 30 R20.htm IDEA: XBRL DOCUMENT

Organization and Basis of Presentation (Tables)

6 Months Ended

Feb. 28, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Foreign Currency Translation, Exchange Rate Used

The following table details the exchange rates used for the respective periods:

	February 28, 2019		February 28, 2018		August 31, 2018
Period end: CAD to USD exchange rate	$	0.7596	$	0.7808	$	0.7647
Average period: CAD to USD exchange rate	$	0.7578	$	0.7959

XML 31 R21.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Feb. 28, 2019

Accounting Policies [Abstract]

Schedule of Estimated Useful Lives of Assets

Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows:

	Leasehold improvements	5 years
	Clinical equipment	5 years
	Computer equipment	3 years
	Office equipment	5 years
	Furniture and fixtures	5 years

XML 32 R22.htm IDEA: XBRL DOCUMENT

Accounts Receivables, Net (Tables)

6 Months Ended

Feb. 28, 2019

Receivables [Abstract]

Schedule of Accounts Receivables, Net

Accounts receivables, net at February 28, 2019 and August 31, 2018 consisted of the following:

	February 28, 2019			August 31, 2018
Trade receivables	$	1,610,117		$	1,564,180
Amounts earned but not billed		242,362			237,892
		1,852,479			1,802,072
Allowance for doubtful accounts		(473,585	)		(464,527	)
Accounts receivable, net	$	1,378,894		$	1,337,545

XML 33 R23.htm IDEA: XBRL DOCUMENT

Other Receivables (Tables)

6 Months Ended

Feb. 28, 2019

Receivables [Abstract]

Schedule of Other Receivables

Other receivables at February 28, 2019 and August 31, 2018 consisted of the following:

	February 28, 2019			August 31, 2018
Notes receivable dated April 1, 2015 and amended on May 23, 2017; accrued interest at 8% per annum; secured by certain assets; due March 1, 2019	$	284,849		$	286,763

Advance to corporation; non-interest bearing; unsecured; due no later than November 18, 2020		30,384			30,588

Advance to corporation; accrues interest at 12% per annum; unsecured; due September 2019		75,960			76,470

Advance to corporation; accrues interest at 10% per annum; unsecured; due May 1, 2022		56,970			57,352

Advance to corporation; accrues interest at 10% per annum after the first 60 days; unsecured; due February 7, 2020		225,924			-
Total other receivables		674,087			451,173
Current portion		(586,733	)		(393,821	)
Long-term portion	$	87,354		$	57,352

XML 34 R24.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

6 Months Ended

Feb. 28, 2019

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment at February 28, 2019 and August 31, 2018 consisted of the following:

	February 28, 2019			August 31, 2018
Leasehold Improvements	$	433,756		$	372,010
Clinical equipment		276,954			269,741
Computer equipment		22,485			22,636
Office equipment		27,382			24,658
Furniture and fixtures		39,356			39,620
		799,933			728,665
Accumulated depreciation		(372,738	)		(328,344	)
Total	$	427,195		$	400,321

XML 35 R25.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

6 Months Ended

Feb. 28, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets at February 28, 2019 and August 31, 2018 consisted of the following:

	February 28, 2019		August 31, 2018
Land use rights	$	21,600,000	$	-
Software license		758,567		-
		22,358,567		-
Accumulated amortization		-		-
Total	$	22,358,567	$	-

XML 36 R26.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

6 Months Ended

Feb. 28, 2019

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

Accrued expenses at February 28, 2019 and August 31, 2018 consisted of the following:

	February 28, 2019		August 31, 2018
Accrued liabilities	$	131,422	$	266,123
Accrued payroll		89,637		106,761
Other		33,608		11,114
	$	254,667	$	383,998

XML 37 R27.htm IDEA: XBRL DOCUMENT

Notes Payable (Tables)

6 Months Ended

Feb. 28, 2019

Debt Disclosure [Abstract]

Schedule of Notes Payable

Notes payable at February 28, 2019 and August 31, 2018 consisted of the following:

	February 28, 2019			August 31, 2018
Notes payable issued in connection with purchase of assets; accrues interest at 0% per annum; due on March 27, 2019.	$	379,800		$	382,350
		379,800			382,350
Current portion		(379,800	)		(382,350	)
Long-term portion	$	-		$	-

XML 38 R28.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit (Tables)

6 Months Ended

Feb. 28, 2019

Equity [Abstract]

Schedule of Stock Option and Warrant Activity

The following is a summary of stock option/warrant activity:

						Weighted
				Weighted		Average
	Options/			Average		Remaining		Aggregate
	Warrants			Exercise		Contractual		Intrinsic
	Outstanding			Price		Life		Value
Outstanding, August 31, 2018		10,030,000			0.30		4.56	$	7,045,500
Granted		75,000			0.95
Forfeited		(10,000	)		2.00
Exercised		-
Outstanding, February 28, 2019		10,095,000			0.30		4.08	$	13,106,250
Exercisable, February 28, 2019		10,095,000		$	0.30		4.08	$	13,106,250

Schedule of Options and Warrants Outstanding and Exercisable

The exercise price for options/warrants outstanding at February 28, 2019:

Outstanding and Exercisable
	Number of
	Options/		Exercise
	Warrants		Price
	5,500,000	$	0.16
	1,000,000		0.32
	50,000		0.33
	120,000		0.40
	2,000,000		0.42
	100,000		0.50
	1,000,000		0.62
	250,000		0.80
	75,000		0.95
	10,095,000

Schedule of Fair Value of Options Granted by Using Valuation Assumptions

Risk-free interest rate	2.78	%
Expected life of the options	3.5 years
Expected volatility	294	%
Expected dividend yield	0	%

XML 39 R29.htm IDEA: XBRL DOCUMENT

Organization and Basis of Presentation (Details Narrative) - USD ($)		6 Months Ended
	Apr. 25, 2017	Feb. 28, 2019
Number of restricted shares of common stock		2,708,113
Common stock issued in connection with reverse merger transaction		$ 6,904
Turbine Truck Engines, Inc [Member]
State country name		Delaware
Date of incorporation		Nov. 27, 2000
Turbine Truck Engines, Inc One [Member]
State country name		State of Nevada
Date of incorporation		Feb. 20, 2008
NHL [Member] \| Share Exchange Agreement [Member]
Number of restricted shares of common stock	167,797,406
Percentage of common stock issued and outstanding	85.00%

XML 40 R30.htm IDEA: XBRL DOCUMENT

Organization and Basis of Presentation - Schedule of Foreign Currency Translation, Exchange Rate Used (Details) - CAD [Member]	Feb. 28, 2019	Aug. 31, 2018	Feb. 28, 2018
Period End [Member]
Foreign currency exchange rate	0.7596	0.7647	0.7808
Average Period [Member]
Foreign currency exchange rate	0.7578		0.7959

XML 41 R31.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Feb. 28, 2019	Aug. 31, 2018	Aug. 31, 2017
Allowance for uncollectible accounts receivable	$ 473,585	$ 464,527
Impairment of its long-lived assets	0	0
Goodwill	600,084	604,113
Refundable acquisition deposits	$ 1,104,985	1,112,404
Potentially dilutive common stock options and warrants outstanding, shares	10,095,000
Translation gains	$ 1,165,795	1,139,815
Apka Health, Inc. [Member]
Goodwill			$ 379,800
Executive Fitness Leaders [Member]
Goodwill		$ 220,284
Land Use Rights [Member]
Intangible asset, useful life amortized over term	50 years
Software License [Member]
Intangible asset, useful life amortized over term	7 years
Novo Healthnet Kemptville Centre, Inc. [Member]
Equity method investment, ownership percentage	80.00%

XML 42 R32.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details)	6 Months Ended
	Feb. 28, 2019
Leasehold Improvements [Member]
Property and equipment, estimated lives	5 years
Clinical Equipment [Member]
Property and equipment, estimated lives	5 years
Computer Equipment [Member]
Property and equipment, estimated lives	3 years
Office Equipment [Member]
Property and equipment, estimated lives	5 years
Furniture and Fixtures [Member]
Property and equipment, estimated lives	5 years

XML 43 R33.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	Jan. 31, 2018	Feb. 28, 2019	Aug. 31, 2018
Related Party Transactions [Abstract]
Due to related parties		$ 966,102	$ 1,116,261
Related party debt, converted amount	$ 813,125
Debt converted, shares issued	1,976,483
Debt conversion, description	The per share price used for the conversion of this loan was $0.4114 which was determined based on the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price.
Debt conversion price	$ 0.4114

XML 44 R34.htm IDEA: XBRL DOCUMENT

Accounts Receivables, Net - Schedule of Accounts Receivables, Net (Details) - USD ($)	Feb. 28, 2019	Aug. 31, 2018
Receivables [Abstract]
Trade receivables	$ 1,610,117	$ 1,564,180
Amounts earned but not billed	242,362	237,892
Accounts receivable, gross	1,852,479	1,802,072
Allowance for doubtful accounts	(473,585)	(464,527)
Accounts receivable, net	$ 1,378,894	$ 1,337,545

XML 45 R35.htm IDEA: XBRL DOCUMENT

Other Receivables - Schedule of Other Receivables (Details) - USD ($)	Feb. 28, 2019	Aug. 31, 2018
Total other receivables	$ 674,087	$ 451,173
Current portion	(586,734)	(393,821)
Long-term portion	87,354	57,352
Notes Receivable Dated April 1, 2015 and May 23, 2017 [Member]
Total other receivables	284,849	286,763
Advance to Corporation One [Member]
Total other receivables	30,384	30,588
Advance to Corporation Two [Member]
Total other receivables	75,960	76,470
Advance to Corporation Three [Member]
Total other receivables	56,970	57,352
Advance to Corporation Four [Member]
Total other receivables	$ 225,924

XML 46 R36.htm IDEA: XBRL DOCUMENT

Other Receivables - Schedule of Other Receivables (Details) (Parenthetical)	6 Months Ended	12 Months Ended
	Feb. 28, 2019	Aug. 31, 2018
Notes Receivable Dated April 1, 2015 and May 23, 2017 [Member]
Percentage of interest accrued per annum	8.00%	8.00%
Notes receivable due date	Mar. 01, 2019	Mar. 01, 2019
Advance to Corporation One [Member]
Notes receivable due date	Nov. 18, 2020	Nov. 18, 2020
Advance to Corporation Two [Member]
Percentage of interest accrued per annum	12.00%	12.00%
Notes receivable due date	Sep. 30, 2019	Sep. 30, 2019
Advance to Corporation Three [Member]
Percentage of interest accrued per annum	10.00%	10.00%
Notes receivable due date	May 01, 2022	May 01, 2022
Advance to Corporation Four [Member]
Percentage of interest accrued per annum	10.00%	10.00%
Notes receivable due date	Feb. 07, 2020	Feb. 07, 2020

XML 47 R37.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details Narrative) - USD ($)	6 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Feb. 28, 2019	Feb. 28, 2018
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 46,474	$ 32,719

XML 48 R38.htm IDEA: XBRL DOCUMENT

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Feb. 28, 2019	Aug. 31, 2018
Property and equipment, gross	$ 799,933	$ 728,665
Accumulated depreciation	(372,738)	(328,344)
Total	427,195	400,321
Leasehold Improvements [Member]
Property and equipment, gross	433,756	372,010
Clinical Equipment [Member]
Property and equipment, gross	276,954	269,741
Computer Equipment [Member]
Property and equipment, gross	22,485	22,636
Office Equipment [Member]
Property and equipment, gross	27,382	24,658
Furniture and Fixtures [Member]
Property and equipment, gross	$ 39,356	$ 39,620

XML 49 R39.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details Narrative) - USD ($)	6 Months Ended
Intangible Assets (Details Narrative) - USD ($)	Feb. 28, 2019	Feb. 28, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense

XML 50 R40.htm IDEA: XBRL DOCUMENT

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	Feb. 28, 2019	Aug. 31, 2018
Intangible assets, gross	$ 22,358,567
Accumulated amortization
Total	22,358,567
Land Use Rights [Member]
Intangible assets, gross	21,600,000
Software License [Member]
Intangible assets, gross	$ 758,567

XML 51 R41.htm IDEA: XBRL DOCUMENT

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Feb. 28, 2019	Aug. 31, 2018
Payables and Accruals [Abstract]
Accrued liabilities	$ 131,422	$ 266,123
Accrued payroll	89,637	106,761
Other	33,608	11,114
Accrued expenses	$ 254,667	$ 383,998

XML 52 R42.htm IDEA: XBRL DOCUMENT

Notes Payable - Schedule of Notes Payable (Details) - USD ($)	Feb. 28, 2019	Aug. 31, 2018
Notes payable	$ 379,800	$ 382,350
Current portion	(379,800)	(382,350)
Long-term portion
Notes Payable [Member]
Notes payable	$ 379,800	$ 382,350

XML 53 R43.htm IDEA: XBRL DOCUMENT

Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) - Notes Payable [Member]	6 Months Ended	12 Months Ended
	Feb. 28, 2019	Aug. 31, 2018
Percentage of interest accrued per annum	0.00%	0.00%
Notes payable, due date	Mar. 27, 2019	Mar. 27, 2019

XML 54 R44.htm IDEA: XBRL DOCUMENT

Debentures, Related Parties (Details Narrative)	Jan. 31, 2018 USD ($) $ / shares shares	Dec. 02, 2017	Sep. 30, 2013 CAD ($)	Feb. 28, 2019 USD ($)	Aug. 31, 2018 USD ($)	Nov. 30, 2017 USD ($)
Debentures, outstanding				$ 1,215,837	$ 1,224,000
Accrued interest				$ 181,740	$ 156,121
Debt converted, shares issued \| shares	1,976,483
Debt conversion price \| $ / shares	$ 0.4114
Debt conversion, description	The per share price used for the conversion of this loan was $0.4114 which was determined based on the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price.
Five Debentures [Member]
Debentures, outstanding						$ 4,968,990
Debt interest rate			8.00%
Debt due date			Sep. 30, 2016
Debt extended due date		Sep. 30, 2019
Five Debentures [Member] \| CAD [Member]
Debentures, outstanding			$ 6,402,512
Debentures [Member]
Debentures, outstanding	$ 3,894,809
Percentage of debt converted	75.00%
Accrued interest	$ 414,965
Debt converted, shares issued \| shares	10,475,872
Debt conversion price \| $ / shares	$ 0.4114
Debt conversion, description	The per share price used for the conversion of each debenture was $0.4114 which was determined based on the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price.

XML 55 R45.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit (Details Narrative) - USD ($)			6 Months Ended		12 Months Ended
Stockholders' Deficit (Details Narrative) - USD ($)	Jan. 16, 2018	Sep. 08, 2015	Feb. 28, 2019	Feb. 28, 2018	Aug. 31, 2018
Convertible preferred stock, shares authorized			1,000,000		1,000,000
Convertible preferred stock, par value			$ 0.001		$ 0.001
Convertible preferred stock, shares issued			0		0
Convertible preferred stock, shares outstanding			0		0
Common stock, shares authorized			499,000,000		499,000,000
Common stock, par value			$ 0.001		$ 0.001
Common stock, shares issued			223,048,205		207,881,743
Common stock, shares outstanding			223,048,205		207,881,743
Number of restricted shares issued			2,708,113
Proceeds from issuance of restricted shares			$ 2,579,923
Shares issued price per share			$ 1.655
Stock options granted weighted-average grant date fair value					$ 0.39
Stock options/warrants weighted-average exercise price					$ 0.40
Stock option expense			$ 70,846	$ 1,109,416
Unamortized stock option expense			$ 0
August 31, 2019 [Member]
Stock options granted weighted-average grant date fair value			$ 0.94
Stock options/warrants weighted-average exercise price			$ 0.95
2015 Incentive Compensation Plan [Member]
Number of shares issued for granted			4,987,500
2015 Incentive Compensation Plan [Member] \| Maximum [Member]
Number of common stock shares issued		5,000,000
2018 Incentiven Plan [Member]
Number of common stock shares issued	10,000,000
Number of shares issued for granted			9,875,000
Joint Venture Agreement [Member]
Number of restricted shares issued			12,000,000
Proceeds from issuance of restricted shares			$ 21,600,000
Shares issued price per share			$ 1.80
Licensing Agreement [Member]
Number of restricted shares issued			458,349
Proceeds from issuance of restricted shares			$ 758,567
Shares issued price per share			$ 1.655

XML 56 R46.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit - Schedule of Stock Option and Warrant Activity (Details)	6 Months Ended
	Feb. 28, 2019 USD ($) $ / shares shares
Equity [Abstract]
Options/Warrants Outstanding, Beginning Balance	10,030,000
Options/Warrants Outstanding, Granted	75,000
Options/Warrants Outstanding, Forfeited	(10,000)
Options/Warrants Outstanding, Exercised
Options/Warrants Outstanding, Ending Balance	10,095,000
Options/Warrants Outstanding, Exercisable	10,095,000
Weighted Average Exercise Price, Outstanding, Beginning Balance \| $ / shares	$ 0.30
Weighted Average Exercise Price, Granted \| $ / shares	0.95
Weighted Average Exercise Price, Forfeited \| $ / shares	2.00
Weighted Average Exercise Price, Outstanding, Ending Balance \| $ / shares	0.30
Weighted Average Exercise Price, Exercisable \| $ / shares	$ 0.30
Weighted Average Remaining Contractual Life, Outstanding, Beginning Balance	4 years 6 months 21 days
Weighted Average Remaining Contractual Life, Outstanding, Ending Balance	4 years 29 days
Weighted Average Remaining Contractual Life, Exercisable	4 years 29 days
Aggregate Intrinsic Value, Outstanding, Beginning Balance \| $	$ 7,045,500
Aggregate Intrinsic Value, Outstanding, Ending Balance \| $	13,106,250
Aggregate Intrinsic Value, Exercisable \| $	$ 13,106,250

XML 57 R47.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit - Schedule of Options and Warrants Outstanding and Exercisable (Details)	Feb. 28, 2019 $ / shares shares
Number of Options/Warrants, Outstanding	10,095,000
Number of Options/Warrants, Exercisable	10,095,000
Exercise Price Range One [Member]
Number of Options/Warrants, Outstanding	5,500,000
Number of Options/Warrants, Outstanding, Exercise Price \| $ / shares	$ 0.16
Number of Options/Warrants, Exercisable	5,500,000
Number of Options/Warrants, Exercisable, Exercise Price \| $ / shares	$ 0.16
Exercise Price Range Two [Member]
Number of Options/Warrants, Outstanding	1,000,000
Number of Options/Warrants, Outstanding, Exercise Price \| $ / shares	$ 0.32
Number of Options/Warrants, Exercisable	1,000,000
Number of Options/Warrants, Exercisable, Exercise Price \| $ / shares	$ 0.32
Exercise Price Range Three [Member]
Number of Options/Warrants, Outstanding	50,000
Number of Options/Warrants, Outstanding, Exercise Price \| $ / shares	$ 0.33
Number of Options/Warrants, Exercisable	50,000
Number of Options/Warrants, Exercisable, Exercise Price \| $ / shares	$ 0.33
Exercise Price Range Four [Member]
Number of Options/Warrants, Outstanding	120,000
Number of Options/Warrants, Outstanding, Exercise Price \| $ / shares	$ 0.40
Number of Options/Warrants, Exercisable	120,000
Number of Options/Warrants, Exercisable, Exercise Price \| $ / shares	$ 0.40
Exercise Price Range Five [Member]
Number of Options/Warrants, Outstanding	2,000,000
Number of Options/Warrants, Outstanding, Exercise Price \| $ / shares	$ 0.42
Number of Options/Warrants, Exercisable	2,000,000
Number of Options/Warrants, Exercisable, Exercise Price \| $ / shares	$ 0.42
Exercise Price Range Six [Member]
Number of Options/Warrants, Outstanding	100,000
Number of Options/Warrants, Outstanding, Exercise Price \| $ / shares	$ 0.50
Number of Options/Warrants, Exercisable	100,000
Number of Options/Warrants, Exercisable, Exercise Price \| $ / shares	$ 0.50
Exercise Price Range Seven [Member]
Number of Options/Warrants, Outstanding	1,000,000
Number of Options/Warrants, Outstanding, Exercise Price \| $ / shares	$ 0.62
Number of Options/Warrants, Exercisable	1,000,000
Number of Options/Warrants, Exercisable, Exercise Price \| $ / shares	$ 0.62
Exercise Price Range Eight [Member]
Number of Options/Warrants, Outstanding	250,000
Number of Options/Warrants, Outstanding, Exercise Price \| $ / shares	$ 0.80
Number of Options/Warrants, Exercisable	250,000
Number of Options/Warrants, Exercisable, Exercise Price \| $ / shares	$ 0.80
Exercise Price Range Nine [Member]
Number of Options/Warrants, Outstanding	75,000
Number of Options/Warrants, Outstanding, Exercise Price \| $ / shares	$ 0.95
Number of Options/Warrants, Exercisable	75,000
Number of Options/Warrants, Exercisable, Exercise Price \| $ / shares	$ 0.95

XML 58 R48.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit - Schedule of Fair Value of Options Granted by Using Valuation Assumptions (Details)	6 Months Ended
	Feb. 28, 2019
Equity [Abstract]
Risk-free interest rate	2.78%
Expected life of the options	3 years 6 months
Expected volatility	294.00%
Expected dividend yield	0.00%

XML 59 R49.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) - USD ($)	6 Months Ended
	Feb. 28, 2019	Feb. 28, 2018
Commitments and Contingencies Disclosure [Abstract]
Operating leases expiration date	2023
Rent expense	$ 498,237	$ 409,350

XML 60 R50.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($)		6 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Apr. 03, 2019	Feb. 28, 2019
Number of restricted shares sold		2,708,113
Purchase price of restricted shares		$ 2,579,923
Subsequent Event [Member] \| Accredited Investor [Member]
Number of restricted shares sold	116,078
Purchase price of restricted shares	$ 149,740

EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ") BTX?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ (D"+3B?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " B0(M.LZE@QN\ K @ $0 &1O8U!R;W!S+V-O M&ULS9+;2@,Q$(9?17*_.TDK'L)V;RR]4A L*-Z%9-H&-P>2D=V^O=FU MW2+Z %YFYL\WW\ T.DH=$CZG$#&1Q7PUN,YGJ>.*'8BB!,CZ@$[ENB1\:>Y" MA:^ "&&&$R>7O IJ9.%7_Q$X=8*?DD.V&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T M$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY M\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4? M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M M&N#C\7@XMLO2BW A(5M>5 TR 6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2. MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$. M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07 M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL! M_]':-\*K^(+ .7\N?<^E[[GT/:'2MSAD M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W MF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>( M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K> M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5 MYYN MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+ MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> , M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H: M,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ M 5!+ P04 " B0(M.ZIG?!7P" !!"0 & 'AL+W=OU#4NI/?0EOITS9\;#Q%,,C+^*BE+IO;5-)[9^)67_' 3B7-&6B"?6TTZ= M7!EOB51+?@M$SRFY&%+;!#@,TZ E=>>7A=D[\K)@=]G4'3UR3]S;EO#?>]JP M8>LC_WWCI;Y54F\$9=&3&_U&Y??^R-4JF*UB5W!OYPH9/= HH\;TI^B_T01L%UYXHC3-K MA/GUSGP_08I,>&'B_HB74!+B*%!1)0(''H MF27@(G)8( 4%4H>^L01Q:L-,.8-:2 M@N#R19&K@FT5%[.J E$X(I';D'CV X) MP"0K*G#9([>J<6JK )AL104N?>06-LYM%0"SL52"Q8/44GXS;[?PSNS>F<9A ML3OW!SML'K2_\+&Y^$KXK>Z$=V)2/8OF\;HR)JER)7Q2UUJI?F9>-/0J]313 MNWS=C>NR?B^'8QV8S!^W; HWQ MQ;[9'9;KU?SNOE^ONI>QW1WB?;\87O;[IO_O+K;=V^T2EN\OONV>M^/THEBO MCLUS_#..?QWO^_147%K9[/;Q,.RZPZ*/3[?+G^"F)IH"9L7?N_@V7-TOIE0> MNN[[]/#;YG9I)D>QC8_CU$23+J^QCFT[M91\_'MN='GITR+!>;^-2\M..W[NW7>$[(+1?G['^/K[%-\LE)ZN.Q:X?Y M[^+Q91B[_;F59&7?_#A==X?Y^G9N_SU,#\!S %X"P'X:0.< 8@'%R=FVZ$^C=6RF20$WE(KY.+V<:S?_EK(=TMO7-9E5\3JU]7A2XVF.M]?QQ)(X2?PL.9R2H)(J\BP5J?.E M*XW3[5C5CI5V++-SDKBK;H#*$"JFJS4=EE=%,R-Z7HQCJ#(3!=+77H M?*A,I?L)JI\@_03F)T@_6$+%AK169,90;JPJU4TEW53,326S1G+!>5X>V98U MNAA !IT@_2#W W*.@K%5X*.E"@&ML1E/ M.DD!I2>.PK/FNBMOC FB2)K. E#&DGS+Y5TM9QVJ*DJ$6'%/C0 M:<*T\\S72>].T8C/[7/-1R.?%18O,+0/KZ*L/_0=2E M4*6E,?.AD@Y9DI#U'/LDV8DV3,7B+S M7--A\+GUFG3$DD2LY]@G2T MBE+?TA979SK3(=L?3?^\.PR+AVX[[T^'6Z6'LCN>#N^)R>KC^'U!+ P04 " B0(M.O9WS:T(" "V!P M& 'AL+W=O,6N=[; MLR*G5T&J!N^9PZ]UC=C?+2:TV[B>^['Q4EU*H39 D;?H@G]B\:O=,[D"8Y13 M5>.&5[1Q&#YOW$_>>N=!9="*UPIW?#)W5"D'2M_4XMMIXT)%A D^"A4"R>&& M=Y@0%4ER_!F"NF-.99S./Z)_T<7+8@Z(XQTEOZN3*#=NZCHG?$97(EYH]Q4/ M!46N,U3_'=\PD7)%(G,<*>'ZVSE>N:#U$$6BU.B]'ZM&CUW_)$X&F]W@#P9_ M-'CA74,P& +# 'HR7>IG)%"1,]HYK/^U6J0.A;<.Y,L\JDW][O0S62V7N[4<@CU8PEM+*$2Y;$8.DET22+!_7'H'FLF_%$5IYHR9,:/-$B MCTER3S%CB*T,\9(A,QCBAPSW%#.&Q,J0+!@2(\,V>>J,/%+-6%(K2[ID,;)L MTT6U89993\DSRAE39F7*EDS&WWR;+3+Y?@##U(>1P611PB1-O20,[$RR$UAO M)[BD"LSK"3Z-99/^APM,+E#5T7X@=JD:[ARHD'>QOC'/E HLP\*5#%C*)CHN M"#X+-4WDG/6=I%\(V@Y=$HRMNO@'4$L#!!0 ( ") BT[(PCMJ 04 !X7 M 8 >&PO=V]R:W-H965T&ULC5A=;^LV#/TK0=[;B)1D M245:H/D8-F #+NZP[=EMU2:X29S9;GOW[R=_--#.;58^;N,^KZ^(8#^D_ST6YS^OT6K[,JF,9\Z?6 M:+^;H5+9;)]O#].[>?OM2WDW+U[KW?80OY23ZG6_S\O_%G%7O-].8?KQX>OV M95,W'V9W\V/^$O^,]5_'+V5ZFYV\/&WW\5!MB\.DC,^WTWNX66/6&+2(O[?Q MO1H\3QHJ#T7QK7GY[>EVJIJ(XBX^UHV+//V\Q67<[1I/*8Y_>Z?3TYB-X?#Y MP_LO+?E$YB&OXK+8_;-]JC>W4S^=/,7G_'57?RW>?XT](3N=].Q_CV]QE^!- M)&F,QV)7M7\GCZ]57>Q[+RF4??Z]^]T>VM_WWO^'F6R O0&>#-+8EPQT;Z!_ M&)B+!J8W,#\[@NT-+!EAUG%OD[G*Z_QN7A;OD[*KAV/>E!W'+#H(#B'V'++B$#@A9FG\4Q H!;% 9H[G RPYPF4D MAD^=K"\Z.0M3B[G2K;T>VCO9WHCVIK4W0WM/J$D!1P 9HZF8R4A,1C%RE1TB2$ CJQ@$/OH/2!?PR,[.,@M#C1/E*.)TGP9 M8S T31P%&:L##@J:KJ^U@$(8V9M ;KW >Z^GO;?'G,V"\987@(#3J4?3IKJ2 M@,$$Q8I<&EA[')3H.4>Y_0+OOY[V7^"-\,JDV=.4HX#3J7 =XR@ O;5H*4=I M8.V5&UO(<@L&WH,#[<' VV%:36G;H%U8!)JD,Y!NR1)2NV S0VE*+IUVJ,;J M56[&X#A/H#PYANFH'G,6CS5(F^[J)WRM+V/.6;WWF,_K702*]2XAQ7H775ZJ=Y15 W+50$]J"Q2:N$O14Y8<=I6: M?3JJ49*"/\NRMI;\>3<4Y^<$9?F 7#X$*HN0GZ&O@D5@# 4<6.\5/3"L)*1. MRY7J\[7HTJ-)._T(35E!(%<0@:HD%([28-"#-NS21H"FHUP R*B,$+V"2FJ) M'B+7HE<=K#9V1"VCK"50T!)4+_6886;9NNP@?IA\=F[M!\GT!-TL0OJ_@9MU=U?YPW]T<_Y&7 M+]M#-7DHZKK8M_>&ST51QQ2]NDXSLHGYT^EE%Y_KYM&EY[*[L>U>ZN+8WT;/ M3E?B=_\#4$L#!!0 ( ") BT[T&O;@+P0 ($2 8 >&PO=V]R:W-H M965T&UL?9C9CN,V$$5_Q="[1ZSB)C9L RT'00(D0&."29[5 M-KU@M#B2W)[\?:AE/#99G!=+HB^+M[@<45S=FO9K=[*V7WRKRKI;)Z>^O[RD M:;<[V:KH/C476[M_#DU;%;U[;(]I=VEML1\K566*C*FT*LYULEF-96_M9M5< M^_)K2W&T?]G^R^6M=4_I/?M^O$S8XLJ7=]4.( MPET^[-:6Y1#)^?AW#IKKS> MIG^TFJO1%7"N@/<*KNV?5>!S!?ZC@AB3GYR-J?Y2],5FU3:W13N-UJ48)@6\ M<->9NZ%P[+OQ/Y=MYTH_-L#8*OT8 LV:?-+@H^:N2%WT>Q-(-9%C4!V?&]B& M"JWH%CB9!!_K\Z)&B7U*%ER;:027BZ$#C37&#,D M24.2R CI (H,H(*,@'$OI4DC'ZP*);2?4*CBJ,'09C1I1A-FO&9R'32C62:4 M9R94 3 C(#)=,M).1G2NI ,8,H A\O&>T'V#T*F:! M(^X;FC5>4P(\0X2,,XZ1#H8(52#PXP]E/FN>_ BA.?,-A;J,N:D1,40RZ!4P M-*1]0Q@: G0K(G!$" 7/1&S,:&@!)V91X(D'3:&21ON.0ID;-&4BJQ1H"D*( M06"9[T@0R4LC1=!+E% +$YW:- F!0F$L+YJ%0, 0@I=_-?@+'INBD&F XX0PLRM MIAA(:-*""4*/+NAT8@$&L%'(Q)H%%S+ M8,42PB5J)B&VBZ7IB 0=P:V&D:8L$;=&G+880 M=>N?&W\CM26$;F^M5&R#CC1ND=B&8BP$34K="(Y4#T;^2-R&DJV?8XGG%TBUUSK?OA$_FA]'Z.\CH>HWCE.;QLI].0'V&FPYD_ MB_9XKKO%>]/W335^_!^:IK?.(OODQO]DB_W]H;2'?KC5[KZ=#D6FA[ZYS <^ MZ?W4:?,_4$L#!!0 ( ") BTXIXLHLL0$ -(# 8 >&PO=V]R:W-H M965T&UL?5/1;MLP#/P501]0)4JZ=H%MH&DQ;, &!!VV/2LV M;0N51$^2X^[O)\F.YW7&7BR2YAV/%)4-:%]<"^#)JU;&Y;3UOCLPYLH6M' W MV($)?VJT6OC@VH:YSH*H$D@KQC>;=TP+:6B1I=C)%AGV7DD#)TM>=03 M2Y"BQ>MX2I/.8>*_PM8!? +P-P V%DK*GX07169Q(':BFV_"YCET@TY1S''+[,F3-88)]+\+421_X/G*_#=ZL*=PF^^TOA M_3K!?I5@GPCV_VUQ+>?]FR)L,5,-MDG;Y$B)O4F;O(C."_O TYW\21^W_8NP MC32.G-&'FTWSKQ$]!"F;F[!";7A@LZ.@]M&\"[8=UVQT/';3"V+S,RY^ U!+ M P04 " B0(M.X7UL^K(! #2 P & 'AL+W=O0.)7T0)\=#Z+K M77"PJAAX!U_!?1O.QEML96F$ FT%:F*@+>G=X7C*0WP,^"Y@LILS"95<$!^# M\:DI:1($@83:!0;NMRO<@Y2!R,OXN7#2-64 ;L_/[!]B[;Z6"[=PC_*':%Q? MTEM*&FCY*-T#3A]AJ><-)4OQG^$*TH<')3Y'C=+&E=2C=:@6%B]%\:=Y%SKN MTWR39PML'Y N@'0%W,8\;$X4E;_GCE>%P8F8N?<##T]\.*:^-W5PQE;$.R_> M>N^U.F1)P:Z!:(DYS3'I-F:-8)Y]39'NI3BE_\'3?7BVJS"+\.POA2_DSW<) M\DB0OUKB7LR_*MFFIPI,%Z?)DAI''2=YXUT']BZ-;_(G?)[V+]QT0EMR0>=? M-O:_173@I20W?H1Z_\%60T+KPO&=/YMYS&;#X;#\(+9^X^HW4$L#!!0 ( M ") BTX/#LVIM $ -(# 8 >&PO=V]R:W-H965T&UL M?5/;;IPP$/T5RQ\0[P)I5RM RJ:J&JF15JG:/GMA "N^$-LLR=]W; BE+>J+ M[1G/.7-F/,Y'8Y]=!^#)JY+:%;3SOC\RYJH.%'--XVQBGLT; T:W.)%1R,>8Y& ]U07=! M$$BH?&#@N%WA'J0,1"CC9>:D2\H 7)_?V3_'VK&6"W=P;^1/4?NNH =*:FCX M(/V3&;_ 7,\M)7/Q7^$*$L.#$LQ1&>GB2JK!>:-F%I2B^.NT"QWW<;I)#S-L M&Y#,@&0!'&(>-B6*RC]QS\O;"M,(3_]0F&T39)L$623(_EOB M5LSM7TG8JJ<*;!NGR9'*##I.\LJ[#.Q=$M_D=_@T[8_7S;VOS'& M TK9W> (=?C!%D-"X\/Q(Y[M-&:3X4T__R"V?./R%U!+ P04 " B0(M. M:%LT:+0! #2 P & 'AL+W=OO&IE7$Y;[[L38ZYL00MWAQV8<%.CU<('TS;,=19$E4!:,;[9 M')@6TM B2[Z++3+LO9(&+I:X7FMA?YY!X9#3+7US/,FF]='!BJP3#7P%_ZV[ MV&"QF:62&HR3:(B%.J9>7;G!XIJ: 6O?)/.'R$ MJ9YWE$S%?X8;J! >E80<)2J75E+VSJ.>6((4+5['79JT#^,-/TRP=0"? 'P& M'%,>-B9*RM\++XK,XD#LV/M.Q"?>GGCH31F=J17I+HAWP7LKMKM#QFZ1:(HY MCS%\&3-'L, ^I^!K*<[\'SA?A^]6%>X2?/>'POMU@OTJP3X1[/];XEK,\:\D M;-%3#;9)T^1(B;U)D[SPS@/[P-.;_ X?I_V+L(TTCES1AY=-_:\1/00IF[LP M0FWX8+.AH/;Q>!_.=ARST?#833^(S=^X^ 502P,$% @ (D"+3CM-2KFU M 0 T@, !D !X;"]W;W)K&UL?5/;;M0P$/T5 MRQ]09YU RRJ)U"U"((&T*J(\>Y/)1?4EV,ZF_#UC)PT!(EYLSWC.F3/C<3X9 M^^PZ $]>E-2NH)WWPY$Q5W6@A+LQ VB\:8Q5PJ-I6^8&"Z*.("493Y*W3(E> MTS*/OK,M0)IIH(>Z*OCL6\['QRLS ?1PE?PWX:S18NM M+'6O0+O>:&*A*>C]X7C*0GP,>.IAZH$D0!!(J'Q@$;E=X M "D#$4U-"(4?I',WV$I9XW ME"S%?X8K2 P/2C!'9:2+*ZE&YXU:6%"*$B_SWNNX3_,-3Q?8/H O +X"[F(> M-B>*RM\++\K#"$]\.'+L316BA/_!\[WX>FNPC3"TS\4WNX39+L$623(_EOB3DR6_)6$;7JJ MP+9QFARIS*CC)&^\Z\#>\_@FO\/G:?\B;-MK1R[&X\O&_C?&>$ IR0V.4(Q]1N7OP!02P,$% @ (D"+3J]D]9.S 0 MT@, !D !X;"]W;W)K&UL?5-A;]P@#/TKB!]0 M+KELJTY)I%ZG:956Z=1IVV>E=2VH)US_8$Q6W6@N+W"'K2_:= H[KQI6F9[ [R.("59NMM]9(H+3H75?0:TIJ:/@@W0..7V&NYP,E<_'? MX +2AP%TL:55(-UJ&86+T7QYVD7.N[C=),E,VP;D,Z = %Y/&-_D3/DW[/3>MT):&PO=V]R:W-H965T29M<<7!1@7\#K]^P)V'+>U^@+,,.?,F6%(!S1OM@%PY%U) M;3/:.-<=&+-% TK8*^Q ^YL*C1+.FZ9FMC,@R@A2DO'-YIHIT6J:I]%W,GF* MO9.MAI,AME=*F%]'D#AD=$L_'$]MW;C@8'G:B1I^@'ON3L9;;&8I6P7:MJB) M@2JC=]O#,0GQ,>"EA<$NSB14QL^) MD\XI W!Y_F#_$FOWM9R%A7N4KVWIFHS>4E)")7KIGG#X"E,]>TJFXA_A M*' M!R4^1X'2QI44O76H)A8O18GW<6]UW(?Q9K^;8.L /@'X#+B->=B8*"I_$$[D MJ<&!F+'WG0A/O#UPWYLB.&,KXIT7;[WWDF^3)&670#3%',<8OHR9(YAGGU/P MM11'_@^&UL?5/;;IPP$/T5RQ\0[P)MMBM RJ:J M6JF55JF:/GMA "N^4-LLZ=]W; BE#--XVQBGLT;_KB>!!MYX.#E7G/6_@._D=_MFBQA:46"K031A,+34'O M]L=3%N)CP*. T:W.)%1R,>8I&%_J@NZ"()!0^<# <;O"/4@9B%#&KYF3+BD# M<'U^8?\4:\=:+MS!O9$_1>V[@AXHJ:'A@_0/9OP,E&". MRD@75U(-SALULZ 4Q9^G7>BXC]--FLZP;4 R Y(%<(AYV)0H*O_(/2]S:T9B MI][W/#SQ_IA@;ZK@C*V(=RC>H?=:[K/;G%T#T1QSFF*2=/J/PL,V0;9)D$6"[,T2MV(^_)>$K7JJP+9QFARIS*#C)*^\ MR\#>)?%-_H9/T_Z-VU9H1R[&X\O&_C?&>$ INQL&UL?5-AC]0@$/TKA!]P=-D][[)IF]R>,9IH MLCFC?F;;:4L.F IT>_Y[@?9JU>H78(9Y;]X,0SZB?78=@"OI(&S)6[0 M6M@?)U X%G1'7QU/LNU\=+ R[T4+G\%_Z<\V6&QAJ:4&XR0:8J$IZ,/N>#K$ M^!3P5<+H5F<2*[D@/D?C0UW0+ H"!96/#")L5W@$I2)1D/%]YJ1+R@A 1U3=9^ZZ@]Y34T(A!^2<%RJ65 M5(/SJ&>6($6+EVF7)NWC=,/O9M@V@,\ O@#N4QXV)4K*WPHORMSB2.S4^U[$ M)]X=>>A-%9VI%>DNB'?!>RUWMUG.KI%HCCE-,7P=LT2PP+ZDX%LI3OPO.-^& M[S<5[A-\_YO"?^0_;!(<$L'AOR5NQ?RIDJUZJL&V:9H&UL?5/;;MP@$/T5Q >$7=9)5RO;4C95E4JMM$K5YIFU MQQ<%&!?P.OW[ G8<)W7S LPPY\R984@'-$^V 7#D64EM,]HXUQT8LT4#2M@K M[$#[FPJ-$LZ;IF:V,R#*"%*2\8J]DZV&DR&V5TJ8/T>0 M.&1T2U\<#VW=N.!@>=J)&GZ ^]F=C+?8S%*V"K1M41,#549OMX=C$N)CP*\6 M!KLXDU#)&?$I&%_+C&Z"()!0N, @_':!.Y R$'D9OR=..J<,P.7YA?U+K-W7 ME/@="$^\/7#? MFR(X8ROBG1=OO?>2;Z]W*;L$HBGF.,;P9P\=I M_RY,W6I+SNC\R\;^5X@.O)3-E1^AQG^PV9!0N7#\Y,]F'+/1<-A-/XC-WSC_ M"U!+ P04 " B0(M.4BM K0! #2 P &0 'AL+W=O_4M0"!O6AF?TS:$[LB8+UO0PM_8#@S> MU-9I$=!T#?.= U$ED%:,;S:W3 MI:)$EW]D5F>V#D@;.COA>:^%^GD#9(:=; M^NYXD4T;HH,562<:^ +A:W=V:+&9I9(:C)?6$ =U3A^VQ],^QJ> ;Q(&OSB3 M6,G%VM=H?*QRNHF"0$$9(H/ [0J/H%0D0AD_)DXZIXS Y?F=_3G5CK5D@EKT*KS8X0-,]1PHF8K_!%=0&!Z58([2*I]64O8^6#VQH!0M MWL9=FK0/XPWG$VP=P"< GP'W*0\;$R7E3R*((G-V(&[L?2?B$V^/''M31F=J M1;I#\1Z]UV)[.&3L&HFFF-,8PY MKA/L5PGVB6#_WQ+78N[^2L(6/=7@FC1-GI2V-VF2%]YY8!_2([+?X>.T?Q:N MD<:3BPWXLJG_M;4!4,KF!D>HQ0\V&PKJ$(]W>';CF(U&L-WT@]C\C8M?4$L# M!!0 ( ") BTY:(O_&M@$ -(# 9 >&PO=V]R:W-H965T"[@,$MSB14>4 ;@\O[-_BK5C+1?NX,'('Z+R M;4X/E%10\U[Z9S-\AJF>/253\8]P!8GA00GF*(UT<25E[[Q1$PM*4?QUW(6. M^S#>[-,)M@Y()T Z PXQ#QL31>4?N>=%9LU [-C[CHB\W^D+%K()IB3F-,NHR9(QBRSRG2M12G]!]XN@[?KBK<1OCV#X4?U@EV MJP2[2+#[;XDK,;?)7TG8HJ<*;!.GR9'2]#I.\L([#^Q]?$3V.WR<]B=N&Z$= MN1B/+QO[7QOC :4D-SA"+7ZPV9!0^W"\P[,=QVPTO.FF'\3F;US\ E!+ P04 M " B0(M.DHW3F+0! #2 P &0 'AL+W=O,ZW;1IM+2=+I\O-S?.PX^6C=D^\ GG6ROB"=B'T1\9\U8$6_L;V8/"FL4Z+@*9K MF>\=B#J!M&)\M[ME6DA#RSSYSJ[,[1"4-'!VQ ]:"_?C!,J.!"#U3,+2M'B>=JE2?LX MW? W,VP;P&< 7P!W*0^;$B7E;T409>[L2-S4^U[$)\Z.''M316=J1;I#\1Z] MUS*[S7)VC41SS&F*X>N8)8(A^Y*";Z4X\;_@?!N^WU2X3_#];PK_07#8)#@D M@L-_2]R*V?^1A*UZJL&U:9H\J>Q@TB2OO,O WO/T)K_"IVG_)%PKC2<7&_!E M4_\;:P.@E-T-CE"''VPQ%#0A'E_CV4UC-AG!]O,/8LLW+G\"4$L#!!0 ( M ") BTZ/I?RSG0( *L* 9 >&PO=V]R:W-H965TU,H^@_U% M:=&,+&8K#7L?WE5KW[?A2Y:-83B C@%T"BBL3C0(V9U_8IIM5E+< CG\_([U M9TR6U/R;?;]H?X7]9C:OS.IU0Q;I*KKV1"-F.V#H/69"1(9]DJ!(8DMGX12' M)W"'B0U/[M43CWX*"5)+D/Z78N:DB# ++))!D0P0Y(X(PA189 %%%H"@=$0 M)H^Q2 Y%!/*5&[X#"#!X,2LW!/*5&[X&"/!X4;@Z M".2K WP3$&#S.J#X.J# MZ:5;!Q#DUD%TURLT7)YLEZ2"O;BTMD6[6YTZL4=J>XU_\*&-^\[DJ6I5\"JT MZ5AL7W$40G.SE_C!U/[9=([3I.9'W0]S,Y9#^S1,M.C&UC":^M/-7U!+ P04 M " B0(M.?^WF1[0! #2 P &0 'AL+W=OM&I?2VOMVSYC+:]#"W9@6&OQ3&JN%1]=6 MS+461!%)6C&^6MTQ+61#LR3&CC9+3.>5;.!HB>NT%O;O 93I4[JFE\"+K&H? M BQ+6E'!3_"_VJ-%CTTJA=30.&D:8J%,Z<-Z?]@&? 3\EM"[F4U")R=CWH+S MK4CI*A0$"G(?% 0>9W@$I8(0EO%GU*13RD"I6%KU.Z MHZ2 4G3*OYC^*XS]W%(R-O\=SJ 0'BK!'+E1+GY)WCEO]*B"I6CQ/IRRB6<_ MZE]HRP0^$O@5@0V)8N5/PHLLL:8G=IA]*\(5K_<<9Y.'8!Q%_(?%.XR>L_7] M+F'G(#1B#@.&SS$3@J'ZE((OI3CP3W2^3-\L5KB)],T\.]\M"VP7!;918/NA MQ?NK%C]C<*^ODK#93#78*FZ3([GIFKC)L^BTL \\WLE_^+#M/X2M9./(R7B\ MV3C_TA@/6,KJ!E>HQ@&PO=V]R:W-H965T- VSO0%1 M19!6C"?)#=-"=K3(HN]DB@P'IV0')T/LH+4POX^@<,SICKXYGF33NN!@1=:+ M!KZ#^]&?C+?8PE))#9V5V!$#=4[O=H?C/L3'@)\21KLZDU#)&?$Y&(]53I.0 M$"@H76 0?KO /2@5B'P:+S,G720#<'U^8_\2:_>UG(6%>U2_9.7:G-Y24D$M M!N6><'R N9YK2N;BO\(%E \/F7B-$I6-*RD'ZU#/+#X5+5ZG779Q'Z>;:S[# MM@%\!O %P3S[(L&W)([\'SC?AJ>;&:81GJ[5T__H[S<)]I%@_U>) M_$.)6S'I!Q&VZJD&T\1ILJ3$H8N3O/(N WL7'Y&]AT_3_DV81G:6G-'YEXW] MKQ$=^%22*S]"K?]@BZ&@=N'XR9_--&:3X;"??Q!;OG'Q!U!+ P04 " B M0(M.D+#AH+.9MYX*#E'G/6G@! M][,_&6^11:7F$I3E6B$#38'O=H=C%O 1\(O#:%=G%"HY:_T:C.]U@9.0$ BH M7%!@?KO /0@1A'P:?V9-O(0,Q/7Y4_TQUNYK.3,+]UK\YK7K"KS'J(:&#<(] MZ_$;S/5<8S07_P,N(#P\9.)C5%K8N*)JL$[+6<6G(MG;M',5]W&Z2?>9>!O:/Q3?["IVE_8J;ERJ*S=OYE8_\; MK1WX5)(K/T*=_V"+(:!QX7CKSV8:L\EPNI]_$%F^&PO=V]R:W-H965TG31;9EII6U29M4M1IW6]B7]NH?'B X^[M!]CQW-9_@'LY MY]P/+MF@S:MM 1QZDT+9'+?.=0=";-F"9/9&=Z#\3:V-9,Z;IB&V,\"J2)*" MT"2Y(Y)QA8LL^DZFR'3O!%=P,LCV4C+S]PA"#SG>X*OCF3>M"PY29!UKX">X M7]W)>(O,*A67H"S7"AFH0(@@Y-/X,VGB.60@+L]7]:=8NZ_ES"P\:/&;5Z[-\1ZC"FK6"_>L MAZ\PU7.+T53\=[B \/"0B8]1:F'CBLK>.BTG%9^*9&_CSE7..W\VXYB-AM/=](/(_(V+?U!+ P04 " B0(M. MURY;\[4! #2 P &0 'AL+W=O\3EG M+A[G$YIGVP$X\J)5;PO:.3<<&;-5!UK8&QR@]S<-&BV<-TW+[&! U)&D%>-) M\HYI(7M:YM%W-F6.HU.RA[,A=M1:F%\G4#@5-*6OCB?9=BXX6)D/HH6OX+X- M9^,MMJK44D-O)?;$0%/0^_1XR@(^ KY+F.SF3$(E%\3G8'RJ"YJ$A$!!Y8*" M\-L5'D"I(.33^+EHTC5D(&[/K^H?8NV^EHNP\(#JAZQ=5] [2FIHQ*C<$TX? M8:GGEI*E^,]P!>7A(1,?HT)EXTJJT3K4BXI/18N7>9=]W*?Y)DL7VCZ!+P2^ M$NYB'#8'BID_"B?*W.!$S-S[080G3H_<]Z8*SMB*>.>3M]Y[+7F:Y.P:A!;, M:<;P#29=$W\V\YC-AL-A^4%L_<;E;U!+ P04 " B0(M.MZ5X M6;8! #2 P &0 'AL+W=O'$F*TZ4,+>X0#:WS1HE'#>-"VS@P%11Y*2C!\.[Y@2 MO:9E'GT74^8X.MEKN!AB1Z6$^7T&B5-!$_KJ>.K;S@4'*_-!M/ -W/?A8KS% M5I6Z5Z!MCYH8: KZD)S.6)KLYDU#)%?$Y&)_K@AY"0B"A$3YLZ]=5]![2FIHQ"C=$TZ?8*GG M2,E2_!>X@?3PD(F/4:&T<275:!VJ1<6GHL3+O/R?$K,W)>YAW@9A MFYXJ,&V<)DLJ''6]J_"M+VVY(K.OVSL?X/HP*=RN/,C MU/D/MAH2&A>.[_W9S&,V&PZ'Y0>Q]1N7?P!02P,$% @ (D"+3JKOPCBV M 0 T@, !D !X;"]W;W)K&UL;5/;;IPP$/T5 MRQ\0+X8DJQ4@95-%J=1*JT1MG[TP@!5?B&V6].]C&T)HRHOM&9]SYN)Q/FKS M8CL A]ZD4+; G7/]@1!;=2"9O=(]*'_3:".9\Z9IB>T-L#J2I"!TM[LADG&% MRSSZ3J;,]> $5W RR Y2,O/W"$*/!4[PA^.)MYT+#E+F/6OA&=RO_F2\11:5 MFDM0EFN%##0%ODL.QRS@(^ WA]&NSBA4]+C(\SU7&,T M%_\#+B \/&3B8U1:V+BB:K!.RUG%IR+9V[1S%?=QNDG3F;9-H#.!+H1]C$.F M0#'S;\RQ,C=Z1&;J?<_"$R<'ZGM3!6=L1;SSR5OOO90TN&PO=V]R:W-H965T@NBBB"M&$^23TP+V=$B MB[Z3+3(S>"4[.%GB!JV%?3V",F-.4_KN>))-ZX.#%5DO&O@!_F=_LFBQA:62 M&CHG34X@,+PD EJE$:YN))R<-[HF053T>)EVF47]W&ZX3.O2F#,[8BWF'R#KV7@J=W&;L$HCGF.,7P54RZ M1#!D7R3XEL21_P/GV_#=9H:["-^MU:__H[_?)-A'@OU:GR\_@F?\.G:7\4MI&=(V?C\65C_VMC/& JR16.4(L? M;#$4U#X<;_!LIS&;#&_Z^0>QY1L7;U!+ P04 " B0(M. K;:E-,! "< M! &0 'AL+W=ORA\Z>5%()9JRI:J)[!:ST08(3NMDD1+"VPWGJ M?6>5IW(PO.W@K) >A&#JSPFX'#.\Q>^.I[9NC'.0/.U9#3_!_.K/REID82E; M 9UN98<45!F^WQY/B<-[P.\61KW:(U?)1VVE@O3\"#YO?4=]<' M?)K;'TS5;:?111K;H[Z3*BD-V%0V=[;@QCX5B\&A,FZ[MWLU#7)B*3RJENH%6U:#T)Y\+_0#<[&EJ" M0SS5T*O9W+.E'(1XML&74^$'-B/@<-16@IGA!CO@W"J9/'Z-HO[D:8GS^:OZ M)U>\*>; %.P$_UF?=%7X:]\[P9E=N7X4_6<8"UKYWEC]5[@!-W";B?$X"J[< MKW>\*BV:4<6DTK"78:Q;-_;#3I*--)P0CH1P(M#XGX1H)$1_"8DK?LC,E?J1 M:5;F4O2>'/ZMCMF/@FXB'3$]?^0=02P,$% @ (D"+3E39X0/M 0 M7 4 !D !X;"]W;W)K&ULC53MCILP$'P5Q /$ M?!A((D#J)3JU4BM%5_7ZVX$EH#.8LYUP??O:AM"$6-7Q WN7F?'.8CL=&'\3 M-8!T/EK:BRW"(FBAI:(%>NA4U\JQELB5LK.D30<'[HASVQ+^YPDH&S+7=Z^)E^942YU >=J3$_P$^:L_9ZNB"@4$BM0-1P M@1U0JH54&>^3ICLOJ8FW\ZOZL_&NO!R)@!VCOYM2UIF[=IT2*G*F\H4-7V'R M$[G.9/X[7( JN*Y$K5$P*LS;*"'A!0*,5TYL]D21/.1L6RG]6EUUX2O6BCT*8X+6N&KT,C\:<[J-(;X^BYOI.GD1C[^REJKFQ2W6(]$D) MOG-&=141A%A4\[()5PNW]ZA6"WDV5=F(1Q7HZ?A$+,U'/]_\_[%)6^3>>9: MK&7UI]R9XS+,PF G]OQ+4O/7[EHV[GKM[J1);P8;D-Z # ;X8X.X-XAO!NQ# ]H;T)L!==7J4G&U MV7##5PLEKX'J'N^)MV\1OJ>V^MMVTQ7;W;/ET7;WLB(T6T27UE&O*3H-&6GP M>\5ZJB T'S21)1@P"(11D*D#+\14$7L4&\!)@F"*&"Q&[!S0=PZ\($6G84[3 M. U-XR1+/%Q QFA"4AB'@C@4P/'*4G2:9!0'>20?*=Y!)"!$,H&@L<>03"(P MA%!&/1!(1C&.81H&TC"@)#X.FY0>8T3SR2-B$QZ,,:&(PD I")0"0%[B13H- MA%">V!K!D3(P4@9$\E(J,B!UEJ2YGWH&I![G&4Y@H!P$R@$@!CO "&X^Z-.7 M:]-KQCG%:9[-U0[/M#D,P,X<1@RVJ =,/H5=]YHQ+"&(9#.O%(;;$(;Z4#;C M FX=&.H=N=_7 1&;JRO<'?"T/1"&9US 1QI#9WJ""H@8F8D#GU0,'%4VTWPP M? 0Q< :9?]I!D7^PHM'WN1;JX&8?'6SEN7&#UVAWF*\>B/N^W^3=&PO=V]R:W-H965TS_6C1^[0?]*PPET(-"18'.[6OI$WOD79EB1*=D%JM_\EKDSCM?4 M[DWI@GXK_#MK7MOHI:!)DI&+$QHPVQY#;S#QB"!6?4Q!L11;^HE.@#KY;J>#4IX;WVIOHF-'W?B&2O[!^W;\@ZE3W>A@+XWM/+X_ M'*4T8+U$#_93K^P?8%QP.!HW3>U<]6VP7QC9#BV>C/^9XB]02P,$% @ M(D"+3@,>&UL M?539CILP%/T5Q ?$&,R2")":1%4KM5(T5=MG)[D): RFMA.F?U_;,(@0=U[B M[2SWW&#G/1>OL@)0WEO#6EGXE5+=!B%YJJ"AYW3N(,NH6#L*3MZ:AXN\6&.\+'_OO&R_UM5)F Y5Y M1Z_P ]3/[B#T"DTJY[J!5M:\]01<"O\3WNQ3@[> 7S7TKC##A@S0KJ,/Z.F/UD:XGS^KO[99M=9CE3"CK/?]5E5A9_Y MWADN],;4"^^_P)@G]KTQ_#>X ]-P4XGV.'$F[:]WNDG%FU%%E]+0MV&L6SOV MPTF'?[:CY MB/"&Z.Z?S*9MMCW3[9%Z]UZ&:9RCNQ$:,=L!$SY@DD?,SH%Y1.R?$1&>($@7 M.54:.BL-+3^:\7%$W *14R"R F0F0-:+% ,DL9#60M9)@H-EE&<8QC@)D__D M(C#( V29TFJ4, +TP&# YF<8(5P7CYM:#9)3&OW'&PO=V]R:W-H965T@!LGH MT05U', DR4%'VSZN2C>WDU4I+IJW/=O)2%VZCLJ_3XR+<1NG\6WBN3TWVDZ MJASHF?U@^N>PDV8$%I=CV[%>M:*/)#MMXX_IIB96[P2_6C:J53^RE>R%>+&# MK\=MG%@@QME!6P=JFBNK&>?6R&#\F3WC):4-7/=O[I]=[::6/56L%OQW>]3- M-B[BZ,A.],+ULQB_L+D>'$=S\=_8E7$CMR0FQT%PY7ZCPT5ITK^!21 ML $*&B!GD+TI WEE3)K<:?HI29XF:4J\8@(ZG&=ID82!LB!0%@#*/*!)@U>) M8 91[B]N0(9(\0C#.#B(@P,XV,/!=WG2 L.,/'H$5T"$_(.4!X$R@- N0>4 MWR7ZD!&$?? ZI,LS#-\Y020(1.Z D+]?Y/Y@F(TH'CU='=(A@C/L\8#5);6/ MYG&PO=V]R:W-H965T MNE/)NRJ,6+"O2Y MJKCZ]RQ*>5V%*+P-O!;'DW$#T7K9\*/X)977;Z(SE(1!Y_Z'N(C2 MRAV)G6,G2^VOP>ZLC:RZ+!:EXA_MO:C]_=H^8;0U4.UN-=R]%&A![&+NW*!?.__,NM5V]++&&5M&%Y>HTSRW M&CS4W"LV4P5!O22R #T%!BFPCZ=W%-F(HM6D7E-[3 M. 3 R43P"HI.),D:2,<.*,9'>W"!I*E+)W9;0;B,,#/S()D8(+L 3_9 M!)3$)!OO#J1*!KGN8'(0)@?:LXDG0#;_#2&XQ""@QN3)3 JX*""@*DP]T4D] MQ#C)\?C- Y+1\2Y%@T/%G?(_N3H6M0ZVTMCSR9\B!RF-L/GB)[L$_MCT7=* M<3"NR6Q;M:=KVS&RZ?X&PO=V]R:W-H965TJ[*6:S]7JED%@BG.@6P$HT?K5)5!B% <5+2H M_32QMKU($WY195&SO?#DI:JH^+ME);^M?>Q_&%Z+S3T3RH'S-[/X>ES[R"AB)#__8/]L@]?!'*AD.U[^+HXJ7_L+WSNR$[V4 MZI7?OK NH)GO==%_8U=6:KA1HL_(>"GMKY==I.)5QZ*E5/2]'8O:CK=V9QYW M;K!#V#F$O0.>=B"= W$<@E:9#?43531-!+]YHOVW&FHN!5X1G*9!0S%P$<%0 M%1DE=PPB:.:*F08-Q< %"4.5Y!$%7$HP5$M&R84*Q2BYTZ"A&+B<8*B>C)([ M!A$4NV*F0:V8X.Z)K)@XVVY">AF_U+:5N;/V'.%=,:T$O.C&Y[K#Z1B[:-J-=*-YT+530]W'I/U!+ P04 M " B0(M.""'*[N$! !F! &0 'AL+W=O%9FSG621B5&SKH>3#-3(.95_#\#$E*,(O1F>NJ;5 MUH"+;* -_ 3]:SA)<\*+2M5QZ%4G^D!"G:/':'],+-X!GCN8U&H?V$S.0KS8 MP[YG*F"HV"_NTJW M.7I 004U'9E^$M-7F/.Y1\&<_'>X #-P&XGQ40JFW#UC M4\S2&EWMW)W)5AGKI8C#-,,7*S1C#AY#5IAH06"COK@@6RX.Y(9./CHXWB+2 MW;:'>#.)V/'C=8 )V19(-@42)Y!\J,+#514\9NV$"OK,BR/Q#[OE?U@ALCW_+N,G\ ?5#9=KX*ST*9Y MW!/70F@P089WIJU;,_3+@4&M[38U>^E;WQ^T&.:IQLNOI?@'4$L#!!0 ( M ") BTX 39F3@@( - ( 9 >&PO=V]R:W-H965T[U0K_4J!'XA9SXP?#VH5G+EOC1D\KDA:+Y.2->LU3I\%7&GRK6$\5! V2 MQ $,%!BDP"&>WL2G(XI.PX*F"1I>% 4A(Q1 AG/&,AB'@#@$P$$CG$Z37Z&0BBCDJLA$/($M3@F>V*P-QL@D.9APV M8* !NV._V124$)ZQ43Y3F=N&],KM!H>#.'R:#Y\QR$&#_(Y\\@DHYJS(Z"@? M0,8*3F?VIP!Q"B"?&0.4PF4AO2.C7G3#BFD^?N- &2-L!FBF3B$@)S)C 1<9 M=$^5Z46WVT3R2<$#9)1E^0P07&;0M,Y@/E,7$%P8$%09)CG124TD!9E\2:", MX?&'D%P=+?ZL_RGTOFQ,]*:L.Z7"6;)3RDIGF3ZX!3JXWXNA4\F=]4WNVKH[ M8[N.56W__Y ,/S&K_U!+ P04 " B0(M.$7FX>]8! !@! &0 'AL M+W=OM,8, M>TIUV8)@^DX.T.--+95@!H^JH7I0P"I'$IS&87A/!>OZH,B<[:2*3(Z&=SV< M%-&C$$S].P"74QY$P:OAJ6M:8PVTR ;6P$\POX:3PA-=5*I.0*\[V1,%=1X\ M1OMC:O$.\+N#2:_VQ&9REO+9'KY5>1#:@(!#::P"P^4"1^#<"F$8?V?-8'%I MB>O]J_H7ESOF_-KU;IW\S2Z9:=N$>";$"P%]?T1(9D+R1G#5I#XR ME^IG9EB1*3D1Y1]K8+8GHGV"Q2RMT=7.W6&V&JV7(HF2C%ZLT(PY>$R\PD0+ M@J+ZXB+>P?'6\3#_;:'9#.)Q/&3=8#I;EL@W11(G4#ZK@KI515N M,6EXE<>'$!\&73V, -6X'M:DE&-O; E6UF5,'F/[L%?V XZ/[_8W&3][/YAJ MNEZ3LS38-NYQ:RD-8(3A'39TB^.^'#C4QFX?<*]\T_N#D<,\SW3YJ13_ 5!+ M P04 " B0(M."RG?* D" !!!@ &0 'AL+W=OF.FS 8?!7$ ZPYPJ&((#6IJE9JI6BK=G\[Y".@-9C:3MB^ M?7T0E&!GN_S U\QXQC:F&"E[Y0V \-XZTO.-WP@QK!'B50,=YD]T@%Z.U)1U M6,@F.R$^,,!'3>H(BH(@11UN>[\L=-^>E04]"]+VL&<>/W<=9G^W0.BX\4/_ MVO'X]!O?$_A>M=KO :\+N%D=_4 M/97D0.FK:GP[;OQ &0("E5 *6!87V $A2DC:^#-I^O.4BGA;OZI_T=EEE@/F ML*/DI3V*9N/GOG>$&I^)>*;C5YCR)+XWA?\.%R 2KIS(.2I*N'Y[U9D+VDTJ MTDJ'WTS9]KHI<03X1X04#&F8[Z&0M<%HR.'C.;-6!U M)L)U+!>S4IUZ[?283,ME[Z6,PZ1 %R4T8;8&$]U@HGO$SD;$X0Q!TL#L(G*Z MB#1_=<=/%RX,)M68WKB(XB1/TFQAQA9;!6XSL=-,[#"SF&-K8V[F,#;>A=S9 M6#EMK!PV%NN^-9CD_VMBBSTRDSC-)!8_2G*W0.H42#^PPZF=)DP#]2S2V&*/ MTF1.,YF=)GUP7G.G0/Z!-+EU7C/7SMA25A9T\S&KR_4'9J>VY]Z!"GDOZ*^W MIE2 E N>Y/(U\CZ?&P1JH:J9K#-SJYF&H,-T8:/YKU'^ U!+ P04 " B M0(M.PJ>_G 8" !_!0 &0 'AL+W=O*U%H_.P-*;=(:3/)=1E6 ;]X M4BT0B2*&:EXU89'YN:,J,GDWHFK@J )]KVNN_NQ!R"X/9?<9ACQ)& SAO\(#A(4[)W:/LQ3:OX/S71M9#RK62LU?^[9J?-OU M*RP=:.L$,A#(2,#Q?PET(- 9 ?7.?-2/W/ B4[(+5/^Q6N[N!-Y1>YAG-^G/ MSJ_9M-K./@J*TPP]G-" V?<8,L&0]XC#$D'Q"$'6P.B"K+H@GD\G?!RGZP)T M58!Z@?B=@>TL1H]A'M/TFU PF')8H;)]XW0Q;-<,69N)9YCU; M?H$D9FQ^-$L83>EV.[\W:/(KN-+TC:M;U>C@)(W]J_S=OTIIP$I&3S9:::OA M.!!P-:Z[L7W5UX1^8&0[E#LTUMSB+U!+ P04 " B0(M.T*NQX^T! !] M!0 &0 'AL+W=O\;_C+^Q\60CXR^B M 9#>:T=[D?N-E,,.(5$VT!'QP ;HU4K->$>D,OD9B8$#J4Q01Q$.@A1UI.W] M(C.^(R\R=I&T[>'(/7'I.L+_[8&R,?=#_\WQU)X;J1VHR 9RAE\@GX]QJ'/_<[@[I%IO!+];&,5B[NE*3HR]:.-[E?N!!@(*I=09B!JN M< !*=2*%\7?*Z<];ZL#E_"W[5U.[JN5$!!P8_=-6LLG]C>]54),+E4]L_ 93 M/8GO3<7_@"M0)=IPRRUTYR=65/5"N6]%A'& M&;KJ1)-F;S5XH5DI#K>**)PE2 ',%-A)@4U\_(XB6E%836HTO=4\;C=!L$)Q MR#8X2@(W3N3$B6YP\&:[PK&:9+'/)R>/2W<'*'8"Q;= V]5&^UM-O&:Y*WF' MD3@Q$LX$J3-!^H%[3C]VSPZ9ZUC1XB'HQO23\'/;"^_$I'I3YL^O&9.@ M4@8/JKY&]<+9H%!+/7U4&PO=V]R:W-H965TX,J;=$:*S"@33=[*%QKXII!+,V%"51+<*6.Y)@A.Z MV6R)8'6#T]CGCBJ-96=XWR00J*!#\'NT/D\![PNX9>S_;(57*2\LT%W_($;YPAX) 9 MI\#LNXQ&HO_#F?@%NZ&ULC59A;YLP$/TKB!]0?,: J9)( M2]-VDS:IVK3M,TV19FU-[(6E?ZRETV9*3UL#D%;-R+;=:2R""@A<5!F>>6O M%MW<4[-:R),J\DH\-5Y[*LNL^;L6A;PL??#?)K[GAZ,R$\%J46<'\4.HG_53 MHT?!$&67EZ)JW;U7\59%!IN,M$:6UFTW:^W/;5*EC:*3J7,7OMG7G7/ M2_^%<4O#"=02Z$#@Y%U": GA0(#X70*S!#80*+Q+B"PA^B@AMH3XHX3$$I() M(>AWMRO7)E/9:M'(B]?T)Z[.S,&&VT0?B*V9[.K??=,5:_7L>172=!&<32"+ M6?<8>HT)R1ASAV%@C-E@&#K&W&.8<(QYP#!LC'G$,-& "?2>#!M#T8VA70 V M"A!/DNTQ<8>I.@Q0B'B83!+&<)010O"$0C2AT$D(R$3H/G2%."1L4JP'!!;% M.G4\'8:FPY#]F:2S[C'1M4Z:Q(R'N%"$"D6($)\(]1@@5TKDA@$P7"A&A6)' MB"93*R 8/E/%!!5)D-6D> ".!N#_/Y>/W*DO2V.>IC.9IJA0Z@I-#]+&Q="4 MXR*F.%C_(8B,TS@P$)W1F>ES@(0(ITT, 9&9PPIXVP"D;["98PBXT<%UNE/B M#;@>CAFA$YLZIK6[:<(*&33#A)<76;,#?E;UASRJO6>I=+WHN[VLI=2"1V0W.@] M.NI+^3 HQ%Z9UT2_-_W-M!\H6=M;=S!<_5?_ %!+ P04 " B0(M.LP$W M7]D# B$@ &0 'AL+W=O:. DJX QHT_W[&7 S;)^3Y$-X>\[WV'?W M'&9VDLU+>Q"B"]ZKLF[GX:'KCO=1U&X.HLK;.WD4M7JRDTV5=^JRV4?ML1'Y M=C"JR@C',8^JO*C#Q6RX]]0L9O*U*XM:/#5!^UI5>?/W093R- ]1^''C>[$_ M=/V-:#$[YGOQ0W0_CT^-NHK.HVR+2M1M(>N@$;MY^ G=KPGM#0;$KT*IB\ MFLQSWHJE+'\7V^XP#],PV(I=_EIVW^7IL] 38F&@9_]5O(E2P7LFRL=&ENWP M'VQ>VTY6>A1%INL'TIB'$8.G&!:;F"6$029FY6*PB7AT$0DW(6O T7\_D9KK><(8G# > M[.G$GB<6SQ'"!D@]0% \_"PJUW$&'P+R(2X?:\JK$9),_,1W<6RM[OH:RN!" M02[4Y9):7*@S9WM5+B$,#@SDP%P.5CZNV%4.EQ &!PYRX Z'Q,YE[GB@609F MR2U(@U,"94ZL\:8Q#3%,;/X ,@X25.4 M4 )SRD!.F*@TRO"5QBI#/ET?)$>#+7@(- MXE-?+,DR[/,%BRAR590P:OO"3J:A.\Z8QQ,LC\C51\+L<&E0:N0TR3R.8.U# MKO@1YC0?"CBB'C^POB%7X BS.Y &3<.D,H):=!X!&$)Q1A'W4(+E#KEZ1Y@M M_!K$KVLJ@@4,N0I&F"]&L.X@5WB<9%AID!FCC&3&S^,6EA;D:HN3&BL-LMQZ MDAW#">5<:P"F! !;C=O#3([$EIPGP="7M>I0 5X-@S!%S>&"AO;HG6 M4H.F=-FE!HKA"L= A7-/\6*X>#%0O#;=!^R^?>CW0A]?N"PQ4)9N*-W7BS&2 M/E]P<6*@.+DO>>'BQ%!QVKT.N]T>X8MK Y).F_&KQ;C12>/^HM,=/XLM/@'4$L#!!0 ( ") MBTY&;O(GM ( &@* 9 >&PO=V]R:W-H965T4@9,.TV&U^*ZBG%\.WBN MCB=M#Y)UV;$C_\KUM^Y)FETR1ME7#6]5)=I(\L,J?L#W&X*L@[/X7O&KFJPC M6\I6B!>[^;1?Q.1:1VGZUOT#ZYX4\R6 M*?XHZA_57I]6,8VC/3^P^V?5>N>UR'^S0UV((,#&1W2PM72@USF[YEFZU**:R3[R^^8?7=9H797*Q@0:;36]#)C9XM$A,]!%!(,2&S-S3G,(! M4C#'U 5(I_PLAP,LP +%V#Q)H.E5V1ODSF;MH<@E"+S@4D92,KFI )YI&Q& M*K(@)@@T,M9AF]M"9*6 M &GAD9;_2<((;BL$L#*_KWHC.H&ANS3 ";0O!CBYSQF:'+\!+;, ">SB!TP MTDPIR.SZ2( "MSI. 0KU*2E43^CB8$G @"84OB8,1O_V@F!!P( B4%\10*. MQF)8$3 @"=1O5= H5 ^L"!B0!.HW$6@4XL"J@ %9H+,&ZHWRJ92B198%FQ76 M!0P( YTU$: ,*48YR0(P BL# 92!^GTT&.5_AR63/_J&RZ,;<52T$^?6S5>3 MTW&,>B!N4/ACWL]@7Y@\5JV*MD*;<<,-!0.FY@=MEX59 MRW[VZ3=:=,-&PO=V]R:W-H965T MA,RW.]<>B);S?;8U/XW[ MM7^H_5YTSK+.2U,UN:V"VFP6X2=Q>Z?3=D 7\3LWQ^9B.VA;>;+VN=WYMEZ$ M<3LC4YB5:U-D_N/%W)NB:#/Y>?SMDX;GFNW R^VW[%^ZYGTS3UEC[FWQ)U^[ MW2),PV!M-MFA<(_V^-7T#25AT'?_W;R8PH>W,_$U5K9HNK_!ZM X6_99_%3* M[/7TF5?=Y['/_S8,#Y#] 'D>H+H!T:E0-_//F@_JT^/NL/LP)(%HGQ]F@6T/-(4MBP0 MYNLSW0T'(J68]]T$IN6'-,2F=;$-YW$IB7'M!R:'F\* MJY8U0JJ)QP^%52N.:D7=J8E2 MQ$,W1[5"JJF6L&HU5*W)J6+5BJ-:#56//K\HK%IQ5"ND>D( 4%BUXJA60]7C M36'5BJ-:(=5D4UBU&JK6L< I-%:M.:KU4+4<>8316+7FJ-9(-7%7TEBUYJC6 M0]6C+6'5FJ-:(]542\0/::2:N%8T5JTYJO50]73D1S\VK3FF-3)-_7K4V+3F MF-9#TV,M8=&:(UHCT8.6HHNW3NU;O1]9O\VTL=89G]%_]X?! MSF3K\TYA-J[=G/KM^O0V[;3C[+Y_4QB=7U&UL;53;;IPP M$/T5Y ^(@>62K@ IFRAJI59:I6K[[(7AHMB8VF9)_[ZV82EE_8(]XS/GS P> M9Q,7[[(%4-X'H[W,4:O4<,18EBTP(A_X +T^J;E@1&E3-%@. DAE@QC%H>\G MF)&N1T5F?6=19'Q4M.OA+#PY,D;$GQ-0/N4H0#?'6]>TRCAPD0VD@>^@?@QG MH2V\LE0=@UYVO/<$U#EZ"HZGU. MX&<'D]SL/5/)A?-W8WRI&'E+\5_A"E3#329:H^14VJ]7CE)QMK#H5!CYF->NM^NT\-_"W 'A$A"N M 8%M#IZ%;.8O1)$B$WSRQ-S[@9A?'!Q#W9O2.&TK[)E.7FKOM8C\0X:OAFC! MG&9,N,$$*P)K]E4B=$F=R(NS">W2.H42>\) G\G9<@4[%?]!= M;?5[M!H4:F6VJ=Z+>2IG0_%A>7#P^NH5?P%02P,$% @ (D"+3CS1U5KN M 0 S00 !D !X;"]W;W)K&UL?53;CILP$/T5 MBP]8\HBISWBC8M' 62/6-$_-T#Y<,NB(*;XZ6YU,HX<)%WY (_0?WJCD); M>%*I&@:M;'B+!)QWP5.T/60&;P&_&QCD;(],)2?.7XWQK=H%H4D(*)3**!"] M7.$ E!HAG<;;J!E,(0UQOK^I/]O:=2TG(N' Z9^F4O4N> Q0!6?24_7"AZ\P MUI,%:"S^.UR!:KC)1,*LY&%9T*(^]N;5J[#NYD=:/Y"?%(B"=" ME/V7D(R$Y$Y(;?$N,UOJ%Z)(D0L^(.%^5D?,G8BVB6YF:9RV=_9,5RNU]UJD M493CJQ$:,7N'B6>8.P)K]2E$[ NQCS_1XX\!#I\1ZY4_0N(M(K'\9)Y@MO$+ MI%Z!U JD'[JP2'+OPR3^()DW2.812!=!'&9E,:W#;![C9+UHF <6;I(L7*2# M9[> @;C8@9&HY'VK3+]GWFDFGV)SBQ;^O9Y5-UIW&3?H/XBX-*U$)Z[T';4W MZ&UL MA53;CML@$/T5BP]8C*])9%MJ4E6MU$K15FV?B3V)K07C HFW?U_ 7BL7VGT) MS' N,Q-,,0KYHEH ';QRUJL2M5H/&XQ5W0*GZDD,T)N3HY"<:A/*$U:#!-HX M$FLB19+2[S>OZE_UZ]TZ3B=I M/M/\A&@F1 N!)/\EQ#,AOB/@J3+7ZD>J:55(,09R^K,&:N\$V<1FF+5-NMFY M,].M,ME+E9"TP!PUBCU&JSNC"9-=&Z7Y>AW]PRCQ&B4>H[5?(/4*I.^/9)L^ MC(20+,Q7?I_,ZY.]/Y%M]C 1DJSS)+SSP5>WSKX"WZ@\=;T*#D*;"^RNV5$( M#48R?#)5M^;A60(&1VVWN=G+Z?.; BV&^67!R_-6_0502P,$% @ (D"+ M3CG(F%8O,P ./( !0 !X;"]S:&%R9613=')I;F=S+GAM;.U]67/P"[BR0L-- &&J3HV!__Y5$7 M@$(?FL/'\F%&S>XZL_+.K*S?%\5:?%DF:?&';Q[6Z]5W;]X4\P>YC(JC;"53 M^.4NRY?1&O[,[]\4JUQ&B^)!RO4R>=/K=$9OEE&,L%8>B>(AR6?S^S?K[ MW[_!/MQO)-YGZ?JA@#X+N:C_>B9OCT1O$HI>ISNM_SA;Y4>BT_*C6<_,NYYZ M<]7BH[R/BW4>0;\/T5+66WW('C,892WO\V@M%^)Z'LMT+HL0OIP?M8QY#*O( MHP2:+.07\2?Y7&_7Z72ZW?YD.IZT;N+F>=583+=S^.?6#ER,(8"QKG+(GNZ[_>14G1&/&XS'/J$!=SV.Q_RRAOG?WPL#,Y['=; MX'46)S(7Q]#O/LL;P/J0I8?1?"ZA#1T!M6X9Z7H9)8EX5Q9Q*HO"NY=U7C:6 MIWJ?+F5^'Z?WXH<\>UH_B.-LN8K2QH)TZR_B!O"FB G;&?QM")$ME]#F>IW- M/X?BFLA"7);K8@VT Q/6N\&X^+6X?E[>9DD#(#]=7K>B@3H-A0UG\'6# /_< MV]:;SM+;UX<[QQG@>5K T<"G(DOB!9W3NRB)@%1@N\!3"F 'GZY/Q*N#UPW4 M*^^/1+]+1-V@!XUDLZ* 0;YK_!P5#\1_YOA!_JV,'Z,$VC?6/9O/D8,5(I=S M"8UN$QF*5*[K[2[7#X"*MA$0^EPM897E/CYRE$S>E0.3BM+[&-;L'PM%P7?%*IK+/WP# MO+Z0^:/\YGNQ P!@,I'=;8/#; [+4\2PD*L,/C:V\T.6+9[BI('1-YPR,'D"S%J]6>9S. MXQ5PDV>QS@ >">'T*LIQ 0T-6Q*KB1V*WWYAS MVK("!O3%^>S=^<7YS?EI$]K J>(U(ADC\AQ$-7 BD'F>T8#<'P$[">XD M+'4A"N1R;\5!YPBD'"Y$ $V6\JWHAB#W\#^E&(BH7#]D>?QWN7@K.C2=^2DN M"CP0HB7+)T4$+$K>YF64/QLE@1H!$RGAW%K9"#/@RM*IV#I,KE R!W M_"@!C>%O'Q&4RY+18R'OXGG?;9< &XHK9AQ-Q?7-Y_*_YYIN7+ 74\QQ%WC>ERM4 M0^&8F3\>5PCO(@.E\]6G-"J!?.7B=;O2T]_9"&KPAG.B;KNL#?CV43[*M/0Q M[H*0-V_Y'?1?V,@JS^Z:/$(! *A:2].&.+Z63/9MXO8'F4JTCQ" T6(9IV2! MK1&";5V84V2-N>OMZ 3N\FRIV\)!>9B3,Q(S2_%*C=@XJ7.M$_BYJOE9]6]9 M.''I;5/1XF\EF*R:AXMU]*6YR7/S6]NL'T!E2V"TMN]!,*WS^+9$_ :])=V- M7;?TWL]&KE(,#M? GS, 0'R?*MUG#AH8VED)NQ7N(Q"&K[!? W[-H>LM_@+C M/N :(^!LT;U$P4D\HL$<@'1OHR*>$Y(NX@0WVPJ/%8M@,](NG7?B-F3?G"79 MTXYLY7AV_:,XN[C\R[4X^WCY7EQ>G7Z%W\%783G M)"46<&$.1C8I_K0_1!'X3$9669"B[% 0<)[XT:^8GT@X$)"./OWV+(J52,"= M/@*^:>D"8WL)]_@!+!QD]Y79R=@A2">[F C6M-EF!?B.>RL(MIW(^8>?3J^W MG'M)%J6P.N ABNDXIMS6#<4I'L-^&SH[ M_S#[<+QE0Q_!1GYV,&RCD0)&[US*A>+CL E1@%%/)J@CT1N]] 30('4-K=9= M@WQ[C$'ZBMMG\4J!X+6X8X5N(PQ.[^[DG"2H_#(GI!3(^L1<(6B6\@R[>"8^ MG-X 4AQ_/)U=GXI7)Z?\Z35\)PC4J.?2!U1O?YI=G'[PV,AM#4/Q[O2'\P\? M\'@NSP1P@_/+DSUZG\*WF_M=SKJXO0]S W* M_H?+#XQ,K=7Z/!S/8C;MVHT..R^58WS>V[0F2"Z( I:EQQ4IFTTNXA3(BKC+=UB M][WZS_^8]'J=M]@LL,WHV^[;U^(I*DAKR5<9]P>&<@*4_H0"$>:$?G)Y"QRI M-T;%%LQM48((S(G"TPAPXJ;,;W%1-WD)QW8*!Y6:V2]3QY+NA $, /HQ=E5> M6IH_EX>+;!FC]"+5!'\G$.-&/\C':!$=":9>5!'^6";/HMLC/7M<&0UWU1V_ M+7AA.#33ME%X@G9 _04T$&:IP']EG/+ 0 W+@CXI.*J90@5 _?63K']3%OH+ M/#;U95;FZMN 3#.?(H;-8\"LN:M@%.5M$2_B* >^=B1N'O*LO'_@KC_**%D_ MH*2_B)>H:=@S__%"GW,8P-3B">QU@%WVA,+F.$HC&#&U8S^'XDF*A4P RKE8 MELDZ/ES$Q3Q>@8*)1[C*XR7^^T!3SA%%8 ,9MAXH1\P*4%7YH=*2'7&\6%I M=R@,JAWR,N8P=CQG52 BSQ52$_P .WK*\L^( ].QB.[N0$D@=NUTZ/5Z0J(+ M@M8RQP@.Z&\/P*I0ILX9GG.TBP+:+N#1)2QC+:,ECKO"J6@LBH&A%RG*-B)"X"Z3S.@54"07$9K_G:%^NT2IKB7_ 5HM*S6&-(--/16 M9,#AU[R:8H7*5H)VLT V$<^5/QI$W:* M\1[F B$0BFP^+U>1%E!QH 4J?*'XC"0?XR^X*M!#RZ+ 75N T'Y NP;<2F6P M9GT%T U.*C54NY+)(QX?81?8_NAB+<12+H UI.[R8/2"6,%"NM "80WX >I= MP=O'$X1I@+:A)=I+:ZT]F+,@O*$9T*6E@!^B:47,!W%6+E=)]BQ1-6%0TZ=Z M=UA@J!R)N3U%-6N.F@3J@GJJ ) J+?,"%98$6H)%<21F!9(?^V[9,WU;Q@F/ MR# 1!?.L8 6J&,9(<8U^E%%41ZPK5LQ%R;&UG#^D=%C4Q<54 *F: E I)4-K M!?^RTPS7@2I@#NN_U>+GGH-NY J0,*)"U0*/1B;9"G=H&IN*L_&9KQYBL+$R(,@ MUHLQ]S4C&\P)'0[O,_RL!LM*XN:II(V(IQ@ 5AD1]!X$#:S@5CZ#A(3@BV$:B!!U:)5%,5*0<[8"VCL8$D%M& MZ[5F[D0+0,W$D0PYX,1Z)B2LU%@Z9/04,@*S+M3XS-Q]K0TN"K8LE\!=B8.; M036@@&IEGBHO&4@9H!!#?B3*04.: 3=)1&_(D!"O'&W#*#T!QN>-,*]H4)J: MZ @CCE.+4VWAS.YSR1S8';>MD5$+;YDWW((,EJ 7O8I?!\Z<;^&+^+4 _8(^ MP#8Y_&U>!_#[#(1/T3/*1#L6;2, 1%! MBRRJ:WW_P]F-Z1J\@I[=7G3'^J9B@6VG%+IG(2+\FI UFK.8,19X?5Z!>19J<.T\NQ.W M 1MI+,,J40-2 G_\2($EIJ0U0V]@_K((=H-QJQ&!DS$5N#F@/ZYEUFRVFQC M>2C-S+)\>KWK2@B#HIRC@(O6,&&29$](D=AK#JP9/V\#HW\13UF)0O)ZB8'>3V59T'3%)ARN83+\5J^C)=KH'P1$UER%_5BD M$KN!X[O'K"<>)E C*L<;L#ZP>7+\O7#1P86\.PGH47IIUKA"/@.2I5RS &2] MTQY*=9R QZ$C0!B#)?%7%.7$B&#<]% 'PC_*^U*Y@J]A', O/BSHB&8:F93K MZ#-I"U5$)<$FP*@)Z3#4*%&:T"OM,MP"0PE6Y!XYS$0 M$@7)3EQL=KMF:\11DK8L#EVG.6(-*#;!NKY2=!?GZ$53<%'BTY%@1/+$X!A: M=%YH\' GHC-6;RBR0RE3#)('T,I OR ;0;M, %.,RT11!XZCL-,T$T7%D0XS M>Z#LK,*S="0OU+GI5R/7 5]OXY1:O"5#@N(UJ.BC,B@HWQ (S>9!Q@5JEXQ! M ,QUA;$LE&_"!2OC'IKARK>M?D_D/6Q?T6(>;CFVD!6<@U$X[0QX[Z6.(%0] M E[0DFJ*J4VY7-0(*41DJ\B:O$R4HI4;ZK2R1P+I6E7,' "EFK!UI^7C]:D1 M[4?!#=D;%H[D""\>C%L%YKI+)%HHR,PB&\0@PY'L.N3<:4($F.(X"1XR\!'B M@&Z'IP>0Z"AX<,%H:L"$K(Y;.QPA HHWX #2-.S\+HIS&)R YI4Q%AE7*C> MCY:9!P$(K1BKDX;68WR'09] B[\5I?,Y"'\DCI'-D<_>@@A[WV79&OW?&NDP M+TCM/GG6 ^!6V:WBIQA]\@&V(_(GX4M$[+ 5E26%AW_/,5V8 G,U5\K_AVO_ ME,8FL$5[GH&2"S1M3OW3T?61^&$VN[*N1,3<##1SZ!BXR$9RVHMMC.$.9!U- M7T.QB+^@S8)A=XEA=U]N#AXRT+P^:% D 09H]Y%,4RBMI]$#/V.^)%M/M MZ9'?@TRK14@2QB@+;PM)$E0,36)*4$9GCQFF=#(&D R,.CHVW71 D^I7XX,Q M*6=S,.4*5@]UOQ,0;[!1?6['LQ/MF 0XV"\/K,;\D#VAU&*TWV&[HK;=0$=^ ME;9C&3YLOXI8O+C"K.Z@N;9/UR=6WNL@\['>[8T39-:G4Z;K-@TR\(*3$$@; M\;Q,@,B1;\!"-GLZVR4C#,.\'A(T\8-@9HGQ&M7 * =L?9XOXCE##@=\8=)9\(?1H-Q,%/A?>:;6\<8JZ[3X;21 M$'M=+I=*B;N&C1.@,"'9 O(*\-B7'NEILB%7A^(Y/4+5+F"M?]K -^8G#A2? M@L!;$BD@LC&?,#K8=NZRB9]HMV/A^F$!GLOHLQ32S$N.=S DELJ*8&V>8Z7, M-M$/BZ3,P6J4L/[PO4JM?7@65Z7:RF4"[IGW8B<4H -L]R=3[Q&E3R)(:M K?/X#.L.T*W-P9)K7TQC_-Y MN413DS3,FAK#^A/YD?&76Q)Y*!V7;(G]M5S<*[WR-BN5"@P&)HD"R@$A*W@# M,B@!DJ/*0MA0K&OG8FQ']I,#;T9E9+6*&$24$T;;+S*PE62AF?*Z)+V0]A)8 MN-6U7MC*,Z D&ISH"H16K.U0#AM99O"7\9?49:\Y1IB5=6;RMZ[9@E!2@P<- M>!)2Y8W;C'I44&'=6'P(0IP21?Q:$";>X_$R0:(*>675-S+(W;#U5^@G.K:T M;A>>)B3I-Y5C1"TR%VOQR(\86=!12?7KS(32BH -'CJ+5$PZW]I,_CBMC_4G M"13T","0?%%+:GLI E4-G50IRC3X4'7KX> \B.JFG.<*Q*"H KZ0F3FSKK$Z M&C0$?B5@;JDMB9X,Z*XPT(2$C-FG[*<,A8Y!XERT5W52K#"Q."[$0P1B^!;Q M1Z*C.XWHV&O)V2:#T65 [ 8K!"H/ E0!K0)T.[7\AI"Z(5QU=B.EYE53!$F- M_'!\CK9PP7()J64A"Q!MD6,KM&-RFFD\?W<%Q) /2NC6=:8"ZE-F%@_4"YQ9$PJ6T?3:J7\*2[ M$;YI;PW=ZB'YB^=,FB6RZT56WJ[ORL32+X6R(V01N82EH*'UWNH ("%C^:1] M.$MMYCK>I^H*B$"CY/GO,)Z55L%MQ("@VU;P[9).,Z4HO,(R^ST8/R"SGD#P M/I!'QEZDP<1%S/Y OTZZ4!=8;,Z@&4+EHF&$"F,J)/<6$AWF&!R.&1&V 090 M.5H /L YPQ&DACNW-U]">V!\$A6M)%$A/$:[ -HF2O7 IFDFD@S6G:-/Z19A M=X2Y-''ZMY(4(!X5Y"Q=8F!6\I2CO9P>9IAV<+"DIC4&C72I-#"F0%E'BP)FC411\EG8F2BM\%%Z B4Y@'H\ Y)K;1*0S) M$U0$QZ09H!INEF=^ BY9(G':G_KJI\L[$!O2T^>LD@)\%W]AQ%(_BPO@%(<7 M,4*>K\E6)#EHP$DLF443@ KEG VL6.^/0*QK_(9/ *EU6$-_YWYI M:Z0;S+AQI+(C: 00I,QMB&DH"P-CFR4Y1)-HSCBGLE^J-AR- 6 ATR:B:#TG MDBZ1@%4^$J>G<4?<8U#;(^D5]5TV(,7^/>7>IQ7],4J)%^(8FC$R5ZSO^\;& M(3@*DA=Z8>Y2:?D:L&I7'/Y MVS=<:EOZ]H/)AY9*!-F3CD5=R;ZA-E0J*D^ M*CV6--J$M+EJ/$.'4Y"NU(Z/Q"?2?QW_LG([*"?]O5Z&DDT6,S#(&!AI,.(]]!K]<)>Y-!]13,Y5N<'VT<-U"' M\%U]CI0%H0)KCB?ACB_>:T>RK,N\L8J=R'E)[/0L7E,^"S B"C4WA@I:AYI0 M?ECCP&O9M!8[F)%KK+0 9=V/_-N<@163O,4O:2@3T];N!67KHAP&_<892<5! M-+Q1H[60.U$*=(4L49U!VP&9L^2T'!B$L$U'PP-BXNNG3*PRM+31[^.>R!R; M+!D& @5GH\=]I!3J.0!6 ?=,-N9Q!.M3H!?W9[X: S<*_]!IL5 MF:KF05=B?M)78FR6^+EC'Z#=,E>QGQ8KTUKGCF$1.M%_&"?#BJ7<$/V5L#U%#WY!0/0+:'J+F0&AE6G4':_09B*\^^ ML$8-#>*SM-KK&YN8 B7L88QFEQMC7F#S=NHCD@ MQ23K0Y#?1RU;^^FR6Q2Y1&@ZD$9#N!#!E..8K'N38$C7./1?H4>1(R:(]A3A MF*(1Z_RU-%&';'\GR*)PIZ1>4.OQIF:9.AM1 S!'(=/ B1FH82TBP[@&$ZMZ MA[&242OUK;U@_G8G(U8&=?95G=KX.KUR+=7H8C !NCCA0#GPN0>D/Z?,!GLS M3WF $TE)T:P)DRML0:5R=C/;@B:WJXH;8,4DTY5%^$P60@N&&F'$[FH;$U19 MP%K3IV)6R(L1X $!_$BH*]'H*\G@9.ATO4&Q3RL*)-APV"<=#@L^9$>XR<%A M!U0'/2 !ZUA=.E FQ+'R.!3"/W&E+ULON CG4H1.R0ZT\P:Z_MVX"OD81YT1 M42W:^RDI7M':.O&?;9X$&T1T)^-9"UV3\PW G)OE4G8%NGN(O- ICF*!=?F% M,LT43:LD;4)LDSLG.3,6+"5-89)4%YUW9$'DSY$U&4*)[#:)[Y7C4+D<'1M5+\V.IETFD>.K$8Z+E7DB RD" MBO?/M=-4Z,Y0B_9/0OZ!UCDH.]4,ECM(9@-9G QC;"%->P4,4-PA96T8G]A3 M@7P4\X\3K9-'A3(PB1HMX@;V!H37#YXETJQJK@I_A:S#8]R3M7H)V&0QZ,+PCK\_(-&A,1536A&'VH2A2*10XUHF"+ M%@@\NN1YI!(!Q W^595R6FGDNYGV8J@O[\C*K?&@$U8'9-[E12)DJQ<,BGA]:MQP_[A04:+\'BUZU0#9 M$XRKM\:\$^_58))CSCL9=KX-U,Y08Y!,#NK*6):ZBSKB$(FS33:[ER!5M:VY M"\!@A90=Z:PM<.CSJ&'8I9F)A:);5]DZU8505FSZ;!.RJH'X2J8;Z*RPPP94E '*5A.Z@G4QZZ-7SC.K/?-(Q0Q0COCP>)QO$YOJ9 MO!"'OA2/"$UD/B17K]+C,O+YW,J*N]>&#VU>HPWXA3:-3%]_HR3A6*IJ GCV M?/<1Y'[@1'S\"F3(:82 :147-'/2UL(C*O%;AR^K%]K(&T:*,@@^-[!3548! M%W'F&#:&LA-#/'QH%@"<9VH&+U39@T9@D\G&D[47M#@%_.EJBI-PCEJMR@K- MC5Z-T3 <3ZV3HS\-)]UA:VVS8*.30^TOP9N7&/@AJ*8$$@KLMD=RE1QWJX7I MY$5EY"C0!RV@=\MV.855CDV0MS5](W#CS11I,13(G*)<*;4-=3AS%@A@"D6P M J)RTMQB-CFGA,S<*P7: V+OCK7EQ9B&09)[3J(&/@,Z^*(XHZUQ+B\BS-D'/S6LY3<3E?9W3UO],=L49(O%/= M.@';"@W$T2'^6)'KKXS ?_T=1B#RZ/"42ZH2LF(N#CHR&3R72K<"=#I/\5XT MZ)0XN5,W8./LG5XH*+!CYIT,>J]Q!+P8@@:?M[, \MM&9=](Z0WC.$O[REJ-7>4>\>XO9\KO(HR#3,*\>7-M"A*6TL/3=K2 MK8QR?2U4>529R2PD6&8+?QQC0ZR<5AHL_/N@R/AT- J[G9YU98_"WJA;]U!? MVJB4G2&JC/B,;@(L' A_'TRZ_;#;&_+M6'M3S917U4'E:OE5RGWNAM/Q*!Q, M^GO#5\':U6_>1$] U-=XL5FSGC"2+9<:(F@,U6=)?$-"]'M?(MMEW&Y MU*94IOSD1O+4=MF@'D]:$&;7-2L'.[]_51&:@2$A[Y0!*C>>?"1567C76(F^ MU$/9"55WTW>>'/-Z1CF6U);N[.( ,&S4[0"FC^GS<#0(NY-.H*D:DS%4;)'8 M,V8,+D1OT O[HY[H]E\;CG!HCK QB&A4A/9J?L$O M?V1<+MG)X.%,0+[DSHU8*8V6'.?,E*3N<\CT;9.QP,HGWQ+E8(!X^195QE+= M<-.&)BM;;RG&]!YO[*NYI@!\#/I.!OQI%(Y'_6#&X3#VWG F)WGC?-S\+4@^ M-2$/CVE>UC8W!9*Z!)%>1_0[87\RP'^&DTGK5+S+HK++;J^RS=J\UWA!:ZD4 MLJD8#\/IJ".0VXX[^TW3V30-'@;!KM<3PQ&P\XX8CL/^L/?U"P\,^H/VJF5O7@8"; Q0?A:#AI2[ "0[.XL M!JUW%JDD.1P)9S@B%0]8C>O#.AK)0AL>#IAY:^*9]!\,+:X<3-B*ITT'G!B3U!%A?;KJPH5?,H@2<+3EKK)5VQCL(]AQM&. MK],&)ZXV6)G3?&&?ROAMCEC/Z_I.0)&"WP<@F>!0T/3I]4T[,+CPF$I7W)G;VU_TB6IN>5+E)^')AI6S5RJEQJU4NG_BO:A@+BF(J MO8P+26*J(DH+SL_#8T :ZP3Z&_UW0YSK!LBFN4V+.#^D_S8]N^'Z#EH>_@ T M,L?D>;$CT,8X6-A6/<,;M[##?C59@H$:W''=.CV434S#.]@@!< :&79[XM7! M -2[":!F!^%IM$PU]OBU[W38/53)7]3ZL:F$P:>F*G78NCN<96!61?Y2!7K7 M'Q):9P@@X1N,Y^C"C'53GZ>HC:FT/;QUA3DR3G)OM;-.1&LU HCE<<4!=>L& MKR8QGC5.8D0ND!/0&EE])@5)58LQ"S30L 65N+H:-RN5Y0]?-\:?MKA8*N,' M>GSK:!G;XD!V&::X]D$?C4= ]JE8)671M(NPS:"+>#)4SI<.:!'#<#+N;?:^ M! WO2]TOLZ:F[."NUHS=LU'DT:/-670+YFKUM M>GY(5\_:9X,G-E>\5:4,_+GQ/('-R0'[HC,!1:COK6I6K1%&:2JJ[CK7=T=P M@8P",3P%[4N/V>V9MYBV#QIQ=6.;E*89#9@5\7VJBK-E58% I2__F &C$S\I MUF.+&RKRM[S3,07<')Y'05,CR8=W8:SWBA]W*E*<*QZ'MNKHF;W@R$: MC-.OW7HD+LA*H=1,LR>S[JC!G7G%H^&PN7%EYZ@$"ET;[HTI#%?15!A=AE5T MH4 07HB [\A;=TYW.I%'5Y(AT+]1*<]&C?%;6ZA2I=1J^N.XM2D+B-G_*SSH M8?TA+[S&ZX(-A;&NPVMU$%W %,LB<(*QQ"M\7%,UQ->9G^8I/&%$,72+ ^I<%(8^K.%'G:&!Q?#* M0N736:Z$\P6^^1#8ZG<.<%4U!)[;E"KTC<"Q,WU?-J?W7*F,J6UL2Y %MG@C M/^#0G?8'G-K!3N1:6K(.SM+U33H88H&$[S4,E9NE*:^C/60.'<,+*F,,*8*@M%"U,P M^<;#RD-_AAR(?R*^!5Y3N6P"4B7AF+3GF#*$;.4> F7 =*/YIB;=Y^\"_1J1 M^2!4W:+@4O%:_048F$M5%7IV?X])I2 R_J(9\>D7K!I<2)-O4-+M%9 ?( CF M@?/0+);\@ .\B.^DN@MSZ>H)=24$T:3/:-(YZG?$X(@\LV-01X;$5WY0=*E MVCF:#H.S++^3_'H HQD8V#U0B@*]S(4XK$[;A#5VG [=B:FZ$P:3.Z.P-S2# M<91LXP '+4/0V4D-.IO(79=SP;8'';^K0%C=T].+"SZ4)!^!OLRA:D#8$Z1C M"0BF9LW=46!?S(0M](*A^=P/NCW]QZ 3])QV@U[0-7\ H-PQ1KV@9P:9= +W MV!R(G5DH&,[;?L'04_0.$YU50\]M9MH9N:43XH^#G78 MW=[H(#+#I#J]8&5$3@?FZFVC=VU-M1&L@J.'&F+-%#N!S*UD;[_"N1=8<"9* M$J= X!;@T-R"]=S ,U EX7>7L8[V//'FE=)_@@/O3W^Q Q]TON; ]X'*/_J\ M26Q5WE^S_=2V,4>;\\/M/6N\\NFT,4$*<]];/Q_F+X>F+F3XAT"#HQ-.!B.3 M@=29A@-@@HL=S-5F!*1N]+9[9LK4;M"WM$!A!>?B.P78]*MIVB&DXS15P&X@ M*U.^;3OGL&FD[Y)H_OGP>OZ04=TN&OT0SQJG7V8+F;A23$]K'U[P0(%T/:>Z MQ<>X^'QXA]FAQD%(*<^]H_%$?!N]1'V]^CWI#XSWBE%U;AG'SD!>@_]\W[Q+@ M_2%*(EQG@?::TZ4U[?J@A'Q.-J:[1QG_BSEQ:'+BBS.9=I?B31U]64^[WO5E M+'V,U7]SJ]/N;'I^9U8&M$@EQ10W#6QG02]OIC59>J,Z5HY#YU MJ_UBKUG,]K:07$/L%#/DFR\PUAMLY95]IV1MO:]YDJ;O*@&I.Y M^16J%K=>7GHI8OPO5,0XV!I;_0V*&%?>1MZ[B'%3>V[6--ZES;]6W6//!:'M M=8_K8-BA#/)7='FIG/Q2.?FE1_G MB&+;VM/K3WG?>]1WFI,OU29?K?KLIT MDUMYBT[OV.RE-O7/JTWMJW2ZJ53UONU?2EN_E+;^NM+6E_E]E.J0']+..[)V MX,2O6$-2I01OJ"I;(_?X>@YV3YFPL]LK:+4X,??=/Z(X^00,8:>Z8C<5%\.: MRZ]*$)F)B9K1L %QB6J-'\?T5FJ?KVY8_9M)HY+8%=^SD.GB.Q0=*(4_79^8 MJ?E.$MZ4'0^G(_XPH3N^\&$T& ?Z[C0O8NL88]5U.IPV:GWMDS"^PY&=FA@_ M' BFJUR0=]#0>[/4V$LNPCZY"*VEKWV""MOJ5ONQX/]FG>EM MY:!WU8LVU9!N58?^S]=\W@FZFZI$M]=^?BGO_&N5=_867-WI)#D^P-6>B+^J M,D]8Q?J;+81BMD9>,H!LX;"HCMC"POI&<+NB'4-?YOKU;A*TUD*EFT2TV,:F(]E:7,\5*>DYC40+@R MO\5;A#=Y"2.>@DJ;JBJAXG_>DW';J-=!029!KAD-X>"[Z$KS>,^7G4_1+]98 M77E_9&ZD-'[<[[)GPY)MW >AVD$)W7J+O+[]CYNO730.2U_JP(OSF"C"&8X. M8F:.@F$J&U;*P3/+:A!H/3#?Y(WUNS]M)]M^Q:>M!UG'6#'G(UO';>WJYCOE MPJ'+F>1-[=8=ZOGU 4 [\X8,C/5]H:SOMA6,_?UWJTG1#C'.+5"1&:YLQ,7K ML:)&7CS$*[23%#-J<)F.C\OL05]53K,M/&4Y2^,8_5ZN5L[C=2T3&__9]J9]_V3*P;:]?]75=J9=;6W--[Q"O!<3_"-6I];F5MLD M7*60[Q+9MV0XR1@RQL8I-H;IVSO+E1@9L].9UB7LZW/SSG85U=46NQ!TC6[QO%657KKBM1^8.V,;,A8 MGXAMQFC5XU[UAN\CL"N[;*9TIU[3J3OAGWL-TZG;\XIWN3K"V&C+F%VO3L Q M29ZGYS6FQFVK:(O:[2.5?$^=[CA/%0&V+&;#$MIT#C\_:@EY>7G&#F&MO5P1 MGN= MT]1!5/[$C9,W B1[0 <-Q"U-=C4$%2U6-3V)7JB.VU-5&#'RV$V1VVJ MRZQ%=+:OL1(IV3Q3&QO\FO74V!_TVFTN+[NH["'?D:\Y)SVMB9X1S^FQ8TFY0=NPT/$D3%JQX-', M-6[EBA8^&WQ)&S5P\;\M9KU7J836%H*-K:-2;-?4BC$G7(3.\0)[6[0A355^ MC;Q]^=E,\HS[!VE;*VQPD\MKA]U5]81%!?8-GX#7R[>G8?-+/(;YSVS=M 14 M]S9J]2-:7GSJJ'?H]G'=^TW8*_U*(:6[NP_--49HK*1"F'PD!CI>L#0B08TG M3/@1$#HA&T/:.);SK,GF]U VC=*F>'S:\FB&AU568E9M5+?UE0,[ MP-]O()N'X^;:8#[-ME.I#SU@C[48Z9J_O2Y)_E]N"9NQ4\_?F_[\:3?@LDE7 ML@E)G,VQ"Q9_[6!-5-ECI!IN? T;WC=[:$>NO(T=6_%69ST5^.S3;KOL-'=ZNVRT=GJ[X$JT5X]KN,O M>W; ^Z3[=3E%UK%?EP_QQNR2[23W<]+$VLFO)8^JH2,>C2<-PW)3DE6];;\F M#%K'LIE8C35,!S[SMB53JQ$GV?B"VE[FWZ7W]24&NL\Y@.\O-> N[6M,#6QH M/&"T?^Y81SUUM(\!B@\A-&PO[ M->M&\Q(?G:/S/S]9)Y$2U6I#\5V)L0(MH[R.8:E4]<'SZK3$#-6GHL)<1W(A M&5)Z* NOKB1&66V2&/5"WU]X#!$.DX@W[)JI&J2BX2J&\\$%7/Z5R' ,[X_? M?F^$NGP#W//HW=&1?W]R.?4?V\ )!$[C>G\N>NK[CPN;X$1\_DSQ MI[0GTHM'I <4(S:"3=//GKOLI]<]E3\W\EZW?4F4"S[NX@PZAZZ/& 9K1&-X MA2A926*RUMV7 O75"1M5"?&KT<;L>F>_"MQ#EI M[;C-!P"MCJJ*;CY24G"&W6)^6S#8LV 2H;X.*(4D#UK/M$JJ'5A"L,92D73; M\T.B:HE;U;=3F^_+'!X@\TN_YP)S+!'=AM:]_YK?\G\FGIW]/;+]59D"OR"C M.40/ ')^")"+0X \B)X\?_V0LXM_S.AUY_?6)6'GBC!XP:HA5!'>T98DR[#C M,7>T&'XU5T2ZD81>VX/C?(OD)4$L#!!0 ( ") BT[R&B%H+@0 )HA / M>&PO=V]R:V)O;VLN>&ULQ9I;;]LV%(#_"J&7I< V6Q>G;5 7:.-L"S"D05ST MM:"E8YN(1+HDE33Y]3V4ZX6L[8.]'/C)%B_B)TKD=TCIW:.Q]PMC[L7WKM5N MFJV]WUR,1JY>0R?=GV8#&G.6QG;2XZ%=C=S&@FS<&L!W[:@8C\]'G50Z>_]N M=ZY;.XH/C(?:*Z,Q,21\4?#H7O+#H9!8X $^R\4T&V="]M[\I5H/=B8]_&U- MOU%Z-VAY*=DJK3CU#,QRYM7G\QUCU;+27[;RVIFV'6B%CJ(0M MN/]2OH#UJDX*>KFXD\@ZS<['>,('Y=1"M0!G _RTN@&M(-&X#]G6M4@1R,^RE;J&D0$ M61"0Q0DAOQ819$E EB>!G <,8?!\ ME$XY89;BUH*#"/*<@#SGA9SW72?M4Z":JY566$WB6/]0UZ;'L1Y!OB8@7_-" MWH5$O+^WTN+D\]E*[>0PI;N([PW!]X:7[V=O.7$'-:@'B8V[W\4-^ CO+8'W MEOE!]&NP,5L\9X^I27O,"X9NWD"XI8-:OO5J$RK$=*12F)URC1;7J]"H^. < M6C8&HS22,WL$'S?;XW"X^KX)DV#"19DC9U;'#49:#@?IDQS:?8&B3)$SJV(& M"RS0VS BXWE$I?U&>2)G%L7LQ&@9=_]*#E!]R9D',^X6#;WV(4J\> FH,1HDA9S8#J=3< MAJ!"E02SH'Q1,/N"[LTRQJ3$43"+XV@X(,YP =C&F.1JA%DC>V'!%@_R>8U$&/I=2M?%2HJ0D5#)+Z CFKDMC3,I");.%#@1#/SM2 MW$AK8TS*0B6SA?8QCPVABK)0Q6RAO< MH8S?:U24A2IF"Z7A6\J(>3$F9:&* MV4(D9C(A592%*F8+$5M683#%F.0[&&8+'8F*=Z,]QJ0L5)UB=^WEYL>8E(4J M[AE>6$LM!D ML-!H]RU @W=%0W.#33A,KV5;WUH1?K:O+JI)V&Q<]FU[B6F?]+]&#F_OPSEV MGT6\_P%02P,$% @ (D"+3A;_3#;: 0 FQX !H !X;"]?S_LF[0LZIR[FQ#2 MJHZ'*EVT76R&.YNV/U1Y^-IO0U>M7JIM##J?+T(_GE'Z[Z;)]NWH]Q";_4O&] MH B_!^ETD-*#;#K(Z$$^'>3TH'(ZJ*0'+::#%O2@R^F@2WK0U730%3WH>CKH MFAXDNM0&_EZZU M;^7KK4!OY>NM0&_EZVU ;^/K;4!OX^MM0&\[PUD).BSAZVU ;^/K;4!OX^MM M0&_CZVU ;^/K;4!OX^MM0&_CZ^U ;^?K[4!OY^OM0&_GZ^U ;S_#631=]] E!+ P04 M " B0(M.2I4EW<WO&Z:. MJFZ-+TKK;^*"I/>\B5U\O#9)8M4G[(0)OV]LS^-]KVMRKLSI7]',?%YFE)ML M5<=;4F\=Z=P71*&N4E]H1_E;<&6SV.>=:1=>=!T;LTW%?BQ(KYYK/N M#^CI%U!+ 0(4 Q0 ( ") BTX?(\\#P !," + " M 0 !?D !D;V-0&UL4$L! A0#% @ M(D"+3K.I8,;O *P( !$ ( !F0$ &1O8U!R;W!S+V-O M&UL4$L! A0#% @ (D"+3IE&PO=V]R:W-H965T&UL4$L! A0#% @ (D"+3LU7Z55?! 210 !@ M ( !J@L 'AL+W=O%P & M @ &W$@ >&PO=V]R:W-H965T&UL4$L! A0#% M @ (D"+3O0:]N O! @1( !@ ( ![A< 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ (D"+3@\.S:FT 0 MT@, !@ ( !(B 'AL+W=O&PO=V]R:W-H965T(E !X;"]W;W)K&UL4$L! A0#% @ M(D"+3I>@_9*T 0 T@, !D ( !S"< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ (D"+3I*-TYBT 0 T@, !D M ( !3S, 'AL+W=O&PO=V]R:W-H M965T9'M $ -(# 9 M " 0XX !X;"]W;W)K&UL4$L! M A0#% @ (D"+3JCI M6V 0 T@, !D ( !^3D 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ (D"+ M3M&PO=V]R:W-H965T&UL4$L! A0#% @ (D"+3FGPOEJV 0 T@, M !D ( !AT4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ (D"+3E39X0/M 0 7 4 !D M ( !VDL 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ (D"+3@,>&PO=V]R:W-H965T&UL4$L! A0#% @ (D"+3A%YN'O6 0 8 0 !D M ( !(V( 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ (D"+3M"KL>/M 0 ?04 !D ( ! MK6@ 'AL+W=O&PO=V]R:W-H965T!L !X;"]W;W)K&UL4$L! A0#% M @ (D"+3K,!-U_9 P (A( !D ( !%7 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ (D"+3CG(F%8O,P ./( !0 M ( !)H$ 'AL+W-H87)E9%-T&UL4$L! A0#% @ M(D"+3KZDN]U: @ : P T ( !A[0 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ (D"+3A;_3#;: 0 FQX M !H ( !9[L 'AL+U]R96QS+W=O;T J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& #L .P /$ <;\ end XML 62 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 95 201 1 false 42 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://novointegrated.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://novointegrated.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://novointegrated.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://novointegrated.com/role/StatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://novointegrated.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Organization and Basis of Presentation Sheet http://novointegrated.com/role/OrganizationAndBasisOfPresentation Organization and Basis of Presentation Notes 6 false false R7.htm 00000007 - Disclosure - Summary of Significant Accounting Policies Sheet http://novointegrated.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Related Party Transactions Sheet http://novointegrated.com/role/RelatedPartyTransactions Related Party Transactions Notes 8 false false R9.htm 00000009 - Disclosure - Accounts Receivables, Net Sheet http://novointegrated.com/role/AccountsReceivablesNet Accounts Receivables, Net Notes 9 false false R10.htm 00000010 - Disclosure - Other Receivables Sheet http://novointegrated.com/role/OtherReceivables Other Receivables Notes 10 false false R11.htm 00000011 - Disclosure - Property and Equipment Sheet http://novointegrated.com/role/PropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 00000012 - Disclosure - Intangible Assets Sheet http://novointegrated.com/role/IntangibleAssets Intangible Assets Notes 12 false false R13.htm 00000013 - Disclosure - Accrued Expenses Sheet http://novointegrated.com/role/AccruedExpenses Accrued Expenses Notes 13 false false R14.htm 00000014 - Disclosure - Notes Payable Notes http://novointegrated.com/role/NotesPayable Notes Payable Notes 14 false false R15.htm 00000015 - Disclosure - Debentures, Related Parties Sheet http://novointegrated.com/role/DebenturesRelatedParties Debentures, Related Parties Notes 15 false false R16.htm 00000016 - Disclosure - Stockholders' Deficit Sheet http://novointegrated.com/role/StockholdersDeficit Stockholders' Deficit Notes 16 false false R17.htm 00000017 - Disclosure - Commitments and Contingencies Sheet http://novointegrated.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 00000018 - Disclosure - Subsequent Events Sheet http://novointegrated.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 00000019 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://novointegrated.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://novointegrated.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - Organization and Basis of Presentation (Tables) Sheet http://novointegrated.com/role/OrganizationAndBasisOfPresentationTables Organization and Basis of Presentation (Tables) Tables http://novointegrated.com/role/OrganizationAndBasisOfPresentation 20 false false R21.htm 00000021 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://novointegrated.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://novointegrated.com/role/SummaryOfSignificantAccountingPolicies 21 false false R22.htm 00000022 - Disclosure - Accounts Receivables, Net (Tables) Sheet http://novointegrated.com/role/AccountsReceivablesNetTables Accounts Receivables, Net (Tables) Tables http://novointegrated.com/role/AccountsReceivablesNet 22 false false R23.htm 00000023 - Disclosure - Other Receivables (Tables) Sheet http://novointegrated.com/role/OtherReceivablesTables Other Receivables (Tables) Tables http://novointegrated.com/role/OtherReceivables 23 false false R24.htm 00000024 - Disclosure - Property and Equipment (Tables) Sheet http://novointegrated.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://novointegrated.com/role/PropertyAndEquipment 24 false false R25.htm 00000025 - Disclosure - Intangible Assets (Tables) Sheet http://novointegrated.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://novointegrated.com/role/IntangibleAssets 25 false false R26.htm 00000026 - Disclosure - Accrued Expenses (Tables) Sheet http://novointegrated.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://novointegrated.com/role/AccruedExpenses 26 false false R27.htm 00000027 - Disclosure - Notes Payable (Tables) Notes http://novointegrated.com/role/NotesPayableTables Notes Payable (Tables) Tables http://novointegrated.com/role/NotesPayable 27 false false R28.htm 00000028 - Disclosure - Stockholders' Deficit (Tables) Sheet http://novointegrated.com/role/StockholdersDeficitTables Stockholders' Deficit (Tables) Tables http://novointegrated.com/role/StockholdersDeficit 28 false false R29.htm 00000029 - Disclosure - Organization and Basis of Presentation (Details Narrative) Sheet http://novointegrated.com/role/OrganizationAndBasisOfPresentationDetailsNarrative Organization and Basis of Presentation (Details Narrative) Details http://novointegrated.com/role/OrganizationAndBasisOfPresentationTables 29 false false R30.htm 00000030 - Disclosure - Organization and Basis of Presentation - Schedule of Foreign Currency Translation, Exchange Rate Used (Details) Sheet http://novointegrated.com/role/OrganizationAndBasisOfPresentation-ScheduleOfForeignCurrencyTranslationExchangeRateUsedDetails Organization and Basis of Presentation - Schedule of Foreign Currency Translation, Exchange Rate Used (Details) Details 30 false false R31.htm 00000031 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://novointegrated.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://novointegrated.com/role/SummaryOfSignificantAccountingPoliciesTables 31 false false R32.htm 00000032 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details) Sheet http://novointegrated.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfEstimatedUsefulLivesOfAssetsDetails Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details) Details 32 false false R33.htm 00000033 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://novointegrated.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://novointegrated.com/role/RelatedPartyTransactions 33 false false R34.htm 00000034 - Disclosure - Accounts Receivables, Net - Schedule of Accounts Receivables, Net (Details) Sheet http://novointegrated.com/role/AccountsReceivablesNet-ScheduleOfAccountsReceivablesNetDetails Accounts Receivables, Net - Schedule of Accounts Receivables, Net (Details) Details 34 false false R35.htm 00000035 - Disclosure - Other Receivables - Schedule of Other Receivables (Details) Sheet http://novointegrated.com/role/OtherReceivables-ScheduleOfOtherReceivablesDetails Other Receivables - Schedule of Other Receivables (Details) Details 35 false false R36.htm 00000036 - Disclosure - Other Receivables - Schedule of Other Receivables (Details) (Parenthetical) Sheet http://novointegrated.com/role/OtherReceivables-ScheduleOfOtherReceivablesDetailsParenthetical Other Receivables - Schedule of Other Receivables (Details) (Parenthetical) Details 36 false false R37.htm 00000037 - Disclosure - Property and Equipment (Details Narrative) Sheet http://novointegrated.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://novointegrated.com/role/PropertyAndEquipmentTables 37 false false R38.htm 00000038 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) Sheet http://novointegrated.com/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails Property and Equipment - Schedule of Property and Equipment (Details) Details 38 false false R39.htm 00000039 - Disclosure - Intangible Assets (Details Narrative) Sheet http://novointegrated.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://novointegrated.com/role/IntangibleAssetsTables 39 false false R40.htm 00000040 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://novointegrated.com/role/IntangibleAssets-ScheduleOfIntangibleAssetsDetails Intangible Assets - Schedule of Intangible Assets (Details) Details 40 false false R41.htm 00000041 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) Sheet http://novointegrated.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails Accrued Expenses - Schedule of Accrued Expenses (Details) Details 41 false false R42.htm 00000042 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) Notes http://novointegrated.com/role/NotesPayable-ScheduleOfNotesPayableDetails Notes Payable - Schedule of Notes Payable (Details) Details 42 false false R43.htm 00000043 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) Notes http://novointegrated.com/role/NotesPayable-ScheduleOfNotesPayableDetailsParenthetical Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) Details 43 false false R44.htm 00000044 - Disclosure - Debentures, Related Parties (Details Narrative) Sheet http://novointegrated.com/role/DebenturesRelatedPartiesDetailsNarrative Debentures, Related Parties (Details Narrative) Details http://novointegrated.com/role/DebenturesRelatedParties 44 false false R45.htm 00000045 - Disclosure - Stockholders' Deficit (Details Narrative) Sheet http://novointegrated.com/role/StockholdersDeficitDetailsNarrative Stockholders' Deficit (Details Narrative) Details http://novointegrated.com/role/StockholdersDeficitTables 45 false false R46.htm 00000046 - Disclosure - Stockholders' Deficit - Schedule of Stock Option and Warrant Activity (Details) Sheet http://novointegrated.com/role/StockholdersDeficit-ScheduleOfStockOptionAndWarrantActivityDetails Stockholders' Deficit - Schedule of Stock Option and Warrant Activity (Details) Details 46 false false R47.htm 00000047 - Disclosure - Stockholders' Deficit - Schedule of Options and Warrants Outstanding and Exercisable (Details) Sheet http://novointegrated.com/role/StockholdersDeficit-ScheduleOfOptionsAndWarrantsOutstandingAndExercisableDetails Stockholders' Deficit - Schedule of Options and Warrants Outstanding and Exercisable (Details) Details 47 false false R48.htm 00000048 - Disclosure - Stockholders' Deficit - Schedule of Fair Value of Options Granted by Using Valuation Assumptions (Details) Sheet http://novointegrated.com/role/StockholdersDeficit-ScheduleOfFairValueOfOptionsGrantedByUsingValuationAssumptionsDetails Stockholders' Deficit - Schedule of Fair Value of Options Granted by Using Valuation Assumptions (Details) Details 48 false false R49.htm 00000049 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://novointegrated.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://novointegrated.com/role/CommitmentsAndContingencies 49 false false R50.htm 00000050 - Disclosure - Subsequent Events (Details Narrative) Sheet http://novointegrated.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://novointegrated.com/role/SubsequentEvents 50 false false All Reports Book All Reports nvos-20190228.xml nvos-20190228.xsd nvos-20190228_cal.xml nvos-20190228_def.xml nvos-20190228_lab.xml nvos-20190228_pre.xml http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 66 0001493152-19-005137-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-19-005137-xbrl.zip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end